The Journal of Rheumatology, Volume 30, 2003

AUTHOR INDEX

Pages 1 – 2790 and Supplements 67–68

A

Aanerud GJ, 884
Abd El-Aaty G, 1081
Abd El-Aaty H, 1081
Abrahamowicz M, 1326, 1879 (ab), 1880 (ab), 1967
Abril A, 2283
Abu-Shakra M, 2295
Achonu C, 1887 (ab)
Acquafredda V, 1298
Adachi JD, 1877 (ab), 1883 (ab), 1886 (ab)
Adam V, 1886 (ab)
Adams BS, 394
Adams Huet B, 1394
Adler GK, 809
Afeltra A, 220
Aggarwal A, 105, 415, 948, 1248
Aguilar F, 1770
Ahern MJ, 10, 2319
Ahlmèn M, 868
Ahmed I, 2666
Ai M, 1451
Ainola M, 652
Airaksinen KEJ, 74
Åkesson K, S67–21, S67–38
Akisue T, 637, 1097, 1351
Akiya K, 1124
Akst LM, 1017
Alamanos Y, 731, 2641
Álamo F, 740
Alarcón GS, 2420
Alarcón-Segovia D, 1893
Albert D, 1891
Alcina A, 435
Alcocer-Varela J, 256
Aldag JC, 2302
Alderdice CA, 1885 (ab), 2529
Alderman AK, 1464
Alexander H, 1611
Al-Herz A, 493
Allanore Y, 68, 1395
Allison JJ, 2680
Almahrezi A, 1882 (ab)
Almoallim H, 1876 (ab)
Alonso A, 1051
Alsaeid K, 2705
Alsalameh S, 1680
Alsufyani KAM, 1881 (ab)
Altman RD, 1648
Amarelo J, 102
Ambrose K, 567
Amin RJ, 1680
Amoli MM, 913, 2019
Amor-Dorado JC, 1548
Amoroso A, 220
Amoura Z, 1027
Anakinra 960180 Study Group, 225
Anastassiades T, 1878 (ab)
Anaya J-M, 2152
Anderson D, 1990
Anderson J, 449
Anderson JJ, 1110, 1112, 1115, 1648
Andersson-Gäre B, 2275
Andrade LEC, 2606
Andrianakos A, 1589
Ang DC, 1305
Ang HTS, 2315
Aniol J, 534
Anis A, 1883 (ab)
Antoniades C, 1589
Appelboom T, 348
Arai Y, 747
Arana-Gutiérrez MA, 1100
Arayssi R, 1888 (ab)
Arayssi TK, 2722
Arcos-Burgos M, 2152
Arellano J, 2182
Arimura Y, 1534
Ariza R, 2140
Armstrong D, 1875 (ab)
Armstrong MA, 1882 (ab), 2557
Arnold MO, 815
Arnoldi C, 579
Artlett C, 1994
Asare C, 1882 (ab)
Asherson RA, 214
Assefi NP, 804
Astin JA, 2257
Atalar E, 313
Atteno M, 2638
ATTRACT Study Group, 1883 (ab)
Aviña-Zubieta JA, 2382
Avinens O, 1485
Avorn J, 203, 792
Awwad S, 1888 (ab)
Axford JS, 2540
Aya-ay JP, 412
Ayala F, 2638
Ayoub EM, 2705
Aypar E, 2011

B

Bacon P, 1621
Badcock LJ, 2694
Baddour M, 2666
Badley EM, 126, 1846
Bae S-C, 2039
Bakkaloglu A, 2011, 2014
Balci B, 2014
Balint P, 966
Balsa A, 697, 1436
Bambara LM, 298
Bancroft LW, 1347
Bankhurst AD, 1215
Banno S, 1520
Bannwarth B, 421
Bansal S, 972
Baracetti S, 1775
Barbarot S, 1811
BARFOT Study Group, 2590
Bargagli G, 1298
Barile-Fabris L, 2182
Barker S, 2356
Baron D, 2535
Baron M, 1326, 1887 (ab)
Barr SG, 1011, 1876 (ab), 2613
Barrera P, 232, 926
Barrett EM, 2485
Barros F, 102
Barros Neto T, 1060
Bashour Z, 1888 (ab)
Bathon JM, 114
Batthish M, 1887 (ab)
Battista RN, 1967
Baughman J, 449
Baum BJ, 1267
Baumann M, 1070
Baumgartner SW, 691
Bausell B, 2257
Bay ML, 497
Beauchesne C, 622
Beaulieu A, 1011
Beaulieu M, 1877 (ab)
Beehler BC, 355
Bélanger A, 2413
Bellamy N, 1648
Bellisai F, 1244
Belmonte MA, 697, 1436
Bendaoud B, 2535
Benjamin M, 508, 1420
Benöhr P, 1918
Benseler SM, 1875 (ab), 1876 (ab)
Benson LM, 89
Beri R, 1907
Berkovitch M, 594
Berkowitz DV, 1070
Berman BM, 2257
Bernard M, 1886 (ab)
Bernard N, 2005
Bernardeau C, 2428
Bernatsky S, 1326, 1505, 1756, 1876 (ab), 1879 (ab), 1880 (ab), 1886 (ab)
Bernelot Moens HJ, 2325
Berntson L, 2275
Berthelot J-M, 1673, 2535
Bertinotti L, 1231
Bertolaccini ML, 985
Bértolo MB, 2511, 2632
Bertouch JV, 10
Bérubé R, 2413
Besbas N, 2011, 2014
Besedovsky H, 497
Bessant R, 779
Bessette L, 1877 (ab)
Betteridge N, S67–36
Beyan H, 972
Beylot J, 208, 2005
Bezemer PD, 1558
Bhakuni DS, 1248
Biagi F, 1298
Bianchini D, 1775
Biasi D, 298
Bidaut-Russell M, 1940
Biffi M, 1611
Bijlsma JWJ, 339, 648, 1147
Binder A, 972
Bindi G, 179
Bingham SJ, 2287
Birbara CA, 2563
Bird CF, 329
Bird KS, 2064
Bird P, 1364, 1366, 1376, 1380, 1385, 1387
Birnbaum HG, 1318
Birnboim HC, 1173
Black CM, 720
Black RJ, 958
Blake D, 2054
Bland JM, 2540
Blann AD, 1401, 1963
Blaschke S, 1918
Blaszczyk M, 1997
Block JA, 1227, 1822
Boers M, 866, 868, 886, 891, 905, 1102, 1110, 1112, 1115
Bogardus S, 443
Bogoch ER, 934, 1440
Bohn R, 792
Boiardi L, 760, 2160
Boisseau MR, 1963
Boivin J-F, 1505, 1876 (ab)
Bokarewa MI, 1719
Bolster MB, 2064
Bombardier C, 575, 1883 (ab), 1886 (ab)
Bombardieri S, 1122
Bonarek M, 2005
Bonfá E, 1393
Bonilla G, 1272
Bonnet F, 208, 2005
Bonneville M, 1673
Bonnin M, 1951
Bono E, 1611
Boonen A, 1102
Booth DA, 1259
Borba EF, 1393
Borderie D, 68
Bordin T, 2720
Borgato L, 1907
Boros CA, 1877 (ab)
Bosworth HB, 2201
Boszczyk AA, 1420
Boszczyk BM, 1420
Botana MA, 913
Bottasso O, 497

The Journal of Rheumatology, Volume 30, 2003

AUTHOR INDEX

Pages 1 – 2790 and Supplements 67–68

A

Aanerud GJ, 884
Abd El-Aaty G, 1081
Abd El-Aaty H, 1081
Abrahamowicz M, 1326, 1879 (ab), 1880 (ab), 1967
Abril A, 2283
Abu-Shakra M, 2295
Achonu C, 1887 (ab)
Acquafredda V, 1298
Adachi JD, 1877 (ab), 1883 (ab), 1886 (ab)
Adam V, 1886 (ab)
Adams BS, 394
Adams Huet B, 1394
Adler GK, 809
Afeltra A, 220
Aggarwal A, 105, 415, 948, 1248
Aguilar F, 1770
Ahern MJ, 10, 2319
Ahlmèn M, 868
Ahmed I, 2666
Ai M, 1451
Ainola M, 652
Airaksinen KEJ, 74
Åkesson K, S67–21, S67–38
Akisue T, 637, 1097, 1351
Akiya K, 1124
Akst LM, 1017
Alamanos Y, 731, 2641
Álamo F, 740
Alarcón GS, 2420
Alarcón-Segovia D, 1893
Albert D, 1891
Alcina A, 435
Alcocer-Varela J, 256
Aldag JC, 2302
Alderdice CA, 1885 (ab), 2529
Alderman AK, 1464
Alexander H, 1611
Al-Herz A, 493
Allanore Y, 68, 1395
Allison JJ, 2680
Almahrezi A, 1882 (ab)
Almoallim H, 1876 (ab)
Alonso A, 1051
Alsaeid K, 2705
Alsalameh S, 1680
Alsufyani KAM, 1881 (ab)
Altman RD, 1648
Amarelo J, 102
Ambrose K, 567
Amin RJ, 1680
Amoli MM, 913, 2019
Amor-Dorado JC, 1548
Amoroso A, 220
Amoura Z, 1027
Anakinra 960180 Study Group, 225
Anastassiades T, 1878 (ab)
Anaya J-M, 2152
Anderson D, 1990
Anderson J, 449
Anderson JJ, 1110, 1112, 1115, 1648
Andersson-Gäre B, 2275
Andrade LEC, 2606
Andrianakos A, 1589
Ang DC, 1305
Ang HTS, 2315
Aniol J, 534
Anis A, 1883 (ab)
Antoniades C, 1589
Appelboom T, 348
Arai Y, 747
Arana-Gutiérrez MA, 1100
Arayssi R, 1888 (ab)
Arayssi TK, 2722
Arcos-Burgos M, 2152
Arellano J, 2182
Arimura Y, 1534
Ariza R, 2140
Armstrong D, 1875 (ab)
Armstrong MA, 1882 (ab), 2557
Arnold MO, 815
Arnoldi C, 579
Artlett C, 1994
Asare C, 1882 (ab)
Asherson RA, 214
Assefi NP, 804
Astin JA, 2257
Atalar E, 313
Atteno M, 2638
ATTRACT Study Group, 1883 (ab)
Aviña-Zubieta JA, 2382
Avinens O, 1485
Avorn J, 203, 792
Awwad S, 1888 (ab)
Axford JS, 2540
Aya-ay JP, 412
Ayala F, 2638
Ayoub EM, 2705
Aypar E, 2011

B

Bacon P, 1621
Badcock LJ, 2694
Baddour M, 2666
Badley EM, 126, 1846
Bae S-C, 2039
Bakkaloglu A, 2011, 2014
Balci B, 2014
Balint P, 966
Balsa A, 697, 1436
Bambara LM, 298
Bancroft LW, 1347
Bankhurst AD, 1215
Banno S, 1520
Bannwarth B, 421
Bansal S, 972
Baracetti S, 1775
Barbarot S, 1811
BARFOT Study Group, 2590
Bargagli G, 1298
Barile-Fabris L, 2182
Barker S, 2356
Baron D, 2535
Baron M, 1326, 1887 (ab)
Barr SG, 1011, 1876 (ab), 2613
Barrera P, 232, 926
Barrett EM, 2485
Barros F, 102
Barros Neto T, 1060
Bashour Z, 1888 (ab)
Bathon JM, 114
Batthish M, 1887 (ab)
Battista RN, 1967
Baughman J, 449
Baum BJ, 1267
Baumann M, 1070
Baumgartner SW, 691
Bausell B, 2257
Bay ML, 497
Beauchesne C, 622
Beaulieu A, 1011
Beaulieu M, 1877 (ab)
Beehler BC, 355
Bélanger A, 2413
Bellamy N, 1648
Bellisai F, 1244
Belmonte MA, 697, 1436
Bendaoud B, 2535
Benjamin M, 508, 1420
Benöhr P, 1918
Benseler SM, 1875 (ab), 1876 (ab)
Benson LM, 89
Beri R, 1907
Berkovitch M, 594
Berkowitz DV, 1070
Berman BM, 2257
Bernard M, 1886 (ab)
Bernard N, 2005
Bernardeau C, 2428
Bernatsky S, 1326, 1505, 1756, 1876 (ab), 1879 (ab), 1880 (ab), 1886 (ab)
Bernelot Moens HJ, 2325
Berntson L, 2275
Berthelot J-M, 1673, 2535
Bertinotti L, 1231
Bertolaccini ML, 985
Bértolo MB, 2511, 2632
Bertouch JV, 10
Bérubé R, 2413
Besbas N, 2011, 2014
Besedovsky H, 497
Bessant R, 779
Bessette L, 1877 (ab)
Betteridge N, S67–36
Beyan H, 972
Beylot J, 208, 2005
Bezemer PD, 1558
Bhakuni DS, 1248
Biagi F, 1298
Bianchini D, 1775
Biasi D, 298
Bidaut-Russell M, 1940
Biffi M, 1611
Bijlsma JWJ, 339, 648, 1147
Binder A, 972
Bindi G, 179
Bingham SJ, 2287
Birbara CA, 2563
Bird CF, 329
Bird KS, 2064
Bird P, 1364, 1366, 1376, 1380, 1385, 1387
Birnbaum HG, 1318
Birnboim HC, 1173
Black CM, 720
Black RJ, 958
Blake D, 2054
Bland JM, 2540
Blann AD, 1401, 1963
Blaschke S, 1918
Blaszczyk M, 1997
Block JA, 1227, 1822
Boers M, 866, 868, 886, 891, 905, 1102, 1110, 1112, 1115
Bogardus S, 443
Bogoch ER, 934, 1440
Bohn R, 792
Boiardi L, 760, 2160
Boisseau MR, 1963
Boivin J-F, 1505, 1876 (ab)
Bokarewa MI, 1719
Bolster MB, 2064
Bombardier C, 575, 1883 (ab), 1886 (ab)
Bombardieri S, 1122
Bonarek M, 2005
Bonfá E, 1393
Bonilla G, 1272
Bonnet F, 208, 2005
Bonneville M, 1673
Bonnin M, 1951
Bono E, 1611
Boonen A, 1102
Booth DA, 1259
Borba EF, 1393
Borderie D, 68
Bordin T, 2720
Borgato L, 1907
Boros CA, 1877 (ab)
Bosworth HB, 2201
Boszczyk AA, 1420
Boszczyk BM, 1420
Botana MA, 913
Bottasso O, 497

Boutros-Toni F, 1272
Boutry N, 671
Bouysset M, 1951
Bové A, 1552
Bowes K, 1878 (ab)
Bowman SJ, 1259
Bowyer SL, 394
Boyko EJ, 455
Boyle E, 1440
Boyvoda S, 352
Bozonnat M-C, 2344
Brassard N, 1875 (ab)
Braun GS, 196
Bravo MJ, 1051
Brazis PW, 1347
Breban M, 2428
Brennan MT, 1267
Brent LH, 630, 1354
Bresnihan B, 2540
Brewster DH, 958
Brik R, 308
Brin S, 2572
Brinckerhoff CE, 211
Brison R, 1878 (ab)
Brockbank JE, 1880 (ab)
Brooks P, 866
Brooks WM, 1983
Brophy S, 316, 2054
Brown J, 1877 (ab), 1886 (ab)
Brown R, 1621
Bruce B, 167, 2226
Bruce IN, 288
Brunner HI, 292
Bruyere O, 1043, S67–14
Bruynesteyn K, 1102
Buch MH, 2287
Buchwald D, 804
Buckland-Wright JC, 329
Buckley LM, 132
Buffet C, 1473
Bulpitt KJ, 449, 705, 2123
Burant CJ, 1305
Burke TA, 203
Bush TM, 241
Busque L, 2385
Bustamante R, 2382
Bykerk V, 1888 (ab)
Byrd MG, 2374

C

Caballero A, 1051
Cabral DA, 585, 832, 1881 (ab)
Caccavo D, 220
Cacoub P, 1027, 1473
Cagetti F, 1244
Calamia KT, 191
Çalgüneri M, 313
Calin A, 316, 2054
Cáliz R, 435
Callman ML, 2283
Campbell NRC, 1948
Campbell R, 1311
Canadian Council of Academic Rheumatologists, 1882 (ab)
Cannick L III, 2500
Cantagrel A, 2344
Cantini F, 760
Capell HA, 2085
Caramaschi P, 298
Carbal AR, 256
Carette S, 1884 (ab)
Carletto A, 298
Carlson P, 1841
Carlsten H, 1456
Carlström K, 2338
Carmona L, 697, 1436
Carr A, 880
Carr M, 880
Carracedo A, 102
Carroll WR, 2420
Carruba G, 2597
Carter JD, 2078
Carter L, 720
Carty SM, 425
Casale R, 1231
Casali B, 2160
Casanova A, 1552
Castagnetta LA, 2597
Catanoso MG, 760, 2160
Cauli A, 1120
Cawston T, 238
Çelik I, 313
Çerçi Özkan H, 2725
Cerhan JR, 952
Cermak JM, 2413
Cerù S, 1907
Cervera R, 1552
Chaiamnuay S, 1354
Chajek-Shaul T, 1119
Chakravarty EF, 241
Chalès G, 2535
Chalmers A, 1889 (ab)
Chan EKL, 2374, 2613
Chan James, 1017
Chan TW, 2627
Chan WW, 225
Chang B, 2398
Chang E, 2385
Chang S-YP, 1611
CHAP Team, 1883 (ab), 1886 (ab)
Charlier C, 1395
Chartash EK, 2563
Chatterton RT, 2302
Cheang M, 585, 832
Checchetto C, 2170
Cheetham TC, 2241
Chelliah G, 1621
Chen C-J, 438, 1120
Chen I, 1882 (ab)
Chen Juan, 2689
Chen JiaM, 321
Chen LX, 1191
Chen Q, 2160
Chen Simon, 355
Chen ShuJ, 321
Chen ShunL, 2252
Chen Z-K, 2033
Cherkas LF, 720
Cherqui D, 1624
Cherruau B, 68
Chew L-H, 2268
Chiappelli F, 364
Chieco Bianchi F, 2170
Chirammal Valappil U, 1793
Cho C-S, 1529
Cho M-L, 1529
Cho W-G, 1203
Choi J-H, 2422
Choi J-J, 1529
Choquette D, 1011, 1877 (ab), 1878 (ab)
Chosa E, 2553
Chou Chan-T, 2627
Chou ChungT, 321
Choy G, 1877 (ab)
Christian CL, 1090
Christopher-Stine L, 2725
Christoyannis F, 1589
Chung CP, 1878 (ab)
Chung KC, 1464, 1788
Churchill CH, 2283
Cibere J, 465
Ciconelli RM, 379
Cimaz R, 179, 579
Cisneros M, 2140
Citores MJ, 740
Cividino A, 1011, 1877 (ab), 1878 (ab)
Clark CA, 2127
Clark GT, 364
Clark P, 1584
Clark SJ, 2700
Clarke AE, 1011, 1505, 1756, 1876 (ab), 1878 (ab), 1886 (ab), 1967
Claudepierre P, 2428
Clauw DJ, 567, 2088
Claxton AJ, 1318
Clegg DO, 1127
Clements PJ, 1630, 1885 (ab)
Cline GA, 329
Clowse MEB, 1341
Cohen Marc, 523
Cohen Marc D, 191
Cohen RD, 2103
Cohen SB, 225, 449
Coimbra IB, 2511, 2632
Colburn KK, 993
Coldrick AR, 139
Coleman M, 2319
Collado MD, 435
Collantes-Estévez E, 2729
Collette JH, 1043
Collins D, 1878 (ab)
Collins MT, 1267
Collins S, 884
Comar C, 1775
Combe B, 1485, 2344
Combe C, 208
Compagnone D, 2563
Conaghan PG, 1364, 1366, 1376, 1385, 1387, 2287
Concato J, 443
Conde RA, 2511, 2632
Conner-Spady B, 941
Connors M, 1948
Conri C, 1963
Constans J, 1963
Conti T, 1298
Convery H, 1877 (ab)
Cooke TDV, 2521
Cooper DML, 2659
Cooper GS, 60, 276
Cooper NJ, 2485
Cornelis F, 926
Corominas H, 1191
Correa PA, 2152
Corrocher R, 1907
Cosentini E, 2638
Cosentino R, 200
Costallat LTL, 2511, 2632
Coste J, 1054
Coste-Burel M, 1673
Costedoat N, 1027
Cotten A, 671
Covelli M, 2710
Cox B, 96
Coy TV, 804
Coyle D, 886, 891, 1879 (ab), S68–31
Coyle Y, 1394
Coyte PC, 1846
Cozzi F, 1231
Cozzi L, 2170
Cragun JD, 89
Cranney AB, 1878 (ab), 1879 (ab)
Crater S, 2500
Crawford S, 1884 (ab)
Criswell L, 952
Croft JD Jr., 1739
Croft PR, 2694
Crotti TN, 2319
Cuadrado MJ, 985
Cuello C, 10
Cunnane G, 2287, 2540
Curtis J, 2680
Cutolo M, 2597
Czernichow P, 2492

D

Da Costa D, 154, 1011, 1879 (ab), 2476
da Mota Falcão D, 379
Da Silva Simoes C, 1485
Dababneh A, 913
Dagenais P, 1886 (ab)
D'Agostino RB, 714
Dai S-M, 2245
Daily JP, 851
Dal Canto N, 1298
Dalbeth N, 2510
Dale K, 386
Daltroy LH, 1657
Damen C, 648
Dana MR, 2413
Dancheva M, 2078
D'Angelo S, 2147
Daniels TR, 1440

Dantis P, 1589
D'Arienzo A, 2638
Darlington P, 1882 (ab)
Darmawan J, 2252, 2312, 2437, S67–51
Daurès J-P, 2344
Davies J, 575
Dawes PT, 764, 1406
Day RO, 642
Dayal R, 1248
de Assis M, 1060
De Benedetti F, 1611
de Brum-Fernandes AJ, 622
De Ceuninck F, 1561
De Civita M, 1326, 1880 (ab)
de Dios Colmenero J, 1051
De Faucal P, 2165
de Fornel D, 918
De Haas M, 1911
de Jong B, 825
De Keyser F, 2306
de Klerk E, 44, 2469
de Koning MHMT, 1691
de Kort S, 825
de la Red G, 1552
de la Serna R, 2572
de Nanteuil G, 1561
De Queiroz Cunha F, 485
De Roux-Serratrice C, 2716
De Stefano R, 200
de Wit M, 884
de Witte S, 208, 2005
DeArment MC, 1347
Deberg MA, 1825
Deesomchoke U, 2365
Deguchi H, 1426
del Rey A, 497
Del Rosso A, 1231
Delchier J-C, 2428
Dellalibera-Joviliano R, 485
den Broeder AA, 232
Denburg JA, 1006
Denburg SD, 1006
Deng Z, 465
Denny-Waters A, 884
Derk CT, 1616, 1994
Deschênes I, 622
Deslandre CJ, 1395
Dessein PH, 1403
Dessole G, 1120
Devauchelle V, 2535
Deveber G, 1875 (ab)
Devine A, 2689
Devins GM, 1011
Devogelaer J-P, 2444
Dewar C, 2503
Dhaliwal SS, 2689
DiBattista JA, 1879 (ab)
Dick IM, 2689
Dickson E, 575
Didoli G, 497
Dieppe PA, 1311, 1656
Dieudé M, 1875 (ab)
Dijkmans BAC, 825, 1558, 1691, 2080
Dimou G, 731
Ding W-Z, 276
Dion L, 622
Disdier P, 2716
Dixey J, 96
Dobkin PL, 1011, 1326, 1879 (ab), 1880 (ab), 1886 (ab), 1887 (ab), 1967
Dockerty JL, 2510
Dolan AL, 799
Dominick KL, 2201
Dominitz JA, 455
Donada C, 1775
Donadi EA, 485, 2511, 2632
Donadon V, 1775
Donaldson C, 1886 (ab)
Donovan J, 1656
Dooley MA, 276
Doran MF, 316
Dorner M, 269
Dos Reis ML, 485
Dougados M, 421, 1648, 2344, 2572
Douglas GC, 2064, 2500
Doupe M, 1888 (ab)
Downie-Doyle S, 2406
Doyle DV, 799
Doyle J, 1725
Drista M, 1011, 1879 (ab), 2476
Drosos AA, 731, 2641
Drummond M, 886, 891, S68–5, S68–19, S68–26
Dryhurst G, 89
Dubois A, 2344
Dubord P, 1889 (ab)
Dubrez-Daloz L, 918
Ducoroy P, 918
Dudley TK, 2201
Dumont D, 1054
Duong LT, 2207
Duong T, 1884 (ab)
Dupuy R, 1963
Dutartre P, 918
Duvoux C, 1624
Duzova A, 2014
Dwosh I, 1888 (ab)
Dziedzic K, 764

E

Ebringer A, 972
Echasserieu K, 1673
Edmonds J, 1364, 1366, 1376, 1380, 1385, 1387
Edworthy SM, 1011
Egrise D, 348
Ehrlich GE, 1666, S67–26
Eid H, 774
Eiselt M, 1087
Ejbjerg B, 1364, 1376, 1380, 1385, 1387
Ekindjian OG, 68
El Gaafary M, 2666
El Hajjaji H, 2444
El Kouri D, 2165
El Miedany YM, 2666
El-Garf A, 1081
Eliachar I, 1017
Eliaou J-F, 1485, 2344
Elias I, 544
Ellis BD, 625
Ellman MH, 202
El-Maadawy S, 910, 1880 (ab)
Elst EF, 2059
EMECAR Study Group, 697, 1436
Emery P, 260, 417, 1102, 1364, 1366, 1376, 1385, 1387, 2287, 2572
Endo H, 1712
Endo N, 2207
Ené N, 2716
Ensworth S, 493, 1011
Enzenauer RJ, 2508
Erausquin C, 740
Ernestam S, 1748
Ertenli I, 313
Escudero-Contreras A, 2729
Esdaile JM, 465, 493, 1011, 1875 (ab), 1883 (ab)
Espinoza LR, 193, 2140, 2725
Esquivel-Nava G, 2382
Esquivel-Valerio JA, 193, 2725
Ethgen O, 1043, 2452
Eto T, 2553
Euller-Ziegler L, S67–42
EURIDISS Group, 2585
Evidence-based Medicine Working Groups in Rheumatology, 1739

F

Facchini A, 345
Faccini G, 298
Falappone P, 2710
Falcini F, 179
Falk W, 269
Falkenbach A, 2186
Fam AG, 2070, 2733
Fan B, 1479
Fan M-Y, 114
Fanciullacci M, 1231
Fantini F, 579
Faour W, 1879 (ab)
Faraawi R, 1880 (ab)
Farewell VT, 4
Farnetti E, 2160
Farver C, 1541
Fasth A, 2275
Fatica RA, 1508
Fautrel B, 1886 (ab)
Fearon U, 260
Featherstone K, 646
Fedetz M, 435
Feinn R, 2045
Feldman BM, 292, 1875 (ab), 1885 (ab), 1887 (ab)
Feldman D, 1060
Feletar M, 1880 (ab)
Felländer-Tsai L, 2338
Felson DT, 443, 1110, 1112, 1115
Fenlon D, 480
Fernández-Melón J, 1272
Ferraccioli GF, 2517
Ferrari M, 298
Ferrari R, 1882 (ab)
Ferraz MB, 379
Ferreirós-Vidal I, 102
Ferrer MA, 435
Ferri C, 1244
Ferri GM, 220
Ferro F, 2170
Feyler A, 2005
Field A, 1259
Fierz W, 2133
Fiessinger J-N, 1344
Fietta P, 618
Fifield J, 2045
Fijnheer R, 1401
Fiocco U, 2170
Fiorini M, 345
Fischkoff SA, 2563
Fish EN, 934
Fishbain DA, 1124
Fitzcharles M-A, 154, 1879 (ab), 1880 (ab), 1882 (ab), 2557
Fitzgerald A, 1875 (ab)
FitzGerald O, 2540
Flatø B, 386, 1602
Flavin S, 829
Fleischmann RM, 691, 2563
Flipo R-M, 671
Flores-Alvarado DE, 193, 2725
Flume PA, 2064
Foeldvari I, 1087
Fong K-Y, 2268
Fonseca A, 1272
Font J, 1552
Ford-Hutchinson AF, 2659
Formica MK, 1222
Førre Ø, 386, 1602
Forrester DM, 2713
Forsblad D'Elia H, 1456
Forslind K, 2590
Fortin PR, 1011, 1657, 1871, 1875 (ab), 1878 (ab), 1886 (ab), 1888 (ab), 1967, 2112, 2385
Forys KL, 2257
Foulc P, 1811
Fox DA, 1464
Fox PC, 1267
Fraenkel L, 443
Fraga A, 2182
Frank C, 575
Franke A, 2186
Fraser A, 260
Fraser PA, 276
Frati E, 200
Frazer DH, 412
Frears ER, 2540
Freed GL, 2700
French Group for Quality of Life Research, 1054
Freundlich B, 36

Fricton J, 1841
Fried LP, 114
Fries JF, 167, 1130, 1891, 2226
Friman C, 468
Fritzler MJ, 1876 (ab), 2374, 2613
Fuchs D, 1935
Fujii H, 1524
Fujii T, 2673
Fujimoto J, 1093
Fujimoto M, 1524
Fujisaku A, 1253
Fukuchi M, 1036
Fulminis A, 1122
Funaki H, 2207
Funauchi M, 207
Furst DE, 449, 1630, 1875 (ab), 2123, 2563
Furuse S, 1524
Furuzawa-Carballeda J, 256

G

Gabriel SE, 886, 891, 1739, 1940, S68–1, S68–26
Gabrielli A, 1122
Gaines JM, 1571
Galeazzi M, 1244
Galindo-Rodríguez G, 2382
Galluzzi F, 179
Galluzzo S, 220
Gan X, 1451
Gangji V, 348
Gano AD Jr., 1739
García-Carrasco M, 1552
Garcia-de la Torre I, 1491
García-Laorden MI, 740
Garcia-Porrua C, 913, 1548, 2019, 2729
Gardam M, 1397
Garg N, 1793
Garratt AM, 764
Garrett ES, 114
Garza-Elizondo M, 193, 2725
Garzia P, 220
Gattinara M, 579
Gay RE, 146
Gay S, 146
Gaylis N, 407
Gazarian M, 594
Genant HK, 1102, 1364, 1366, 1376, 1385, 1387
Gendi NST, 632
Generini S, 1231
Gennari C, 1298
Gennari L, 1298
Genovese M, 449, 2547
Gentiel A, 2710
Georgountzos A, 1589
Geraci S, 1298
Gérard N, 2585
Gerloni V, 579
Gershoni-Baruch R, 308
Gervais R, 1882 (ab)
Ghaussy NO, 1215
Gheith R, 1081
Giacomelli R, 1122, 1231
Giacosa R, 618
Giacovelli G, 1043
Giannini EH, 603
Giasi V, 1626
Gibson T, 518
Gignac MAM, 2299, 2476
Gijón-Baños J, 1272
Gilkeson GS, 60, 276
Gindl S, 2506
Ginsburg WW, 191, 2283
Giordano N, 1298
Giovanni A, 2716
Giustino J, 1878 (ab)
Gladman DD, 4, 288, 292, 1011, 1022, 1356, 1880 (ab), 1881 (ab), 1884 (ab), 1885 (ab), 1888 (ab), 1955, 1960, 1977
Glazier RH, 1846
Gleich GJ, 89
Glinska O, 1997
Glossop JR, 1406
Glueck CJ, 783
Glynn RJ, 792
Goel A, 1090
Goeree R, S68–21
Goh PS, 634
Goktan C, 352
Gold RH, 705
Goldbach-Mansky R, 41
Goldenberg DL, 151, 809
Goldstein R, 1173
Gómez-Reino JJ, 102
Gonzalez A, 102
González S, 505
González-Álvaro I, 697, 1436
González-Escribano MF, 1770
Gonzalez-Gay MA, 913, 1548, 2019, 2729
Goodman SB, 326, 829, 2547
Gordon C, 1878 (ab)
Gordon DA, 1665, 1851, 1874
Gordon TP, 2296, 2374, 2406
Goto D, 2524
Goto T, 2193
Goudreau L, 2218
Goulet J-R, 1011, 1878 (ab)
Goupille P, 2344
Gourley M, 41
Goyal M, 2070
Gracely RH, 567
Graham ID, 575, 1878 (ab)
Grahame R, 799
Grainger A, 238
Grambow SC, 2201
Granata OM, 2597
Granel B, 2716
Grant E, 1875 (ab)
Granton JT, 1881 (ab)
Grassi W, 908
Grattagliano V, 2710
Graus F, 1552
Green LM, 993
Green P, 1882 (ab)
Greenberg PE, 1318
Greer W, 2521
Griffiths I, 238
Grigolo B, 345
Grimshaw J, 575
Griosios K, 260
Grisius MM, 1267
Grodzicky T, 1878 (ab), 1886 (ab)
Grolleau J-Y, 2165
Grypiotis P, 2079
Guarnieri MV, 2718
Guérin V, 1963
Guess HA, 1196
Guevara-Gutierrez E, 1491
Guh D, 1883 (ab)
Guillemin F, 891, 1054, 1886 (ab), 2585
Guillevin L, 1344
Guillou GB, 1825
Gulan G, 660
Gulko P, 41
Guthrie JA, 1888 (ab)

H

Haagsma CJ, 2325
Hada T, 1036
Hadler NM, 1668
Hafström I, 1748, 2338, 2590
Haga H-J, 207
Haider MZ, 2705
Haig A, 829
Haines CJ, 1479
Hajeer AH, 913
Hajidiacos NP, 1886 (ab)
Hakala M, 74, 2296
Hallgrímsson B, 2659
Halser F, 680
Hamada H, 2553
Hamano T, 1093
Hamidou MA, 1811, 2165
Hamilton SF, 1885 (ab), 1948, 2529
Hamra R, 1888 (ab)
Han X-H, 2245
Hangartner TN, 329
Hanly JG, 1875 (ab), 1882 (ab), 1990
Hannah M, 1883 (ab)
Hannonen P, 2580
Haralambous S, 652
Haraoui B, 1882 (ab)
Hardin JA, 2374
Harding S, 1877 (ab)
Harris C, 779, 1227
Harris-Love M, 603
Hart BL, 1983
Hart DJ, 799
Hart LE, 1006
Haruda Y, 1782
Harvey B, 1846
Hasegawa J, 474
Hasegawa M, 1524, S67–48
Hashimoto A, 1712
Hashimoto H, 998, 1208, 1534
Hashimoto N, 1093
Hashkes PJ, 597
Hassell AB, 1406
Hatachi S, 1410
Hatamochi A, 1253
Hatano H, 2207
Hatcher-Roberts J, 575
Hausfater P, 1473
Hauzeur J-P, 348
Hawker GA, 1846
Hay EM, 2694
Hayami T, 2207
Hayami Y, 1520
Hayashi I, 1712
Haynes DR, 2319
Haywood KL, 764
Hazes JMW, 902
Haznedaroglu IC, 313
He QW, 1879 (ab)
He Y, 465
Hedman K, 459
Hefferton D, 1885 (ab)
Hei Y-J, 355
Heiberg T, 868, 873, 1115
Heide L, 1125
Heim HM, 1733
Hein G, 2350
Helbling M, 2095
Helders PJM, 1075
Helfgott S, 2315
Hellio Le Graverand-Gastineau MP, 1880 (ab)
Helliwell PS, 7, 2356, 2645
Helmick CG, 160
Helmke K, 2157
Henderson M, 139
Hengstman GJD, 1892
Henrotin YE, 1043, 1825, S67–14
Her Majesty the Empress of Japan, S67–3
Herborn G, 1102
Herlin T, 2275
Hernández-García C, 1436
Herold M, 1935
Héron E, 1344
Herr A-L, 2385
Hewlett SA, 868, 877, 880, 1115
Hezode C, 1624
Hibbert J, 518
Hidalgo V, 1272
Higgins GC, 394
Hill BS, 60
Hillner BE, 132
Himori K, 2218
Hinsenkamp M, 348
Hirakata M, 2082
Hiraki Y, 2207
Hiramitsu T, 1164
Hirani N, 1960
Hirata G, 1280
Hirataka M, 2673
Hirokawa K, 998
Hirsch R, 41
Hirvonen H, 1928
Hisamichi S, 747
Hissaria P, 948

Hitora T, 1097, 1351
Ho CTK, 1513
Hoang S, 2535
Hobbs MR, 60
Hochberg MC, 1648, 1739, 2257
Hoekstra M, 2325
Hoey J, 1661
Hoffman GS, 1017, 1541
Holman AJ, 2733
Holman HR, 1130
Homaidan F, 1888 (ab)
Honda I, 1032
Hong P, 815
Honjo T, 1410
Hoogen VD, 1875 (ab)
Hooiveld M, 339
Hopman W, 1879 (ab)
Horiuchi K, 1799
Houssaint E, 1673
Howard P, 829
Howell KJ, 720
Hrycaj P, 204
Hsu B, 1191
Hsu CM, 321
Hsu FC, 455
Hu C-J, 438
Huang D, 1541
Huang F, 2627
Hudson M, 2385
Hughes GRV, 897, 985
Hughes L, 972
Hughes R, 868, 880
Huh S-J, 1203
Hui BK, 1887 (ab)
Huikuri HV, 74, 2296
Huizinga TWJ, 1904
Hukkanen MVJ, 652, 2033
Hulme J, 575
Hum V, 1879 (ab)
Hummel K-M, 1918
Humphrey-Murto S, 1881 (ab)
Hunder GG, 1119
Hungerford DS, 783
Hurwitz S, 809
Husby G, 283
Huse DM, 714
Hutton E, 1883 (ab)

I

Iannone F, 2294, 2710
Iazzetta J, 2503
Ibañez D, 288, 1880 (ab), 1881 (ab), 1884 (ab), 1955, 1960, 1977
Ibrahim R, 2385
Ibrahim SA, 1305
Ignat GP, 1761
Ikeda K, 998
Ikenoue T, 326
Imai N, 1426
Ingegnoli F, 1611
Ingelmo M, 1552
Inman RD, 1291, 1356, 1628, 1887 (ab), 1888 (ab), 2112
Inoue H, 247
International Myositis Assessment and Clinical Studies Group, 603
Ioan-Facsinay A, 1904
Ioannidis JPA, 979
Ionescu M, 544, 1880 (ab)
Isenberg DA, 603, 1878 (ab)
Ishikawa K, 404
Istok R, 2027
Itoman M, 1712
Iverson K, 1397
Iwai Y, 1410
Iwamoto Y, 1280
Iwaniec T, 723
Iwasaki H, 1032
Iwasaki T, 1093

J

Jablonska S, 1997
Jacobs C, 449
Jacobson LD, 1354
Jadad A, 575
Jalby J, 1951
James P, 575
Jansen LMA, 1691
Jantti JK, 1393
Jara LJ, 2140
Jarrett SJ, 2287
Jarry A, 1811
Jasin HE, 1680
Jauregui E, 1883 (ab)
Jeanes D, 575
Jee S, 2700
Jerome D, 480
Jiang X-R, 89
Jimenez SA, 1616, 1994
Jiménez-Balderas FJ, 2182
Jin T, 1719
Jirik FR, 2659
Joe G, 603
Joffe BI, 1403
Johnson Kent, 1110, 1115
Johnson Kenneth L, 89
Johnson SR, 863, 1881 (ab), 2503
Johnston V, 386
Johnstone R, S67–59
Jones H, 518
Jones JV, 1658
Jones LC, 783
Jones PF, 260
Jones S, 96
Jong P, 1883 (ab)
Jorapur V, 1793
Joseph L, 1505, 1756, 1876 (ab), 1878 (ab)
Joshi VR, 1121
Jousse S, 2535
Juarez L, 2680
Juby AG, 1881 (ab)
Judd MG, 575
Juhani Airaksinen KE, 2296
Julkunen H, 1928
Julovi SM, 1164
Jurik A, 1102

K

Ka T, 1036
Kaarela K, 1393
Kaarud S, 884
Kaburagi Y, 1524
Kaburaki J, 2392
Kagal AD, 423
Kahan A, 68, 1395
Kaipiainen-Seppänen O, 2460
Kakehi T, 1426
Kakishita E, 1093
Kalden JR, 2374
Kalk WWI, 206
Kalyoncu M, 2292
Kamatani N, 1157, 2369
Kamel M, 774
Kamphuis SSM, 2059
Kanamaru A, 207
Kane D, 966
Kanegae F, 1782
Kaneko Y, 404, 857
Kaplan B, 1884 (ab)
Kapur S, 1881 (ab)
Kara M, 1948
Karamitsos D, 1589
Karanikolas G, 1589
Karassa FB, 979
Karsh J, 1356
Karvosky ME, 529
Kasapçopur Ö, 2724
Kaser S, 1935
Kaskani E, 1589
Kassis J, 2385
Kataria RK, 1354
Kato H, 247
Katrib A, 10
Katsimpri P, 731
Katsumata S, 474
Katz A, 1888 (ab)
Katz JN, 1657, S68–12
Katz S, 1887 (ab)
Kaufman D, 2234
Kaufmann J, 2350
Kautiainen H, 459, 2580
Kavanaugh AD, 449, 1394, 1739
Kawaguchi Y, 1253
Kawakami Y, 2392
Kawamoto T, 1097, 1351
Kawano S, 1410
Kawasaki A, 1534
Kaya M, 1036
Kaziolas G, 1589
Kazma I, 1888 (ab)
Keat A, 779
Kedem R, 2620
Keller C, 2590
Kellner H, 196
Kellner W, 196
Kelly JP, 2234
Kennedee R, 1884 (ab)
Kenzian H, 2506
Kerrigan DC, 529
Keystone EC, 934, 1881 (ab), 1882 (ab), 1888 (ab)
Khamashta MA, 985
Khan M, 1022
Khanna D, 1248, 1864
Kherani RB, 1883 (ab)
Khoor A, 191
Khraishi MM, 1885 (ab), 2529
Kidd BL, 139
Kielstein V, 2350
Kikuchi K, 1253
Kikuchi M, 1032
Kilian S, 2350
Kim HA, 550
Kim HM, 1464
Kim S-J, 1529
Kim S-S, 2422
Kim W-U, 1529
Kim YH, 550
Kindopp-Bugo K, 1876 (ab)
Kinne RW, 1680
Kinoshita K, 207
Kiraz S, 313
Kirazli S, 313
Kirwan J, 868, 880, 1110, 1115
Kishimoto T, 22, 1426
Kitamura K, 2553
Kitano M, 1093
Kitasato H, 1712
Kitti U, 2033
Kitumnuaypong T, 1191
Kivitz A, 449
Klareskog L, 1748
Klarlund M, 1364, 1366, 1376, 1385, 1387
Klarskov K, 89
Kleen M, 1029
Klestov AC, 1733
Klinkhoff A, 1875 (ab), 1876 (ab)
Kneer J, 680, 2123
Koarada S, 1782
Kobayashi Hideyuki, 22
Kobayashi Hiroki, 2075
Kobayashi M, 1410
Kobayashi S, 1534
Koh D-R, 2268
Koivula M-K, 468
Koizumi K, 2369
Kojo S, 2524
Koks CHW, 2080
Koldingsnes W, 80, 283
Kollias G, 652
Komiyama Y, 1911
Kondeatis E, 518
Kondo H, 1253, 1712
Kondo J, 2207
Kono S, 1712
Kontelis L, 1589
Kontoyanni A, 1589
Konttinen YT, 468, 652, 2033
Koren G, 594
Korendowych E, 96
Koshiba M, 1410
Kostense PJ, 2080
Kotsis SV, 1788
Kovac SH, 2680
Kowalchuk RM, 121

Koziol JA, 2374
Koziolek M, 1918
Krachtis P, 1589
Kraemer MHS, 2511, 2632
Krafchik B, 1877 (ab)
Krasu M, 1997
Kremer JM, 2308
Krishna M, 2283
Krisnani N, 948
Kristinsson J, 2275
Krizova A, 480, 815
Kröger I, 2460
Królicki L, 1997
Kruijens MWM, 2325
Kuamgai S, 1410
Kubes P, 1876 (ab)
Kuis W, 2059
Kumai T, 508
Kunisch E, 1680
Kurata JH, 2103
Kurisu Y, 747
Kuritani T, 1426
Kuroiwa T, 404, 857
Kurosaka M, 1097, 1351, 1410
Kurtin P, 394
Kutluk T, 2011
Kuwana M, 1253, 2392, 2673
Kuykendall DH, 534
Kuzis S, 2732
Kvasz A, 2452
Kvern B, 1888 (ab)
Kvien TK, 868, 873, 1135, 2585
Kvist G, 1456
Kwoh CK, 1305
Kyogoku C, 1534

L

La Montagna G, 2147
Laasonen L, 468
Laboisse C, 1811
Labrie F, 2413
Lacaille D, 1883 (ab)
Lachenbruch PA, 603
Lacki JK, 204
Lacoste D, 2005
Lafeber FPJG, 339, 648, 1147
Lahdenne P, 2275
Lahita RG, 2374
Laina G, 731
Laing H, 985
Lam P, 2039
Lamarque D, 2428
Lambotte O, 1027
Lampa J, 1748
Landewé R, 44, 2469
Lange K, 2319
Langevitz P, 185, 2620
Lapadula G, 2294, 2710
Lapégue F, 671
Lapp V, 1880 (ab)
Lardé A, 671
Larsen A, 1456
Laskin CA, 2127
Lassere MND, 1102, 1110, 1115, 1364, 1366, 1376, 1380, 1385, 1387, 1648
Lau CS, 1513
Lau JT-C, 1440
Lavielle P, 1584
Lavine E, 2070
Laxer RM, 594, 1875 (ab), 1885 (ab)
Le Goff P, 2535
Le Henaff C, 2535
Le Moel G, 1027
Le TB, 783
Le Thi Huong D, 1473
Leakan RA, 1267
Ledochowski M, 1935
Lee E-O, 2039
Lee K-H, 1203
Lee L, 2070
Lee MS, 326
Lee P, 863, 1888 (ab)
Lee Soo-K, 2422
Lee Shin-S, 1529
Lee TH, 1133
Lee W-L, 2257
Lee Y-M, 2422
Leff RL, 544
Lehman AJ, 465, 1875 (ab)
Lehtinen K, 1393
Leirisalo-Repo M, 459, 1928
Lejeune E, 2452
Lelas JL, 529
Lelorier J, 1877 (ab)
Lemaréchal H, 68
Lemmel E-M, 2572
Lems WF, 2080
Leong A, 884
Lertmaharit S, 2365
Lesslie J, 1857
Lester S, 2406
Letellier E, 897
Leung FK, 1871
Levesque MC, 60
Levin R, 792
Levy G, 2241
Lewis D, 523
Lewis M, 2694
Lewtas J, 1890
Li EK, 1479
Li LC, 1883 (ab), 1886 (ab)
Li S-C, 2268
Li Tsai-C, 841
Li Tian-F, 2033
Li XY, 1886 (ab)
Liang MH, 1657, 1739
Lidar M, 308, 2620
Lidgren L, S67–4
Liebling MR, 1864
Lien G, 386, 1602
Ligier S, 41
Liljeström M, 2033
Lin C-C, 841
Lin C-H, 438
Lin H-S, 2627
Lin Y, 465
Linberg JV, 625
Lindsley C, 394
Ling SM, 114, 1571
Liozon E, 1272, 2077
Lipsky PE, 1394
Liu C-S, 841
Liu H-W, 438, 1120
Liu Y, 2245
Livneh A, 185, 308, 2620
Llorca J, 913, 1548, 2019
Lodder MC, 2080
Loeser RF, 1565
Longy-Boursier M, 1963
López-Lagunas I, 505
López-Larrea C, 505
Lorig K, 1130
Lotaif A, 364
Louie JS, 1864
Louis M, 2557
Lourenço DM, 2606
Loustaud-Ratti V, 1272
Lovell DJ, 394
Lowensteyn I, 1879 (ab), 2476
Lucidarme N, 2492
Luft LM, 2613
Lum CA, 2713
Lunardi C, 1907
Luo N, 2268
Luosujärvi R, 2460
Lupi E, 579
Lupisella JA, 355
Ly K, 1272

M

Ma T, 2547
Macchioni P, 760, 2160
MacDonald B, 829
Macfarlane GJ, 958
MacGregor AJ, 720
Mackay K, 316
Madhok R, 2085
Madson K, 394
Maeda K, 1426
Maekawa K, 364
Maetzel A, 886, 891, 1883 (ab), 1886 (ab), 1887 (ab), S68–26
Magari K, 2193
Maguire L, 1883 (ab), 1886 (ab)
Mahmoud G, 1081
Mahomed NN, 1657
Mai T, 523
Maier M, 1029
Maier-Bosse T, 1029
Maini RN, 2374
Majchrzak B, 934
Maksymowych WP, 206, 430, 941, 1356, 1878 (ab), 1883 (ab)
Malleson PN, 585, 832, 1881 (ab)
Mallon C, 941
Manadan AM, 1227
Mancini A, 1879 (ab)
Mandelin J, 468, 2033
Manganelli P, 618
Manganelli S, 200
Mangge H, 2506
Manguso F, 2638
Manicourt D-H, 2444
Manners P, 1857
Mannik M, 1495
Manolova IM, 2078
Mansour R, 774
Maradit Kremers H, 1940
Marcelis A, 2444
March L, S68–26
Marcolongo R, 200, 1244
Margolin L, 628
Marhaug G, 2275
Marshall N, 238
Martín J, 435
Martin LO, 1876 (ab), 1884 (ab), 2613
Martin RW, 691
Martinelli N, 298
Martínez H, 1584
Martin-Garcia N, 2428
Martini A, 1611, 1900
Martini G, 2720
Martín-Mola E, 1272
Marui T, 637, 1097, 1351
Masi AT, 2302
Masi L, 179
Massa M, 1611
Massabki PS, 2606
Masuda I, 1032
Masuda M, 1911
Matesanz F, 435
Mathieu A, 985, 1120
Mathieu J, 1886 (ab)
Matovinovic D, 660
Matsos MP, 1885 (ab)
Matsudaira R, 1208
Matsui T, 1712
Matsumoto T, 860
Matsumoto Yoshifuji, 1520
Matsumoto Yoshihiro, 1280
Matsuo A, 1280
Matsuo M, 247
Matsushita M, 1208
Matsuura E, 1782
Matteson EL, 449, 1119
Mattey DL, 1406
Matthias T, 2157
Mattsson L-Å, 1456
Matucci-Cerinic M, 1122, 1231
Mayorga J, 1491
Mazzaro C, 1775
McAlindon TE, 1222
McCall-Hosenfeld JS, 809
McCown C, 247
McCune WJ, 1508
McCurdy D, 394
McDougal JS, 2374
McEvoy D, 2406
McGowan JA, S67–62
McHugh N, 96
McKendry RJ, 1881 (ab)
McMahon M, 1822
McNeil HP, 10
McQueen F, 1102, 1364, 1366, 1376, 1380, 1385, 1387

Medina G, 2140
Meijerink J, 449
Meliconi R, 2160
Mellgren SI, 283
Mellors R, 884
Mellström D, 1456
Ménard HA, 1884 (ab), 1886 (ab)
Mendez C, 2140
Meng J-M, 2245
Menke DM, 1347
Mercado U, 2078, 2295
Meredith MP, 329
Merkel PA, 1630
Merlino L, 952
Merlotti D, 1298
Merrill CE, 1495
Messner R, 1841
Messori A, 1231
Metge C, 1888 (ab)
METGO Study Group, 1875 (ab)
Metter EJ, 1571
Metyas SK, 2713
Meyer JM, 329
Meyer O, 2344
Michaud K, 1725
Michel BA, 146
Michel M, 1624
Michet CJ, 846
Middel P, 1918
Mielants H, 2306
Miele M, 2597
Migliore L, 1244
Mikkelsen K, 1135
Mikuls TR, 952, 2680
Mili F, 160
Miller FW, 603
Miller JD, 714
Milz S, 508, 1420
Mima T, 22
Mimori T, 2673
Min D-J, 1529
Min S-Y, 1529
Minami Y, 747
Minh Hoa TT, 2252
Minnock P, 868
Minshall ME, 1579
Mintz A, 941
Miossec P, 2294
Misaki Y, 1253
Misra R, 105, 415, 948, 1248
Mitchell H, 880
Mitroi E, 1888 (ab)
Mittal G, 1121
Mitui K, 2207
Miyanishi K, 2547
Miyata S, 2193
Mocci S, 449
Mockenhaupt M, 2234
Mohseni M, 276
Mok CC, 1513
Molano ID, 60
Molina JA, 1552
Monach PA, 851
Mont MA, 783
Moore AD, 1505, 1876 (ab)
Moore TL, 394
Moreau A, 2165
Morel J, 1485
Moreland LW, 691, 2420, 2680
Morely MA, 1318
Morgan E, 2420
Morgenstern KE, 625
Moriarty DG, 160
Moriggl B, 508
Morimoto T, 1911
Morinobu S, 1410
Moriwaki Y, 1036
Morlat P, 208, 2005
Morozzi G, 1244
Morrice D, 575
Morris AJ, 1890
Moseley JB Jr., 534
Möttönen T, 2580
Motyl A, 723
Moulin G, 2716
Moum T, 386
Moyer RA, 849
Mroue KH, 2722
Msika P, 1825
Mugford M, 2485
Mugitani M, S67–47
Muirden KD, 2312
Mulcahy D, 1440
Müller GA, 1918
Muñoz-Fernández S, 1272
Muñoz-Gomariz E, 2729
Muñoz-Villanueva MC, 2729
Mur E, 1935
Murakami T, 247
Murakami Y, 1712
Musial J, 723
Mussini J-MG, 1811
Mutoh S, 2193
Myckatyn SO, 736
Myers LK, 394

N

Naber T, 232
Nadler JN, 2127
Nagasawa K, 1782
Nagashima M, 474
Nagira K, 1097, 1351
Nahm D-H, 2422
Naito M, 1032
Nakagawa A, 1351
Nakagawa T, 1164
Nakamoto K, 1911
Nakamura K, 2673
Nakamura Takashi, 1164
Nakamura Toshitaka, 559
Nakelsky ND, 1739
Nalbant S, 1191
Naniwa T, 1520
Nardacchione R, 2170
Nascimben F, 1775
Nassanov EL, S67–56
Natour J, 1060
Naylor S, 89
Nemec B, 660
Nemoz C, 1951
Neogi T, 1884 (ab)
Neri TM, 618
Neurauter G, 1935
Neville C, 2385
Newman B, 305
Ng S-C, 2268
Ngoc An T, 2252
Niccoli L, 760
Nicoli D, 2160
Nielsen S, 2275
Niemelä RK, 74, 2296
Nietert PJ, 1238
Niimi T, 1520
Nikolia Z, 1589
Nir-Paz R, 1119
Nishida K, 247
Nishigaki F, 2193
Nishijima T, 474
Nishikai M, 1124
Nishimoto N, 1426
Nishimura A, 1712
Nishimura N, 1911
Nishioka K, 22
Nissinen R, 1928
Nityanand S, 1793, 2023
Nixon NB, 1406
Noel E, 1951
Nojima T, 2673
Nojima Y, 404, 857
Nordborg E, 1456
Nordic Study Group, 2275
Nordvåg B-Y, 1135
Norimura T, 559
Nossent JC, 80
Nozaki Y, 207
Nuenninghoff DM, 1119
Núñez-Roldán A, 1770
Nuralim H, 2437, S67–51

O

Oates JC, 60
Obelieniene D, 1882 (ab)
O'Brien BJ, S68–21
O'Connor P, 1364, 1366, 1376, 1385, 1387
Oddone EZ, 2201
Ödemis E, 2292
Oen K, 585, 832, 1887 (ab)
Offer R, 1877 (ab), 1878 (ab)
Ofman JJ, 1739
Ogata A, 1093
Ogawa R, 1911
Ogiuchi H, 1157
Oglesby AK, 1579
Oh M, 705
Ohjimi Y, 1032
Ohkubo Y, 2193
Ohlsson C, 1456
Ohno M, 207
Ohosone Y, 2673
Öhrsvik L, S67–41
Ohshima S, 22
Ohta A, 1782
Okamoto H, 2369
Okamoto T, 1157
Okazaki K, 559
Ökten A, 2292
Okuda K, 1911
Okur H, 2011
Okuzawa C, 857
Oliveira L, 1060
Olivieri I, 760, 1626
Olivieri J, 2680
Oliviero F, 420
Ollier WER, 913, 2019, 2729
Olsen N, 449
Olszynski W, 1877 (ab), 1886 (ab)
O'Malley KJ, 534
Omdal R, 283
OMERACT 6 Economics Research Group, 891
Ootsuyama A, 559
Opara R, 55
Oppermann M, 2157
Oriente A, 2638
Oriente P, 2638
Orozco-Barocio G, 1100
Ortego Centeno N, 1657
Ortiz-Alvarez O, 1881 (ab)
Osiri M, 1182
Osman EM, 632
Østergaard M, 1102, 1364, 1366, 1376, 1380, 1385, 1387
Ostrowski J, 355
Ou R, 465
Ou T-T, 438
Ouimet JM, 480, 815
Oyen WJG, 232
Özbalkan Z, 313
Ozen S, 2011, 2014
Ozmen B, 352
Öztürk MA, 313

P

Pacheco-Tena C, 1888 (ab), 2112
Padeh S, 185
Padula A, 760, 1626
Page GP, 60
Paik D-J, 1203
Palacio LG, 2152
Palerme J-S, 1875 (ab)
Palferman TG, S67–10, S67–33
Palmer JR, 1222
Palosuo T, 1928
Panaritis T, 1886 (ab)
Panda M, 2508
Pandey JP, 2392
Pannarale G, 2710
Pantelidou K, 1589
Panush RS, 202
Papadopoulos NG, 2641
Papaioannou A, 1883 (ab)
Papas AS, 2413
Paradis M, 1886 (ab)
Park GS, 705
Park H-S, 2422
Park KM, 567
Park K-S, 1529

Park S-H, 1529
Parra Ruiz J, 1657
Passo M, 394
Pastoureau P, 1561
Patberg WR, 2728
Patel DD, 412
Patino FG, 2680
Pato E, 1436
Paty J Jr., 2508
Paulus HE, 705, 2123
Payne U, 1291
Pearson RM, 139
Pease C, 417
Pelkonen P, 2275
Peluso R, 2638
Pencharz JN, 1883 (ab), 1886 (ab)
Penrod JR, 1878 (ab), 1886 (ab)
Pepmueller PH, 394
Pérez-Aciego P, 740
Pérez-Guijo V, 2729
Perez-Ordonez B, 2070
Pérez-Rodríguez ME, 2182
Peris P, 2624
Perlemuter G, 1473
Perrot S, 1054
Persellin ST, 191, 1347
Persoli L, 2511, 2632
Person S, 2680
Peschken CA, 1886 (ab)
Peter HH, 2157
Peterfy C, 1102, 1364, 1366, 1376, 1385, 1387
Peterlana D, 1907
Peters ACB, 2059
Petit E, 926
Petri M, 783, 1878 (ab)
Pettitt D, 203, 714
Petty RE, 585, 832, 1663, 1881 (ab)
Petzke F, 567
Peyrat MA, 1673
Pfadenhauer K, 2177
Pham T, 1648, 1885 (ab)
Pham TNQ, 2529
Phan X-V, 1395
Phatak PD, 121
Piccardi N, 1825
Piccoli A, 2170
Pidoux I, 1880 (ab)
Pierlot C, 926
Piertini U, 1231
Piette J-C, 1027, 1473
Pignatti P, 1611
Pignone A, 1231
Pijpe J, 206
Pile KD, 2406
Pilkington C, 603
Pillemer SR, 41, 1267
Pincus T, 1138
Pineau C, 1756, 1876 (ab)
Pineau J-J, 2005
Pirc L, 1877 (ab), 1878 (ab)
Pistorio A, 1611
Pisu M, 1
Pitzalis C, 1611
Platts LAM, 652
Platts RG, 1259
Ploski R, 386
Podack ER, 660
Polak JM, 652
Polisson R, 2123
Politi EN, 731
Poole AR, 544, 1880 (ab)
Pope JE, 480, 815, 1875 (ab), 1885 (ab)
Porciello G, 1244
Porter GG, 2645
Pou A, 1552
Pouchot J, 1054
Pöyhiä R, 154
Pozzato G, 1775
Prakken ABJ, 1075, 2059
Pras E, 185
Pras M, 185, 2620
Prasad K, 105
Prashker M, 1739
Prieur A-M, 2492
Prince RL, 2689
Pruijn GJM, 1696
Psychos DN, 2641
Puccetti A, 1907
Pucino F, 41
Pulsatelli L, 760, 2160
Punzi L, 420
Puolakkainen M, 459
Putz R, 1420

Q

Qualls CR, 1215
Qualman A, 575
Queiro R, 505, 2510
Quest E, 884
Quilty B, 1311
Quinn MA, 2287
Quismorio FP Jr., 2713

R

Raats JMH, 1696
Rabinovich E, 394
Radstake TRDJ, 926
Rahman P, 1885 (ab), 1955, 2529
Rahme E, 1877 (ab)
Rajan R, 1505, 1876 (ab)
Ramanan AV, 401, 1885 (ab), 1887 (ab), 2513
Ramonda R, 420
Ramos-Casals M, 1552
Ramsey-Goldman R, 1505, 1876 (ab)
Rangno K, 1889 (ab)
Rantanen T, 114
Rapti A, 731
Rasheed M, 1994
Rashid T, 972
Rasker JJ, 2437, S67–51
Rat A-C, 1761
Rau R, 680, 1102, 1108, 1891
Rauch J, 1875 (ab), 1882 (ab), 2385, 2557
Ravaud P, 421
Ravlic-Gulan J, 660
Raya Alvarez E, 1657
Raymond Y, 1875 (ab), 1886 (ab)
Raza AS, 2713
Rbeiz JG, 2722
Reczek PR, 355
Reece R, 260
Reed M, 585, 832
Reeves WH, 2374
Reginster J-YL, 1043, 1825, 2452, S67–14
Regula D, 2547
Reinalda MS, 1940
Reiner A, 544
Reinhardt PH, 1876 (ab)
Reisine S, 2045
Renard M, 1963
Renaudin K, 1811
Rennebohm R, 394
Renoux V, 1561
Resplandy F, 1963
Rethage J, 146
Reutter G, 1876 (ab)
Reveille JD, 1630
Reynolds WJ, 1659
Rheumatology Study Group 791, 680
Rheumatology Study Group 825, 2123
Rhodes T, 1196
Rhodus NL, 1841
Ricca L, 2092
Ricci M, 1907
Rich E, 1011
Richardson P, 534
Richardson VJ, 1885 (ab), 2529
Rider LG, 603
Riggin DL, S67–32
Rigon A, 220
Riley PO, 529
Rischmueller M, 2406
Risedronate OAW Study Group, 1877 (ab)
Risedronate VERT Study Group, 1886 (ab)
Riskalla MM, 1508
Ristelli J, 468
Ritter-Hrncirik CA, 329
Rivera D, 2152
Robbins DL, 55
Robertson S, 1173
Roberts-Thomson PJ, 2319
Robinson DB, 1886 (ab), 1887 (ab)
Robinson RL, 1318
Robinson V, 1110, 1115, 1182
Roche PA, 1733
Rodríguez-Gallego C, 740
Rodriguez-Herrera G, 851
Rodríguez-Pérez JC, 740
Roettcher PA, 394
Rogeberg S, 1748
Rogge L, 1611
Rondelli F, 497
Rönnelid J, 1748
Roosendaal G, 339
Ropp AM, 422
Rose AJ, S67–45
Rosenberg AM, 585, 832
Rosenberg L, 1222, 2718
Rosenblum AV, 1885 (ab)
Rosenthal AK, 420
Roseti L, 345
Ross JM, 121
Ross L, 121
Ross S, 1883 (ab)
Rostron J, 1259
Rothfield NF, 2374
Rothschild BM, 2095
Rothschild C, 2095
Roughley PJ, 910
Rovatri LC, 1043
Rovensky J, 2027
Rúa-Figueroa I, 740
Rubaltelli L, 2170
Rubin LA, 305
Rubinic D, 660
Ruffatti A, 2079
Ruiz JC, 2492
Ruiz-Sancho D, 1272
Rukavina D, 660
Russell AS, 206, 736, 941, 1356, 1877 (ab), 1878 (ab), 1882 (ab), 1883 (ab), 1887 (ab)
Russell MW, 714
Ryan D, 121
Ryan S, 880
Rygg M, 2275

S

Saadoun D, 1395
Saag KG, 1, 639, 868, 952, 2680
Sabatini M, 1561
Saeki K, 1032
Saeki Y, 22
Saito S, 1157, 1799
Saito T, 2369
Sakai A, 559
Sakata T, 559
Sakkas LI, 1994
Salazar-Exaire D, 2382
Salazar-Paramo M, 1491
Salemi S, 146
Salonen D, 1628
Salsano F, 1122
Salvarani C, 760, 2160
Samara AM, 2511, 2632
Sampaio-Barros PD, 2511, 2632
Sanchez C, 1825
Sánchez ML, 2182
Sánchez-Román J, 1770
Sanchez-Yamamoto D, 241
Sander O, 680
Sanderson J, 518
Sandhu JK, 1173
Sankar V, 1267
Sanmartí R, 697, 1436
Sanna G, 985

Santacroce C, 1298
Santavirta S, 2033
Santos-Ocampo AS, 638
Sany J, 1485, 2344
Sapp LR, 1335
Saraux A, 2535
Sasaki R, 1799
Sasaki T, 747
Sato B, 1426
Sato Shinichi, 1253, 1524
Sato Shinji, 2673
Sato Y, 2075
Satoh H, 1280
Saulquin X, 1673
Saura R, 1410
Savolainen E, 2460
Sawitzke A, 1127
Saxne T, 1456
Sbaï A, 1473
Scambi C, 298
SCAR Study Group, 2234
Scarano E, 1626
Scarpa R, 2638
Scarpato R, 1244
Schaeverbeke T, 1963
Scharf MB, 1070
Schauenstein K, 2506
Scheinberg MA, 2718
Scheithauer BW, 846
Schentag CT, 1022, 1880 (ab)
Schiff MH, 691, 2563
Schikler KN, 394
Schilling F, 636
Schlincker A, 1272
Schmid H, 196
Schmidt M, 2597
Schmidt PJ, 1983
Schmidt RE, 2157
Schmitt CA, 1029
Schneider R, 401, 594, 1875 (ab), 1885 (ab), 1887 (ab)
Schochet SS, 625
Schölmerich J, 269
Scholte HR, 2263
Schoutens A, 348
Schroecksnadel K, 1935
Schroeder ML, 585
Schulz CU, 1029
Schulz J, 1326
Schumacher HR Jr., 637, 1191, 1393
Schurman DJ, 326
Schwartz MM, 1227
Schwarz A, 1918
Schwarz G, 1918
Scilanga L, 1907
Scott CG, 1940
Scott DGI, 2485
Scudamore RA, 2521
Seavey WG, 2103
Sebaldt RJ, 2308
Sebastiani GD, 220
Seely BL, 1565
Seetharaman M, 630
Segami MI, 1878 (ab)
Séguin C, 2385
Seidel L, 1043
Seigneur M, 1963
Seino T, 2075
Seitz M, 28
Seleznick M, 2092
Selvaag AM, 1602
Selvi E, 200
Senécal J-L, 1011, 1875 (ab), 1878 (ab), 1886 (ab)
Seo Y-I, 1529
Serratrice J, 2716
Sewitch MJ, 1326, 1887 (ab)
Sfriso P, 2170
Shah M, 1394
Shakhapur S, 238
Sharara NH, 2722
Sharp JT, 705, 1102, 1108
Shaulinsky J, 121
Shea B, 575, 868, 1110, 1115, 1182
Shen W, 1579
Sherry DD, 1335
Shi Y, 1451
Shi Y-Q, 2245
Shichikawa K, S67–65, S67–66
Shimizu M, 1164
Shinar Y, 185
Shinawi M, 308
Shindo H, 860
Shiokawa Y, S67–1
Shnier R, 1364, 1366, 1376, 1385, 1387
Shoenfeld Y, 214
Shojania K, 493, 1878 (ab), 1887 (ab)
Shono E, 1032
Shuto T, 1280
Sibbitt WL Jr., 1215, 1983
Sibilia J, 2344
Sicuteri R, 1231
Siegel R, 41
Sillers MJ, 2420
Sills JA, 1123
Silman AJ, 425, 902
Silva L, 1060
Silva NP, 2606
Silver RM, 1238, 2064, 2392, 2500
Silverman ED, 594, 1875 (ab), 1876 (ab), 1877 (ab)
Silverman SL, 1579
Simeoni S, 1907
Siminovitch KA, 305
Simon D, 2492
Simon L, 866, 1110, 1115, 1648
Simonini G, 179
Singh G, 714
Sinha N, 1793, 2023
Sinha R, 105
Sinigaglia F, 1611
Siozos C, 731, 2641
Sisitsky T, 1318
Skogh T, 459
Slavotinek J, 10
Slivka L, 2374
Smedeby B, 884
Smedstad LM, 2585
Smerdel A, 386
Smith AJF, 2296
Smith CD, 1011, 1881 (ab)
Smith EG, 60
Smith MD, 10, 2319
Smith N, 151
Smith RL, 326, 2547
Smith SA, 1990
Smith WR, 804
Smolen JS, 2374
Snowden N, 425
Söderlin MK, 459
Söderlund-Venermo M, 459
Sokka T, 1138, 2580
Solary E, 918
Solau-Gervais E, 671
Solomon DH, 203, 792, 851, 1133
Somers EC, 1508
Song Q, 1451
Song R, 2039
Song YW, 550
Soria P, 1272
Sørskaar D, 386, 1602
Sotosek V, 660
Souza AR, 1875 (ab)
Spady B, 1883 (ab)
Sparsa A, 2077
Spector TD, 720, 799
Speldewinde D, 1857
Spence D, 1877 (ab)
Spence M, 2241
Spencer C, 394
Spencer-Green GT, 691, 1885 (ab)
Spera L, 2700
Spermon N, 1075
Spitzer KA, 2127
Spondyloarthritis Research Consortium of Canada, 1356
Sporn MB, 211
Sprott H, 146
St. Clair EW, 276
St. John D, 849
Stäbler A, 1029
Stafford L, 10
Stagi S, 179
Stamps LD, 1495
Stancíková M, 2027
Stanwix AE, 1403
Starkebaum G, 455
Starrett JE, 355
Steber W, 1876 (ab)
Steer S, 518
Stefano R, 2597
Stein G, 2350
Stein L, 2700
Steinborn M, 1029
Stephenson B, 1725
Sterling L, 575
Stern RS, 2234
Stevens RM, 680, 2123
Stewart KE, 1006
Stewart N, 1364, 1366, 1387
Stoll T, 2133
Stone MA, 1356, 1628, 1887 (ab), 1888 (ab), 2112
Storino F, 1244
St-Pierre A, 1886 (ab)
St-Pierre Y, 1878 (ab), 1886 (ab)
Strand CV, 866, 1102, 1108, 1110, 1115, 1182, 1648, 2563
Straub RH, 269, 2597
Straus WL, 36
Strbo N, 660
Strosberg JM, 422
Struppler C, 196
Stuhlmeier KM, 2330
Sturrock RD, 966
Suarez-Almazor ME, 534, 868, 1182, 1630, 1739, S68–5
Subcommittee on Healing of Erosions of the OMERACT Imaging Committee, 1102, 1108
Suda A, 1060
Suemura M, 1426
Sugiura T, 404
Sugiura Y, 1520
Sugiyama M, 207
Suh C-H, 2422
Suh K, 1888 (ab)
Suh Y-J, 2422
Sullivan DA, 2413
Sullivan RM, 2413
Sultan N, 1875 (ab), 1885 (ab)
Sumida T, 2524
Sun S, 1884 (ab)
Sutcliffe N, 1878 (ab)
Suwa A, 2673
Suzuki N, 1782
Suzuki S, 2075
Svensson B, 2590
Svík K, 2027
Swadzba J, 723
Swiader L, 2716
Sychra JJ, 1761
Symmons DPM, 902, 958, 2485
Szepes Z, 2428
Szer I, 394

T

Taal E, 868
Tada Y, 1782
Tajima N, 2553
Takada I, 247
Takagi N, 1426
Takahashi H, 1911
Takahashi S, 1036
Takasaki Y, 998, 1208, 2374
Takehara K, 755, 1253, 1524
Takeuchi K, 998, 1208
Takken T, 1075
Talavera JO, 2182
Talbot LA, 1571
Tam L-S, 1479, 1955

Tamura S, 404
Tan EM, 2374
Tanaka S, 1712
Tancredi A, 2452
Tang F, 1451
Tarhan S, 352
Tarkowski A, 1719
Tarrant TK, 412
Tatsioni A, 979
Taupin J-L, 2005
Tavaniotou E, 1589
Tavernier T, 1951
Taylor D, 884
Taylor G, 316, 2054
Taylor WJ, 2645
Tebib J, 1951
ten Cate R, 825
Tena X, 697, 1436
Tengstrand B, 2338
Teodorescu M, 1761
ter Steege J, 1147
Terkeltaub R, 420
Thi Nhi C, 2252
Thibault V, 1473
Thiel C, 1087
Thomas E, 958
Thomas GN, 1479
Thomas-Golbanov CK, 1017
Thompson J, 1835
Thomson GTD, 1356, 1888 (ab)
Thomson W, 913
Thorel JB, 2535
Thorne A, 465
Thorne JC, 1882 (ab)
Thumboo J, 2268
Tian X, 1451
Tiittanen M, 1928
Tiliakos AN, 2727
Tiliakos NA, 2727
Tilley B, 41
Tillmann K, 1951
Tindall EA, 691
Tingey DP, 815
Tinturé T, 505
Tishler M, 2157
Tiwana H, 972
Tlacuilo-Parra A, 1100, 1491
Tobin T, 1885 (ab)
Tobin YM, 1885 (ab), 2529
Todd MD, 1565
Todesco S, 2079, 2170
Togashi R, 1782
Tokunaga Katsushi, 1534
Tokunaga Kunihiko, 2207
Tomatsu T, 1157, 1799
Tomlinson B, 1479
Toms A, 863
Tonkin C, 329
Topaloglu R, 2014
Toquet C, 1811, 2165
Torre JC, 505
Torres B, 1770
Tortolani D, 355
Tosteson ANA, S68–15, S68–31
Touchie C, 1881 (ab)
Toyama Y, 1799
Tramposch KM, 355
Tran Van Nhieu J, 2428
Treadwell EL, 276
Tregnaghi A, 2720
Trindade MCD, 326, 2547
Tripathy NK, 2023
Trontzas P, 1589
Trudel G, 2218
Tsai W-C, 438, 1120
Tsang IK, 465
Tsang LM, 1875 (ab)
Tsintzos S, 731
Tsuchiya N, 1534
Tsujita J, 1036
Tsukada Y, 404, 857
Tsurumoto T, 860
Tsutsumi A, 2524
Tsutsumi Z, 1036
Tucker LB, 1881 (ab)
Tucker M, 1311
Tugwell P, 575, 866, 886, 891, 1110, 1115, 1182, 1879 (ab)
Tunbridge D, 1857
Tüysüz B, 2724
Twe C, 364
Tympanidou M, 2641
Tyrrell PN, 1875 (ab)

U

Uaratanawong Somchai, 2365
Uaratanawong Somsri, 2365
Ubel PA, 1464
Uchiyama T, 1157
Udayaraj UP, 632
Udwadia Z, 1121
Ueda R, 1520
Ueki K, 404, 857
Uhthoff HK, 2218
UK Sjögren's Interest Group, 1259
Umeshita-Sasai M, 22
Unlu Z, 352
Urabe K, 1712
Urowitz MB, 288, 292, 1880 (ab), 1881 (ab), 1884 (ab), 1955, 1960, 1977
Urquhart J, 44
Ushiyama O, 1782
Uslan D, 804
Uthman I, 1888 (ab)
Uziel Y, 594, 597

V

Vaarala O, 1928
Vadacca M, 220
Vadillo C, 1436
Vadillo-Buenfil M, 2382
Vafiadou E, 1589
Valentini G, 1122, 1630, 2147
Valeriano J, 2078
Valim V, 1060
Valleala H, 468
Valls J, 1552
Valsakumar AK, 1793
van Bilsen J, 1147
van de Laar MAFJ, 2325
van de Putte LBA, 680, 926
van de Stadt RJ, 1691
van de Winkel JGJ, 648
van den Berg M, 339
van den Heuvel W, 2585
van den Hoogen FHJ, 1696
van Denderen JC, 1558
van der Auwera P, 680, 2123
van der Heijde DMFM, 44, 1102, 1648, 2469
van der Horst-Bruinsma IE, 1558, 1691
van der Linden SM, 44, 2186, 2469
van der Net J, 1075, 2059
van der Tempel H, 44, 2469
van Hung N, 2252
van Leeuwen M, 2585
van Pelt PA, 2080
van Riel PLCM, 232, 680, 1110, 1115, 2572
van Roon JAG, 648
van Rossum M, 825
van Schaardenburg D, 1691
van Soesbergen R, 825
van Venrooij WJ, 825, 1696
van Vollenhoven R, 449
Vanness DJ, S68–23
Varga J, 1761
Vasey FB, 2078, 2092
Vasoo S, 2268
Vaughan R, 518
Vaysburd M, 2713
Veale DJ, 260
Vela-Ojeda J, 2382
Vera-Lastra O, 2140
Vermeulen RCW, 2263
Vezzù M, 2170
Vianen M, 339, 1147
Vidal E, 1272, 2077
Villiger PM, 28, 2133
Vinje O, 386, 1602
Visentin MT, 2720
Vissink A, 206
Vo J, 1761
Vogl D, 269
Volpe A, 298
Voskuyl AE, 905
Voudouris C, 1589
Voulgari PV, 731, 2641

W

Wagner I, 1125
Wagner-Weiner L, 394
Wahid S, 1611
Wahl CL, 1880 (ab)
Wais T, 2133
Wakefield RJ, 417
Wakhlu A, 415, 948
Waldorf JC, 191
Walji S, 1888 (ab)
Walker JG, 2406
Wallace C, 394
Wallace DJ, 1897
Walsh SJ, 2045
Waltbrand E, 1456
Wang BWE, 899
Wang Ping, 783
Wang Peizhong P, 126
Wang Z, 465
Wanten GJA, 232
Ward MM, 2732
Ward RJ, 329
Wardhani E, S67–54
Ware M, 1882 (ab)
Warrington KJ, 846
Wassenberg S, 1102, 1891
Wasserman MJ, 1888 (ab)
Watanabe H, 2075
Waterloo K, 283
Waterman SA, 2296, 2406
Watson DJ, 1196
Watson J, 1948
Watts WN, 1877 (ab)
Wauben M, 1147
Weaver AL, 691
Weber DA, 1888 (ab)
Weber H, 2177
Wechsler B, 1473
Weedon H, 2319
Wegrzyn J, 2294
Wei JC-C, 2627
Wei N, 449
Weil J, 1087
Weiller PJ, 2716
Weinberg JB, 60
Weinblatt M, 2123
Weisbart RH, 993
Weisman MH, 449, 1739, 1897, 2123
Weissman B, 1102
Welch V, 886
Wells GA, 575, 1110, 1115, 1182
Wener MH, 1495
Western Consortium of Practicing Rheumatologists, 705
White AG, 139
White B, 2398
White KP, 1835
White PD, 139
Whittle B, 2428
Wichmann I, 1770
Wigley FM, 1341, 2398, 2725
Wigley RD, 2090
Wiik A, 2374
Wijnen EM, 1696
Wijngaarden S, 648
Wilder RL, 41
Wilkins AL, 1846
Willcocks L, 1621
Williams JI, 1846
Williamson A, 1888 (ab)
Williamson L, 2510
Wilson C, 972
Wilson M, 2374
Wise RA, 2398
Witte T, 2157

Wolfe F, 36, 203, 369, 1671, 1725, 1891
Wolfe R, 523
Wollina U, 146
Won J, 1203
Wong AL, 993
Wong JB, 891, 1883 (ab), 1889 (ab)
Wong RWS, 1513
Wong T, 934
Wong WK, 705
Wood TJ, 1881 (ab)
Woodburn J, 2356
Woodward TA, 1347
Woodworth T, 1648
Woolf AD, S67–6, S67–65
Woolhead G, 1656
Woolley JM, 225, 1881 (ab)
Wray NP, 534
Wright JG, 1846
Wrona M, 89
Wulffraat NM, 2059

X

Xie S, 1579

Y

Yagi J, 1157
Yamagami H, 2413
Yamagiwa H, 2207
Yamaguchi N, 22
Yamakawa K, 1032
Yamamoto M, 474
Yamamoto Tadashi, 2207
Yamamoto Tetsuji, 637, 1036, 1351
Yamamoto Tetsuya, 1097
Yamanaka H, 1157, 2369
Yamanaka J, 1093
Yamasaki T, 1093
Yamashita E, 1164
Yano T, 1208
Yaoeda K, 2207
Yarboro C, 41
Yasuda T, 1164
Yasuoka H, 2673
Yelin EH, 1739, S68–8
Yen JC, 1967
Yen J-H, 438, 1120
Yeung RSM, 1884 (ab)
Yildiz K, 2292
Yilmaz E, 2014
Yim SF, 1479
Yoon K-H, 634, 2268
Yoshida A, 247
Yoshida M, 1534
Yoshida T, 2082
Yoshino S, 474
Yoshinouchi T, 1520
Yoshiya S, 1097, 1351
Yoshizaki K, 1426
Youinou P, 2535
Youn J, 1203
Young TB, 2508
Young-Min SA, 238
Youssef PP, 10
Yu K-H, 1864
Yun H-S, 1203

Z

Zack MM, 160
Zanetti A, 618
Zapata-Zuñiga M, 256
Zarabadi SA, 2092
Zaug M, 680, 2123
Zegels B, 2452
Zemel L, 394
Zemer D, 185
Zeng QY, 1816
Zeng X, 1451
Zerbini CA, 2572
Zhang J, 1032
Zhao D-B, 2245
Zhao H, 1280
Zhou Y, 1541
Zhou ZJ, 1884 (ab)
Ziboh VA, 55
Zinsmeister AR, 1940
Zonana-Nacach A, 2182
Zorat F, 1775
Zulian F, 2720
Zummer M, 1011
Zwicker M, 28
Zwinderman AH, 825

The Journal of Rheumatology, Volume 30, 2003

A

Aborigines
child, 841
Acetaminophen
aspirin, 2226
gastrointestinal system, 2226
ibuprofen, 2226
Achilles tendon
arthritis, 774
magnetic resonance imaging, 774
ultrasonography, 774
Acquired hyperostosis syndrome
lumbar vertebrae, 636
SAPHO, 636
Adalimumab
disease modifying antirheumatic drugs, 2563
monoclonal antibodies, 2563
polymorphonuclear leukocytes, 232
reactive oxygen species, 232
rheumatoid arthritis, 232, 2563
tumor necrosis factor receptors, 2563
ADAM8
giant cells, 2033
hip replacement arthroplasty, 2033
osteoclasts, 2033
synovial membrane, 2033
Adhesion molecules
British Isles Lupus Assessment Group index, 2133
cytokines, 2133
disease activity, 2133
inflammation, 1611
juvenile idiopathic arthritis, 1611
lymphocyte homing receptors, 1611
rheumatoid arthritis, 1611
systemic lupus erythematosus, 2133
T lymphocytes, 1611
Adjuvants
See also Experimental arthritis
cyclophosphamide, 497
cytokines, 497
experimental arthritis, 497
Adrenal cortex hormones
See also Corticosteroids
Adrenomedullin
osteoarthritis, 2553
rheumatoid arthritis, 2553
synovium, 2553
Adult onset Still's disease
cytokines, 2422
hepatitis, 1624
hepatitis B virus, 1624
hepatocyte growth factor, 1093
infliximab, 1624
interleukin 18, 2422
interleukin 2 receptors, 2422
liver failure, 1093
liver transplantation, 1093
Adverse effects
autoantibodies, 2557
congestive heart failure, 792
dermatitis, 2506
drug toxicity, 443
etanercept, 2506
gastrointestinal hemorrhage, 792
gastrointestinal system, 203
infliximab, 1888 (ab), 2557
juvenile idiopathic arthritis, 2506
nonsteroidal antiinflammatory drugs, 203, 792, 2234
rheumatoid arthritis, 443, 1888 (ab)
risk, 443
Stevens-Johnson syndrome, 2234
Afferent neurons
neuropathy, 1552
Sjögren's syndrome, 1552
Agammaglobulinemia
B lymphocytes, 412
common variable immunodeficiency, 412
systemic lupus erythematosus, 412
Age of onset
corticotropin-releasing hormone, 913
depression, 952
disability, 952
disease susceptibility, 913
giant cell arteritis, 1548
HLA-B27, 505
psoriasis, 505
psoriatic arthritis, 505
quality of life, 952
rheumatoid arthritis, 913, 952
rheumatoid factor, 913
sex, 1548
Spain, 1548
temporal arteritis, 1548
Aged
bone density, 1881 (ab)
disability, 2689
etanercept, 691
lower extremity, 2689
memory disorders, 1881 (ab)
pain, 2689
quality of life, 2689
rheumatoid arthritis, 691
tumor necrosis factor receptors, 691
ultrasonography, 1881 (ab)
women, 2689
Aggrecan
chondrocytes, 326
collagen, 326
nitric oxide, 326
osteoarthritis, 326
Aging
hemochromatosis, 121
iron, 121
mutation, 121
osteoarthritis, 121
Alcohol drinking
disease activity, 1215
epidemiology, 1215, 1222
smoking, 1215, 1222
systemic lupus erythematosus, 1215, 1222
Aldolase
creatine kinase, 2077
dermatomyositis, 2077
polymyositis, 2077
Alizarin red
calcium pyrophosphate dihydrate crystal deposition, 1032
diagnosis, 1032
staining and labelling, 1032
Alleles
ankylosing spondylitis, 2511
Brazil, 2511
HLA-B27, 2511
spondyloarthropathy, 2632
Allergy
See also Drug hypersensitivity
See also Hypersensitivity
Alpha-fodrin
autoantibodies, 2157
classification, 2157
Sjögren's syndrome, 2157
Alternative medicine
fibromyalgia, 2088, 2257
meditation, 2088, 2257
Qigong movement therapy, 2088, 2257
Alternative splicing
autoimmune diseases, 2524
major histocompatibility complex, 2524
rheumatoid arthritis, 2524
T lymphocytes, 2524
American College of Rheumatology
codes of ethics, 202
drug industry, 202
medical ethics, 202
Amish
epidemiology, 1835
fibromyalgia, 1835
prevalence, 1835
Amyloidosis
apoptosis, 313
arthritis, 308
complications, 948
epidemiology, 948
familial Mediterranean fever, 308, 313
genetics, 308
giant cell arteritis, 2283
India, 948
jaw abnormality, 2283
polymyalgia rheumatica, 2283
rheumatoid arthritis, 948
sex, 308
Anakinra
disability, 1881 (ab)
Health Assessment Questionnaire, 225
interleukin receptors, 225
quality of life, 225
rheumatoid arthritis, 225, 1877 (ab), 1878 (ab), 1881 (ab)
smoking, 1877 (ab)
Analgesics
ethnic groups, 2201
health services, 2201
nonsteroidal antiinflammatory drugs, 2201
osteoarthritis, 2201
Androgens
dehyroepiandrosterone, 2597
estrogens, 1267, 2413, 2597
hormone replacement therapy, 1267
rheumatoid arthritis, 2597
Sjögren's syndrome, 1267, 2413
synovial fluid, 2597
xerophthalmia, 2413
Angiogenesis
animal disease models, 2207
capillaries, 1529
cartilage, 2207
chondromodulin, 2207
osteoarthritis, 2207
scleroderma, 1529
systemic sclerosis, 1529
vascular endothelial growth factor, 1529

Angiography
immunosuppressive agents, 1793
Takayasu's arteritis, 1793
Angiopoietins
endothelial growth factors, 260
rheumatoid arthritis, 260
Angiotensin converting enzyme
genotype, 2705
juvenile rheumatoid arthritis, 2705
polymerase chain reaction, 2705
polymorphism, 2705
Animal disease models
angiogenesis, 2207
ank, 2659
ankylosis, 2659
autoimmunity, 918
blood, 339
cartilage, 339, 2207, 2218
chondromodulin, 2207
computed tomography, *2659*
cyclosporine, 2027
FK506, 2193
helper-inducer T lymphocytes, 918
hemophilia, 339
histology, 2218
interleukin 1 beta, 2193
interleukin 6, 2193
LF 15-0195, 918
methotrexate, 2027
osteoarthritis, 1880 (ab), 2207, 2218
proteoglycans, 339
rheumatoid arthritis, 918, 2193
ribomunyl, 2027
tumor necrosis factors, 2193
ank
animal disease models, 2659
computed tomography, 2659
Ankle
rheumatoid arthritis, 1951
synovitis, 1951
tendons, 1951
Ankle joint
foot, 196
genetics, 196
hemochromatosis, 196
HFE gene, 196
joint diseases, 196
Ankylosing spondylitis
alleles, 2511
antigens, 972
autoimmune diseases, 102
back pain, 518
biological therapy, 1887 (ab)
Bone and Joint Decade Conference, S67–45
bone density, 779
Brazil, 2511
China, 1816, 2245
colitis, 2306, 2428
Community Oriented Program for Control of Rheumatic Diseases, 2245
consensus development conferences, 1356
Crohn's disease, 102, 518
cytotoxicity tests, 972
diagnosis, 2729, 2732
diagnostic tests, 1878 (ab)
disability, 2186
disease activity, 1878 (ab), 2729
disease modifying antirheumatic drugs, 2627
disease susceptibility, 2054
duodenum, 2428
epidemiology, 1816, 2245
etanercept, 1127, 1356
genetic predisposition to disease, 102
genetics, 2182
glycoproteins, 2729
gout, 2245
HLA-B27, 321, 518, 1120, 2182, 2511
inflammation, 2306, 2428
inflammatory bowel disease, 518, 2054
infliximab, 204, 1127, 1356
juvenile ankylosing spondylitis, 2182
juvenile idiopathic arthritis, S67–45
lumbar vertebrae, 2732
mesalazine, 1558
nitric oxide, 2428
osteoporosis, 779
outcome and process assessment, 764
Patient Generated Index, 764
peptides, 972
physician's practice patterns, 779
polymerase chain reaction, 321
polymorphism, 321
prognosis, 316, 2186
questionnaires, 764
radiology, 316
range of motion, 2732
rheumatic diseases, 2245
rheumatoid arthritis, 972, 2245, S67–45
sacroiliitis, 518
slow acting antirheumatic drugs, 1816
SpA Research Consortium of Canada, 1127, 1356
spondyloarthropathy, 1127, 2306
Taiwan, 321
thalidomide, 2627
therapeutics, 779
treatment, 779, 1816
treatment failure, 204
treatment outcome, 1558
tumor necrosis factor receptors, 2627
vertical disease transmission, 2054
Ankylosis
animal disease models, 2659
ank, 2659
computed tomography, 2659
Annexin V
antiphospholipid antibodies, 1990
thrombin, 1990
Anserine
bursitis, 352
diabetes mellitus, 352
tendinitis, 352
ultrasonography, 352
Anterior uveitis
sulfasalazine, 1277
treatment, 1277
Anti-cyclic citrullinated peptide
juvenile idiopathic arthritis, 825
rheumatoid factor, 825
Anti-endomysial assay
celiac disease, 2613
diagnosis, 2613
Sjögren's syndrome, 2613
tissue transglutaminases, 2613
Anti-osteoporosis agents
cost-benefit analysis, S68–31
Health Economics in Rheumatology Conference, S68–31
osteoporosis, S68–31
Antibodies
citrulline, 1691
cyclic peptide, 1691
diagnosis, 1691
polyarthritis, 1691
prognosis, 1691
rheumatoid arthritis, 1691
Antibody formation
lenercept, 680
randomized controlled trials, 680
rheumatoid arthritis, 680
tumor necrosis factor receptors, 680
Anticardiolipin antibodies
cerebrovascular disorders, 985
factor V, 2385
lupus anticoagulant, 985, 2385
magnetic resonance imaging, 985
neurologic manifestations, 985
prednisone, 2127
pregnancy, 2127
systemic lupus erythematosus, 985, 2127
thrombophilia, 2385
thrombosis, 2385
Anticoagulants
antiphospholipid syndrome, 897
signs and symptoms, 897
Antigen-antibody complex
See also Immune complexes
Antigens
ankylosing spondylitis, 972
cytotoxicity tests, 972
peptides, 972
rheumatoid arthritis, 972
Antimalarials
drug toxicity, 1756
ophthalmologic monitoring, 1756
ophthalmological diagnostic techniques, 1876 (ab)
systemic lupus erythematosus, 1756, 1876 (ab)
vision screening, 1756
Antineoplastic agents
carboplatin, 1341
gemcitabine, 1341
necrosis, 1341
scleroderma, 1341
Antineutrophil cytoplasmic antibodies
Churg-Strauss syndrome, 618
disease susceptibility, 1534
family, 618
genetics, 1534
HLA, 618, 1534
proteinases, 2064
respiratory system, 2420
rheumatoid arthritis, 2064
rheumatoid factor, 2064
systemic sclerosis, 2078
vasculitis, 1534
Wegener's granulomatosis, 618, 2064, 2420
Antinuclear antibodies
autoantibodies, 1473
connective tissue diseases, 736
cryoglobulins, 1473
disease activity, 1761
extractable nuclear antigens, 736
hepatitis C virus, 1473
Raynaud's phenomenon, 736
single stranded DNA, 1761
systemic lupus erythematosus, 1473, 1761
Antiphospholipid antibodies
annexin V, 1990
antiphospholipid syndrome, 55, 214, 723
blood platelets, 55
HIV, 214
infection, 214
lupus anticoagulant, 723

ROC curves, 723
thrombin, 1990
thromboxane A_2, 55
Antiphospholipid syndrome
anticoagulants, 897
antiphospholipid antibodies, 55, 214, 723
blood platelets, 55
classification, 1893
glycoproteins, 1875 (ab)
HIV, 214
infection, 214
lupus anticoagulant, 723
rheumatology, 1893
ROC curves, 723
signs and symptoms, 897
T lymphocytes, 1875 (ab)
thromboxane A_2, 55
Antirheumatic agents
cost-benefit analysis, S68–26
drug dose response relationship, 2517
genetics, 2517
Health Economics in Rheumatology Conference, S68–26
osteoarthritis, S68–26
Aortic valve insufficiency
mitral valve insufficiency, 1087
pediatric spondyloarthropathy, 1087
Aortitis
Takayasu's arteritis, 2508
Apoptosis
amyloidosis, 313
articular cartilage, 559
CD95 antigens, 550
chondrocytes, 550
familial Mediterranean fever, 313
Fas, 550
immobilization, 559
protein 53, 559
systemic sclerosis, 1886 (ab)
Argininosuccinate synthase
GTP cyclohydrolase, 652
nitiric oxide, 652
tumor necrosis factors, 652
Arsenic poisoning
Gottron's rash, 415
Arthritis
Achilles tendon, 774
amyloidosis, 308
Arthritis and Rheumatism International, S67–59
bacterial infections, 1347
Bone and Joint Decade Conference, S67–36, S67–59, S67–62
central nervous system, 1347
classification, 1123, 1335
cross sectional studies, 160
cytology, 2713
disability, S67–36
epidemiology, 160, 2299, 2476
exercise, 2299, 2476
familial Mediterranean fever, 308
genetics, 308
hydrarthrosis, 2713
interferon-alpha, 934
interleukin 1 receptors, 934
jurisprudence, S67–36
juvenile rheumatoid arthritis, 1335
magnetic resonance imaging, 774
musculoskeletal system, S67–62
neoplasm metastasis, 2713
orchitis, 1347
osteoarthritis, S67–62
osteoporosis, S67–62
osteoprotegerin, 934
pain measurement, 1584
patient satisfaction, 1584
pediatric spondyloarthropathy, 1123
prevalence, 126, 1335
psychological stress, 2299, 2476
quality of life, 160
Quebec, 126
rheumatic diseases, S67–59
salicin, 1125
sex, 308
socioeconomic factors, 160
spondyloarthropathy, 1335
stomach, 2713
tumor necrosis factor receptors, 934
ultrasonography, 774
United Kingdom, S67–36
Whipple's disease, 1347
Arthritis and Rheumatism International
arthritis, S67–59
Bone and Joint Decade Conference, S67–59
rheumatic diseases, S67–59
Arthritis Foundation
Bone and Joint Decade Conference, S67–32
preventive medicine, S67–32
United States of America, S67–32
Arthrodesis
arthroplasty, 1440
forefoot, 1440
metatarsophalangeal, 1440
rheumatoid arthritis, 1440
Arthroplasty
arthrodesis, 1440
disease progression, 1822
ethnic groups, 1305
forefoot, 1440
health services, 1305
knee replacement, 1822
metatarsophalangeal, 1440
natural history, 1822
osteoarthritis, 1305, 1822
rheumatoid arthritis, 1440
Arthroscopy
Doppler, 2170
gout, 1868
synovitis, 2170
tophus, 1868
ultrasonography, 2170
Articular cartilage
apoptosis, 559
autoimmunity, 247
gene deletion, 247
immobilization, 559
nitric oxide, 247
protein 53, 559
Articular manifestations
brucellosis, 1051
disease susceptibility, 1051
HLA-B*39, 1051
Aspirin
acetaminophen, 2226
gastrointestinal system, 2226
ibuprofen, 2226
Atlantoaxial joint
cartilage, 1420
cervical vertebrae, 1420
immunohistochemistry, 1420
ligament, 1420
rheumatoid arthritis, 1420
Auscultation
polymyalgia rheumatica, 191
temporal arteritis, 191
Autoantibodies
adverse effects, 2557
alpha-fodrin, 2157
antinuclear antibodies, 1473
autoimmunity, 2374
classification, 2157
complement, 740
connective tissue diseases, 1248
cryoglobulins, 1473
diagnosis, 1451, 2374
disease duration, 1885 (ab)
DNA directed RNA polymerases, 2392
drug induced abnormalities, 2725
enzyme linked immunosorbent assay, 1451, 2374
etanercept, 2725
G binding protein, 993
guanosine, 993
heat shock proteins, 1875 (ab)
hepatitis C virus, 1473
HLA, 2392
immunogenetics, 2392
infliximab, 1882 (ab), 2557
kidney, 1495
mannose binding lectin, 740
neoplasms, 1994
polymorphism, 740
rheumatic diseases, 1882 (ab)
rheumatoid arthritis, 1451, 1884 (ab), 1885 (ab)
scleroderma, 1248, 1994
Sjögren's syndrome, 2157
systemic lupus erythematosus, 740, 993, 1473, 1495, 1875 (ab)
systemic sclerosis, 1994, 2392
vimentin, 1884 (ab)
Autoantigens
HLA-DR antigens, 449
major histocompatibility complex, 449
matrix metalloproteinase-1, 1147
rheumatoid arthritis, 449, 1147
T cell antigen receptors, 449
T lymphocytes, 449
Autoimmune diseases
alternative splicing, 2524
ankylosing spondylitis, 102
Crohn's disease, 102
genetic predisposition to disease, 102
glutathione transferase, 276
major histocompatibility complex, 2524
metabolism, 276
rheumatoid arthritis, 2524
systemic lupus erythematosus, 276
T lymphocytes, 2524
ultraviolet rays, 276
Autoimmunity
animal disease models, 918
articular cartilage, 247
autoantibodies, 2374
cryoglobulinemia, 2005
diagnosis, 2374
enzyme linked immunosorbent assay, 2374
gene deletion, 247
helper-inducer T lymphocytes, 918
hepatitis C virus, 2005
HIV, 2005
LF 15-0195, 918
nitric oxide, 247
rheumatoid arthritis, 918
Autonomic nervous system
baroreflex, 74
cardiovascular system, 74
heart rate, 74
Sjögren's syndrome, 2296
Avocado
cartilage, 1825
cytokines, 1825
osteoarthritis, 1825
soybeans, 1825
Azithromycin
vasculitis, 2292

B

B lymphocytes
agammaglobulinemia, 412
common variable immunodeficiency, 412
systemic lupus erythematosus, 412
Back pain
ankylosing spondylitis, 518
Bone and Joint Decade Conference, S67–26
Crohn's disease, 518
diagnosis, S67–26
epidemiology, S67–26
health status, S67–26
HLA-B27, 518
inflammatory bowel disease, 518
sacroiliitis, 518
treatment outcome, S67–26
Bacterial infections
arthritis, 1347
central nervous system, 1347
orchitis, 1347
Whipple's disease, 1347
Baroreflex
autonomic nervous system, 74
cardiovascular system, 74
heart rate, 74
Bath Ankylosing Spondylitis Disease Activity Index
diagnosis, 1883 (ab)
low back pain, 1883 (ab)
reproducibility of results, 1883 (ab)
BAY 12-9566
cartilage, 544
collagen, 544
matrix metalloproteinases, 544
osteoarthritis, 544
Beer
exercise, 1036
gouty arthritis, 1036
uric acid, 1036
Behçet's disease
eye, 1888 (ab)
inflammation, 1888 (ab)
infliximab, 1888 (ab)
Beta-adrenergic receptors
cyclic amp, 364
fibromyalgia, 364
Bias
randomized controlled trials, 979
research design, 979
systemic lupus erythematosus, 979
Biliary liver cirrhosis
glomerulonephritis, 2710
vasculitis, 2710
Biological agents
Bone and Joint Decade Conference, S67–33
disease-modifying antirheumatic drugs, S67–33
morbidity, S67–33
mortality, S67–33
rheumatoid arthritis, S67–33
Biological markers
bone, 910
cartilage, 910
cartilage erosion, 1561
disease progression, 1043
experimental arthritis, 1561
matrix metalloproteinases, 1561
osteoarthritis, 910, 1043
osteocalcin, 1043
urine, 1561
Biological therapy
ankylosing spondylitis, 1887 (ab)
collagen-PVP, 256
disease modifying antirheumatic drugs, 241
drug induced abnormalities, 241
etanercept, 2315
infliximab, 2315
pregnancy, 241
rheumatoid arthritis, 241, 256, 2315
Biomechanics
gait, 529
knee, 529
osteoarthritis, 529
shoes, 529
Bisphosphonates
See also Diphosphonates, 132
calcium, 132
cost-benefit analysis, 132
experimental arthritis, 1280
glucocorticoids, 132
incadronate (YM175), 1280
inflammation, 1280
joint erosions, 1280
osteoporosis, 132, 1883 (ab)
vitamin D, 132
Blacks
genetic predisposition to disease, 60
microsatellite repeats, 60
polymorphism, 60
promoter regions, 60
systemic lupus erythematosus, 60
Blindness
giant cell arteritis, 625
optic nerve diseases, 625
Blister
lamin type B, 1875 (ab)
systemic lupus erythematosus, 1875 (ab)
Blood
animal disease models, 339
cartilage, 339
hemophilia, 339
proteoglycans, 339
Blood coagulation factors
fibrinolysis, 783
osteonecrosis, 783
thrombophilia, 783
Blood platelets
antiphospholipid antibodies, 55
antiphospholipid syndrome, 55
thromboxane A_2, 55
Blood pressure
cardiovascular diseases, 642
hypertension, 642
osteoarthritis, 642
rheumatoid arthritis, 642
Body mass index
depression, 2103
epidemiology, 2103
osteoarthritis, 2103
radiography, 2350
rheumatoid arthritis, 2350
risk factors, 2103
shared epitope, 2350
Bone and bones
biological markers, 910
cartilage, 910
collagen, 468
etidronate, 468
humerus, 851
immunohistochemistry, 2319
NF-kappa B, 2319
osteoarthritis, 910
osteomyelitis, 851
RANKL, 2319
rheumatoid arthritis, 468, 2319
shoulder pain, 851
tuberculosis, 851
tumor necrosis factor receptors, 2319
Bone and Joint Decade Conference
ankylosing spondylitis, S67–45
arthritis, S67–36, S67–59, S67–62
Arthritis and Rheumatism International, S67–59
Arthritis Foundation, S67–32
back pain, S67–26
biological agents, S67–33
burden of illness, S67–4
chondroitin sulfate, S67–14
cost of illness, S67–38, S67–51
diacerein, S67–14
diagnosis, S67–26
diphosphonates, S67–21
disability, S67–36
disease modifying antirheumatic drugs, S67–10, S67–33, S67–51
epidemiology, S67–26, S67–54, S67–56, S67–66
fractures, S67–21
France, S67–42
glucosamine, S67–14
guidelines, S67–38
health policy, S67–6
health status, S67–26
Indonesia, S67–54
introduction, S67–1
Japan, S67–3, S67–47
Japan Rheumatism Friendship Association, S67–48
jurisprudence, S67–36
juvenile idiopathic arthritis, S67–45
morbidity, S67–10, S67–33
mortality, S67–10, S67–33, S67–51
musculoskeletal diseases, S67–4, S67–38
musculoskeletal system, S67–6, S67–56, S67–62
nutrition, S67–66
osteoarthritis, S67–14, S67–62, S67–66
osteoporosis, S67–21, S67–42, S67–62
preventive medicine, S67–21, S67–32, S67–41
rheumatic diseases, S67–3, S67–54, S67–59, S67–65
rheumatoid arthritis, S67–10, S67–33, S67–42, S67–45, S67–47, S67–48, S67–51, S67–66
rheumatoid factor, S67–51
risk, S67–21
Russia, S67–56
spondyloarthropathy, S67–42
Sweden, S67–41
treatment outcome, S67–14, S67–21, S67–26, S67–51
United Kingdom, S67–36
United States of America, S67–32
World Health Organization, S67–6
Bone density
aged, 1881 (ab)
ankylosing spondylitis, 779
calcaneus, 179
chronic disease, 179
connective tissue diseases, 2673
corticosteroids, 2365, 2673
diphosphonates, 2673
joint erosions, 2590
juvenile rheumatoid arthritis, 179
memory disorders, 1881 (ab)
osteoporosis, 179, 779, 2365, 2673
pediatric rheumatic diseases, 179
physician's practice patterns, 779

rheumatoid arthritis, 2590
sex, 2590
systemic lupus erythematosus, 2365
therapeutics, 779
treatment, 779
ultrasonography, 179, 1881 (ab)
Book reviews
Clinical Pain Management, 1659
Living Well with Arthritis: A Sourcebook for Understanding and Managing Your Arthritis, 1658
Modern Therapeutics in Rheumatic Diseases, 423
Skeletal Muscle Pathology, Diagnosis and Management of Disease, 2734
Brain
calcification, 2724
scleroderma, 2724
systemic sclerosis, 2724
Brazil
alleles, 2511, 2632
ankylosing spondylitis, 2511
HLA-B27, 2511, 2632
HLA-B7, 2632
prognosis, 2632
spondyloarthropathy, 2632
Breast implants
fatigue, 2263
pain, 2263
silicone, 2092, 2263
Breast neoplasms
risk, 1505
risk factors, 1876 (ab)
systemic lupus erythematosus, 1505, 1876 (ab)
British Isles Lupus Assessment Group index
adhesion molecules, 2133
cytokines, 2133
disease activity, 2133
systemic lupus erythematosus, 2133
Brucellosis
articular manifestations, 1051
combination drug therapy, 2666
disease susceptibility, 1051
HLA-B*39, 1051
reactive arthritis, 2666
treatment, 2666
Burden of illness
Bone and Joint Decade Conference, S67–4
musculoskeletal diseases, S67–4
Bursa
dactylitis, 1626
radius, 1626
thumb, 1626
Bursitis
anserine, 352
diabetes mellitus, 352
diagnosis, 1354
rheumatoid arthritis, 1354
synovial membrane, 1354
tendinitis, 352
ultrasonography, 352

C

C-telopeptide
collagen type I, 68
systemic sclerosis, 68
Calcaneus
bone density, 179
chronic disease, 179
juvenile rheumatoid arthritis, 179
osteoporosis, 179
pediatric rheumatic diseases, 179
ultrasonography, 179
Calcification
brain, 2724
scleroderma, 2724
systemic sclerosis, 2724
Calcium
bisphosphonates, 132
corticosteroids, 1
cost-benefit analysis, 1, 132
fractures, 1878 (ab)
glucocorticoids, 1, 132
osteoporosis, 132, 1878 (ab)
vitamin D, 1, 132
Calcium pyrophosphate
osteoarthritis, 420
synovial fluid, 420
transforming growth factor, 420
Calcium pyrophosphate dihydrate crystal deposition
Alizarin red, 1032
diagnosis, 1032
staining and labelling, 1032
Camptodactyly
coxa vara, 1081
families, 1081
pericarditis, 1081
Campylobacter
infection, 459
reactive arthritis, 459
rheumatoid arthritis, 459
Canada
Lithuania, 1882 (ab)
motor vehicles, 1882 (ab)
whiplash injuries, 1882 (ab)
Canadian Osteoarthritis Rx Program
Consortium of Rheumatology Researchers of North America, 2308
data collection, 2308
rheumatic diseases, 2308
The Canadian Database of Osteoporosis and Osteopenia, 2308
Canadian Rheumatology Association Meeting
introduction, 1874
podium presentations, 1875
posters, 1876
Capillaries
angiogenesis, 1529
scleroderma, 1529
systemic sclerosis, 1529
vascular endothelial growth factor, 1529
Carboplatin
antineoplastic agents, 1341
gemcitabine, 1341
necrosis, 1341
scleroderma, 1341
Cardiovascular deconditioning
exercise test, 1075
exercise tolerance, 1075
physical fitness, 1075
Cardiovascular diseases
blood pressure, 642
cerebrovascular disorders, 36
cost-benefit analysis, 714
diagnosis, 493
diagnostic tests, 899
epidemiology, 1196
hypertension, 642, 714
inflammation, 1403
insulin resistance, 1403
mortality, 1196
osteoarthritis, 36, 642, 714, 1196
rheumatoid arthritis, 36, 642, 714, 1196, 1403
risk, 36
risk factors, 493, 1403
systemic lupus erythematosus, 493, 899
Cardiovascular system
autonomic nervous system, 74
baroreflex, 74
cyclooxygenase-2 inhibitors, 421
heart rate, 74
osteoarthritis, 421
rofecoxib, 421
thrombosis, 421
Cartilage
angiogenesis, 2207
animal disease models, 339, 1880 (ab), 2207, 2218
atlantoaxial joint, 1420
avocado, 1825
BAY 12-9566, 544
biological markers, 910
blood, 339
bone and bones, 910
celecoxib, 2444
cervical vertebrae, 1420
chondrocytes, 1565, 1799
chondromodulin, 2207
collagen, 544
cytokines, 1825
diclofenac, 2444
ear piercing, 2716
granzyme B, 1799
hemophilia, 339
histology, 2218
hyaluronan, 2444
immunohistochemistry, 1420
insulin-like growth factor-I, 1565
ligament, 1420
matrix metalloproteinases, 544
oncogene proteins, 1565
osteoarthritis, 544, 910, 1565, 1825, 1880 (ab), 2207, 2218
perforins, 1799
proteoglycans, 339, 2444
relapsing polychondritis, 2716
remodeling, 1799
rheumatoid arthritis, 1420, 1799
soybeans, 1825
trauma, 2716
Cartilage erosion
biological markers, 1561
experimental arthritis, 1561
matrix metalloproteinases, 1561
urine, 1561
cc chemokines
helper-inducer T lymphocytes, 2365
systemic lupus erythematosus, 2365
CD95 antigens
apoptosis, 550
chondrocytes, 550
Fas, 550
Celecoxib
cartilage, 2444
diclofenac, 2444
hyaluronan, 2444
proteoglycans, 2444
Celiac disease
anti-endomysial assay, 2613
diagnosis, 2613
Sjögren's syndrome, 2613
tissue transglutaminases, 2613
Cell communication
cytokines, 1879 (ab)
osteoarthritis, 1879 (ab)
prostaglandins, 1879 (ab)
Cellulitis
gout, 417
ultrasonography, 417
Central nervous system
arthritis, 1347
bacterial infections, 1347
cerebrovascular circulation, 1997
facial hemiatrophy, 1997
juvenile dermatomyositis, 2059
orchitis, 1347

scleroderma, 1997
vasculitis, 2059
Whipple's disease, 1347
Central nervous system lupus vasculitis
cerebrospinal fluid, 485
fatigue, 283
kallikreins, 485
kininogens, 485
psychology, 283
systemic lupus erythematosus, 283, 485
Cerebral blood flow
cerebrovascular circulation, 2075
computed tomography, 2075
neurologic manifestations, 2075
systemic lupus erythematosus, 2075
Cerebrospinal fluid
central nervous system lupus vasculitis, 485
kallikreins, 485
kininogens, 485
systemic lupus erythematosus, 485
Cerebrovascular circulation
central nervous system, 1997
cerebral blood flow, 2075
computed tomography, 2075
facial hemiatrophy, 1997
neurologic manifestations, 2075
scleroderma, 1997
systemic lupus erythematosus, 2075
Cerebrovascular disorders
anticardiolipin antibodies, 985
cardiovascular diseases, 36
lupus anticoagulant, 985
magnetic resonance imaging, 985
neurologic manifestations, 985
osteoarthritis, 36
rheumatoid arthritis, 36
risk, 36
systemic lupus erythematosus, 985
Cervical vertebrae
atlantoaxial joint, 1420
cartilage, 1420
immunohistochemistry, 1420
ligament, 1420
rheumatoid arthritis, 1420
Chemokine receptors
chemokines, 1541
cytokines, 1928
polymorphism, 1541, 1770
rheumatoid arthritis, 1928
synovial fluid, 1928
systemic lupus erythematosus, 1770
Wegener's granulomatosis, 1541
Chemokines
chemokine receptors, 1541
polymorphism, 1541
rheumatoid arthritis, 1918
T lymphocytes, 1918
Wegener's granulomatosis, 1541
Chemoprevention
osteoporosis, 1884 (ab)
rheumatic diseases, 1884 (ab)
Child
aborigines, 841
drug induced, 1876 (ab)
epidemiology, 2275, 2513
erysipelas, 185
erythema, 185
familial Mediterranean fever, 185
genetics, 185
juvenile rheumatoid arthritis, 1881 (ab), 2275
macrophage activation syndrome, 2513
methotrexate, 1881 (ab)
systemic lupus erythematosus, 1876 (ab)
vasculitis, 1875 (ab)
China
ankylosing spondylitis, 2245
Community Oriented Program for Control of Rheumatic Diseases, 2090, 2245
epidemiology, 2090, 2245
gout, 2245
rheumatic diseases, 2090, 2245
rheumatoid arthritis, 2245
Chinese
disease progression, 1513
morbidity, 1513
mortality, 1513
risk, 1513
systemic lupus erythematosus, 1513
Chondrocalcinosis
Mycobacterium tuberculosis, 637
Chondrocytes
aggrecan, 326
apoptosis, 550
cartilage, 1565, 1799
CD95 antigens, 550
collagen, 326
Fas, 550
granzyme B, 1799
insulin-like growth factor-I, 1565
nitric oxide, 326
oncogene proteins, 1565
osteoarthritis, 326, 1565
perforins, 1799
remodeling, 1799
rheumatoid arthritis, 1799
Chondroitin sulfate
Bone and Joint Decade Conference, S67–14
diacerein, S67–14
glucosamine, S67–14
osteoarthritis, S67–14
treatment outcome, S67–14
Chondromodulin
angiogenesis, 2207
animal disease models, 2207
cartilage, 2207
osteoarthritis, 2207
Chromosomes
micronucleus assays, 1244
Raynaud's phenomenon, 1244
systemic sclerosis, 1244
Chronic disease
bone density, 179
calcaneus, 179
juvenile rheumatoid arthritis, 179
osteoporosis, 179
pediatric rheumatic diseases, 179
ultrasonography, 179
Chronic fatigue syndrome
cost of illness, 804
disability, 804
fibromyalgia, 804
Churg-Strauss syndrome
antineutrophil cytoplasmic antibodies, 618
family, 618
HLA, 618
Wegener's granulomatosis, 618
Cirrhosis
hand, 1628
inflammation, 1628
Citrulline
antibodies, 1691
cyclic peptides, 1691, 1696
diagnosis, 1691
monoclonal antibodies, 1696
polyarthritis, 1691
prognosis, 1691
rheumatoid arthritis, 1691, 1696
Classification
alpha-fodrin, 2157
antiphospholipid syndrome, 1893
arthritis, 1123, 1335
autoantibodies, 2157
diagnosis, 1880 (ab)
Durban, 1857
epidemiology, 1665, 1666, 1668, 1671
fibromyalgia, 1665, 1666, 1668, 1671
iatrogenic diseases, 1666, 1668
ILAR, 1857
inclusion body myositis, 1892
jurisprudence, 1665, 1668, 1671
juvenile idiopathic arthritis, 1663, 1857
juvenile rheumatoid arthritis, 1335
LE cells, 1880 (ab)
magnetic resonance imaging, 1892
nomenclature, 1857
observer variation, 2645
OMERACT 6 conference, 1648
osteoarthritis, 1648
outcome and process assessment, 1648, 2645
pain, 1666
pediatric spondyloarthropathy, 1123
physiologic calcification, 1029
polymyositis, 1892
predictive value of tests, 720
prevalence, 1335
prognosis, 1022
psoriatic arthritis, 1022, 2645
radiography, 2645
radiology, 1022
randomized controlled trials, 1135, 1138, 1648
Raynaud's phenomenon, 720
reproducibility of results, 1029
rheumatoid arthritis, 1135, 1138
rheumatology, 1893
shoulder, 1029
Sjögren's syndrome, 2157
spondyloarthropathy, 1335
systemic lupus erythematosus, 1880 (ab)
tendinitis, 1029
thermography, 720
Clinical trials
doxycycline, 41
knee, 329
leflunomide, 2572
osteoarthritis, 329
radiography, 329
rheumatoid arthritis, 41, 2572
treatment outcome, 2572
Clinical trials data monitoring committees
drug toxicity, 1883 (ab)
metaanalysis, 1883 (ab)
Cochrane collaboration
musculoskeletal system, 575
Codes of ethics
American College of Rheumatology, 202
drug industry, 202
medical ethics, 202
Cognition disorders
neurologic manifestations, 1006
questionnaires, 1006

systemic lupus erythematosus, 1006
Cohort studies
disease modifying antirheumatic drugs, 697
rheumatoid arthritis, 697
treatment cessation, 697
Colchicine
familial Mediterranean fever, 2620
intravenous injections, 2620
treatment failure, 2620
Colitis
ankylosing spondylitis, 2306, 2428
duodenum, 2428
inflammation, 2306, 2428
nitric oxide, 2428
spondyloarthropathy, 2306
Collagen
aggrecan, 326
BAY 12-9566, 544
bone and bones, 468
cartilage, 544
chondrocytes, 326
etidronate, 468
matrix metalloproteinases, 544
nitric oxide, 326
osteoarthritis, 326, 544
rheumatoid arthritis, 468
Collagen type I
c-telopeptide, 68
systemic sclerosis, 68
Collagen-PVP
biological therapy, 256
rheumatoid arthritis, 256
Combination drug therapy
brucellosis, 2666
reactive arthritis, 2666
treatment, 2666
Common variable immunodeficiency
agammaglobulinemia, 412
B lymphocytes, 412
systemic lupus erythematosus, 412
Community Oriented Program for Control of Rheumatic Diseases
ankylosing spondylitis, 2245
China, 2090, 2245
epidemiology, 2090, 2245, 2312
gout, 2245, 2312
hyperuricemia, 2312
Indonesia, 2312
rheumatic diseases, 2090, 2245, 2252
rheumatoid arthritis, 2245
self-medication, 2312
Vietnam, 2252
Comorbidity
depression, 1318
disability, 1318
fibromyalgia, 1318
health care costs, 1318
rheumatoid arthritis, 1436
risk assessment, 1436
tuberculosis, 1436
Complement
autoantibodies, 740
mannose binding lectin, 740
polymorphism, 740
systemic lupus erythematosus, 740
Complementary therapies
rheumatoid arthritis, 1883 (ab)
Compliance-Questionnaire-Rheumatology
rheumatic diseases, 2469
rheumatoid arthritis, 2469
Complications
amyloidosis, 948
epidemiology, 948
India, 948
rheumatoid arthritis, 948
Computed tomography
animal disease models, 2659
ank, 2659
ankylosis, 2659
cerebral blood flow, 2075
cerebrovascular circulation, 2075
neurologic manifestations, 2075
systemic lupus erythematosus, 2075
Computer assisted image processing
diagnostic imaging, 238
radiography, 238
reproducibility of results, 238
rheumatoid arthritis, 238
Conflict of interest
disclosure, 1661, 1851
medical ethics, 1661, 1851
research support, 1661, 1851
Congestive heart failure
adverse effects, 792
gastrointestinal hemorrhage, 792
nonsteroidal antiinflammatory drugs, 792
Connective tissue diseases
antinuclear antibodies, 736
autoantibodies, 1248, 2725
bone density, 2673
corticosteroids, 2673
diphosphonates, 2673
drug induced abnormalities, 2725
etanercept, 2725
extractable nuclear antigens, 736
osteoporosis, 2673
Raynaud's phenomenon, 736
scleroderma, 1248
Connective tissue growth factor
fibrosis, 755
systemic sclerosis, 755
transforming growth factor, 755
Consensus development conferences
ankylosing spondylitis, 1356
etanercept, 1356
infliximab, 1356
SpA Research Consortium of Canada, 1127, 1356
Consortium of Rheumatology Researchers of North America
Canadian Osteoarthritis Rx Program, 2308
data collection, 2308
rheumatic diseases, 2308
The Canadian Database of Osteoporosis and Osteopenia, 2308
Controlled trial
rheumatoid arthritis, 2123
tumor necrosis factor receptors, 2123
COPCORD
See Community Oriented Program for Control of Rheumatic Diseases
Corrections
Expanding role of biologic agents in rheumatoid arthritis. JR Kalden, 209
Norepinephrine from synovial tyrosine hydroxylase positive cells ... LE Miller, et al, 1125
Patient compliance in RA, PMR and gout. E de Klerk, et al., 423
Prevalence of rheumatic diseases in urban Vietnam: A WHO-ILAR COPCORD study. TT Min Hoa, et al., 2734
Corticosteroids
bone density, 2365, 2673
calcium, 1
central nervous system, 207
connective tissue diseases, 2673
cost-benefit analysis, 1
cyclophosphamide, 1871
demyelinating diseases, 1871
diphosphonates, 2673
glottis, 1017
glucocorticoids, 1
Kaposi's sarcoma, 622
osteoporosis, 2365, 2673
spinal injections, 207
stenosis, 1017
systemic lupus erythematosus, 207, 1871, 2365
treatment, 1017
vitamin D, 1
Wegener's granulomatosis, 622, 1017
Corticotropin-releasing hormone
age of onset, 913
disease susceptibility, 913
rheumatoid arthritis, 913
rheumatoid factor, 913
Cost of illness
Bone and Joint Decade Conference, S67–38, S67–51
chronic fatigue syndrome, 804
disability, 804, s68–8
disease modifying antirheumatic drugs, S67–51
fibromyalgia, 804, 1886 (ab)
guidelines, S67–38
Health Economics in Rheumatology Conference, s68–8
health resources, 1878 (ab)
mortality, S67–51
musculoskeletal diseases, S67–38, s68–8
patient acceptance of health care, 1886 (ab)
questionnaires, 2485
rheumatoid arthritis, 2485, S67–51
rheumatoid factor, S67–51
systemic lupus erythematosus, 1878 (ab)
treatment outcome, S67–51
women, 1886 (ab)
Cost-benefit analysis
anti-osteoporosis agents, S68–31
antirheumatic agents, S68–26
bisphosphonates, 132
calcium, 1, 132
cardiovascular diseases, 714
corticosteroids, 1
decision support techniques, S68–23
drugs, S68–5
economic models, S68–21
glucocorticoids, 1, 132
government regulation, S68–5
Health Economics in Rheumatology Conference, S68–1, S68–5, S68–15, S68–21, S68–23, S68–26, S68–31
hypertension, 714
infliximab, 1883 (ab)
nonsteroidal antiinflammatory drugs, S68–15
OMERACT 6 conference, 886, 891
osteoarthritis, 714, S68–1, S68–26

osteoporosis, 132, S68–1, S68–15, S68–31
outcome and process assessment, 1739, S68–15
randomized controlled trials, S68–15
reference case, 886
reference standards, 891
reproducibility of results, 1739
rheumatoid arthritis, 714, 891, 1739, 1883 (ab)
rheumatology, S68–5, S68–21, S68–23
vitamin D, 1, 132
Coxa vara
camptodactyly, 1081
families, 1081
pericarditis, 1081
Creatine kinase
aldolase, 2077
dermatomyositis, 2077
polymyositis, 2077
CREST syndrome
impotence, 2503
Raynaud's phenomenon, 2503
sildenafil, 2503
Crohn's disease
ankylosing spondylitis, 102, 518
autoimmune diseases, 102
back pain, 518
genetic predisposition to disease, 102, 305
HLA-B27, 518
inflammatory bowel disease, 518
mutation, 305
sacroiliitis, 518
Wegener's granulomatosis, 305
Cross sectional studies
arthritis, 160
epidemiology, 160
quality of life, 160
socioeconomic factors, 160
Cryoglobulinemia
autoimmunity, 2005
hepatitis C virus, 2005
HIV, 2005
Cryoglobulins
antinuclear antibodies, 1473
autoantibodies, 1473
hepatitis C virus, 1473
systemic lupus erythematosus, 1473
Cultural adaptation
Arthritis Impact Measurement Scale, 379
Health Assessment Questionnaire, 379
Medical Outcome Study SF-36, 379
methods, 379
quality of life, 379
Cutaneous lupus
newborn infant, 1877 (ab)
systemic lupus erythematosus, 1877 (ab)
Cyclic amp
beta-adrenergic receptors, 364
fibromyalgia, 364
Cyclic peptides
antibodies, 1691
citrulline, 1691, 1696
diagnosis, 1691
monoclonal antibodies, 1696
polyarthritis, 1691
prognosis, 1691
rheumatoid arthritis, 1691, 1696
Cyclooxygenase 2 inhibitors
nonsteroidal antiinflammatory drugs, 1888 (ab)
rheumatic diseases, 1888 (ab)
Cyclooxygenase-2
cardiovascular system, 421
experimental arthritis, 1203
interleukin 17, 1879 (ab)
osteoarthritis, 421, 1879 (ab)
rheumatoid arthritis, 1203
rofecoxib, 421
rosmarinic acid, 1203
thrombosis, 421
Cyclooxygenase-2 inhibitors
cardiovascular system, 421
osteoarthritis, 421
rofecoxib, 421
thrombosis, 421
Cyclophosphamide
adjuvants, 497
corticosteroids, 1871
cytokines, 497
demyelinating diseases, 1871
experimental arthritis, 497
pulmonary fibrosis, 1121
systemic lupus erythematosus, 1871
systemic sclerosis, 1121
treatment, 1121
Cyclosporine
animal disease models, 2027
methotrexate, 2027
rheumatoid arthritis, 1889 (ab)
ribomunyl, 2027
scleritis, 1889 (ab)
Cysts
diagnosis, 1097
knee, 200, 1097, 1351
magnetic resonance imaging, 1097
rheumatoid arthritis, 1097, 1351
soft tissue neoplasms, 200
synovial membrane, 1351
systemic lupus erythematosus, 1351
Cytokines
adhesion molecules, 2133
adjuvants, 497
adult onset Still's disease, 2422
avocado, 1825
British Isles Lupus Assessment Group index, 2133
cartilage, 1825
cell communication, 1879 (ab)
chemokine receptors, 1928
cyclophosphamide, 497
disease activity, 2133
etidronate, 474
experimental arthritis, 497
fibromyalgia, 146
gene expression regulation, 1879 (ab)
interleukin, 146
interleukin 18, 2422
interleukin 2 receptors, 2422
methotrexate, 28
osteoarthritis, 1825, 1879 (ab)
osteoporosis, 474
prostaglandins, 1879 (ab)
rheumatoid arthritis, 28, 474, 1157, 1928
skin, 146
soybeans, 1825
synovial fluid, 1928
systemic lupus erythematosus, 2133
T lymphocytes, 1157
tumor necrosis factor, 146
Cytology
arthritis, 2713
hydrarthrosis, 2713
neoplasm metastasis, 2713
stomach, 2713
Cytotoxic T lymphocytes
natural killer cells, 660
rheumatoid arthritis, 660
synovial membrane, 660
Cytotoxicity tests
ankylosing spondylitis, 972
antigens, 972
peptides, 972
rheumatoid arthritis, 972

D

D-penicillamine
glomerulonephritis, 1616
Goodpasture syndrome, 1616
scleroderma, 1616
systemic sclerosis, 1616
D6S439
homozygosity, 2152
major histocompatibility complex, 2152
microsatellites, 2152
Sjögren's syndrome, 2152
Dactylitis
bursa, 1626
radius, 1626
thumb, 1626
Data collection
Canadian Osteoarthritis Rx Program, 2308
Consortium of Rheumatology Researchers of North America, 2308
rheumatic diseases, 2308
The Canadian Database of Osteoporosis and Osteopenia, 2308
Decision support techniques
cost-benefit analysis, S68–23
Health Economics in Rheumatology Conference, S68–23
rheumatology, S68–23
Defensins
inflammation, 1719
rheumatoid arthritis, 1719
Dehyroepiandrosterone
androgens, 2597
estrogen, 2597
rheumatoid arthritis, 2597
synovial fluid, 2597
Demyelinating diseases
corticosteroids, 1871
cyclophosphamide, 1871
systemic lupus erythematosus, 1871
Depression
age of onset, 952
body mass index, 2103
comorbidity, 1318
disability, 952, 1318
epidemiology, 2103
fibromyalgia, 1318
health care costs, 1318
osteoarthritis, 2103
quality of life, 952
rheumatoid arthritis, 952
risk factors, 2103
scleroderma, 1782
Dermatitis
adverse effects, 2506
etanercept, 2506
juvenile idiopathic arthritis, 2506
Dermatomycosis
immune system, 1491
onychomycosis, 1491
systemic lupus erythematosus, 1491
Dermatomyositis
aldolase, 2077
creatine kinase, 2077
edema, 2722
polymyositis, 2077
Diabetes mellitus
anserine, 352
bursitis, 352
hip, 422
infarction, 1881 (ab)
muscles, 1881 (ab)
tendinitis, 352
ultrasonography, 352

Diacerein
Bone and Joint Decade Conference, S67–14
chondroitin sulfate, S67–14
glucosamine, S67–14
osteoarthritis, S67–14
treatment outcome, S67–14
Diagnosis
Alizarin red, 1032
ankylosing spondylitis, 2729, 2732
anti-endomysial assay, 2613
antibodies, 1691
autoantibodies, 1451, 2374
autoimmunity, 2374
back pain, S67–26
Bath Ankylosing Spondylitis Disease Activity Index, 1883 (ab)
Bone and Joint Decade Conference, S67–26
bursitis, 1354
calcium pyrophosphate dihydrate crystal deposition, 1032
cardiovascular diseases, 493
celiac disease, 2613
citrulline, 1691
classification, 1880 (ab)
cyclic peptides, 1691
cysts, 1097
disease activity, 2729
electrophoresis, 2540
enzyme linked immunosorbent assay, 1451, 2374
epidemiology, S67–26
fibromyalgia, 1887 (ab)
glycoproteins, 2729
immunoglobulin G, 2540
immunology, 2535
inflammation, 1900
joints, 1900
juvenile idiopathic arthritis, 1900
knee, 908, 966, 1097
laparotomy, 1621
LE cells, 1880 (ab)
low back pain, 1883 (ab)
lumbar vertebrae, 2732
magnetic resonance imaging, 1097
meningitis, 2070
osteoporosis, 1878 (ab)
polyarthritis, 902, 1691
predictive value of tests, 2535
prognosis, 1691
psoriasis, 1900
purpura, 1621
questionnaires, 1887 (ab)
range of motion, 2732
reproducibility of results, 1883 (ab)
rheumatoid arthritis, 902, 908, 966, 1097, 1354, 1393, 1451, 1691, 2535, 2540
rheumatoid factor, 1393
risk factors, 493
Sjögren's syndrome, 2613
staining and labelling, 1032
sugars, 2540
synovial membrane, 1354
systemic lupus erythematosus, 493, 1880 (ab)
temporal arteritis, 2177
tissue transglutaminases, 2613
treatment outcome, S67–26
ultrasonography, 908, 966, 2177
vasculitis, 1621
Wegener's granulomatosis, 2070
Diagnostic imaging
computer assisted image processing, 238
radiography, 238
reproducibility of results, 238
rheumatoid arthritis, 238
Diagnostic tests
ankylosing spondylitis, 1878 (ab)
cardiovascular diseases, 899
disease activity, 1878 (ab)
systemic lupus erythematosus, 899
thrombosis, 1877 (ab)
Diclofenac
cartilage, 2444
celecoxib, 2444
hyaluronan, 2444
proteoglycans, 2444
Diet
disease activity, 747
fats, 747
systemic lupus erythematosus, 747
vitamin C, 747
Diphosphonates
See also Bisphosphonates
Bone and Joint Decade Conference, S67–21
bone density, 2673
connective tissue diseases, 2673
corticosteroids, 2673
fractures, S67–21
osteoporosis, 2673, S67–21
preventive medicine, S67–21
risk, S67–21
treatment outcome, S67–21
Disability
age of onset, 952
aged, 2689
anakinra, 1881 (ab)
ankylosing spondylitis, 2186
arthritis, S67–36
Bone and Joint Decade Conference, S67–36
chronic fatigue syndrome, 804
comorbidity, 1318
cost of illness, 804, S68–8
depression, 952, 1318
fibromyalgia, 804, 1318, 1880 (ab)
Health Assessment Questionnaire, 167
health care costs, 1318
Health Economics in Rheumatology Conference, S68–8
jurisprudence, S67–36
juvenile rheumatoid arthritis, 386, 832
knee, 114
lower extremity, 2689
musculoskeletal diseases, S68–8
osteoarthritis, 114
pain, 2689
prognosis, 386, 2186, 2344
quality of life, 952, 2689
radiography, 832, 2344
rheumatoid arthritis, 952, 1881 (ab), 2344
risk factors, 386
Stanford Health Assessment Questionnaire, 167
United Kingdom, S67–36
women, 1880 (ab)
Disclosure
conflict of interest, 1661, 1851
medical ethics, 1661, 1851
research support, 1661, 1851
Disease activity
adhesion molecules, 2133
alcohol drinking, 1215
ankylosing spondylitis, 1878 (ab), 2729
antinuclear antibodies, 1761
British Isles Lupus Assessment Group index, 2133
cytokines, 2133
diagnosis, 2729
diagnostic tests, 1878 (ab)
diet, 747
epidemiology, 1215
fats, 747
glycoproteins, 2729
monocytes, 2023
mortality, 1977
neuron specific enolase, 2606
OMERACT 6 conference, 1110, 1112, 1115
outcome and process assessment, 1112, 1115, 1960, 1967
outcome assessment, 1110
patient-physician relations, 1967
platelet activation, 2606
prognosis, 1977
randomized controlled trials, 1110, 1112
rheumatoid arthritis, 1110, 1112, 1115
scleroderma, 2606
single stranded DNA, 1761
smoking, 1215
systemic lupus erythematosus, 747, 1215, 1761, 1960, 1967, 1977, 2133
systemic sclerosis, 2606
Takayasu's arteritis, 2023
vitamin C, 747
Disease duration
autoantibodies, 1885 (ab)
rheumatoid arthritis, 1885 (ab)
Disease modifying antirheumatic drugs
adalimumab, 2563
ankylosing spondylitis, 2627
biological agents, S67–33
biological therapy, 241
Bone and Joint Decade Conference, S67–33, S67–51
cohort studies, 697
cost of illness, S67–51
drug induced abnormalities, 241
monoclonal antibodies, 2563
morbidity, S67–33
mortality, S67–33, S67–51
pregnancy, 241
rheumatoid arthritis, 241, 697, 2563, S67–33, S67–51
rheumatoid factor, S67–51
thalidomide, 2627
treatment cessation, 697
treatment outcome, S67–51
tumor necrosis factor receptors, 2563, 2627
Disease progression
arthroplasty, 1822
biological markers, 1043
Chinese, 1513
HLA, 4
HLA antigens, 96
joint erosions, 905
knee replacement, 1822
morbidity, 1513
mortality, 1513
natural history, 1822
osteoarthritis, 1043, 1822
osteocalcin, 1043
prognosis, 905
psoriatic arthritis, 4, 96
rheumatoid arthritis, 4, 905
risk, 1513
shared epitope, 4, 96
systemic lupus erythematosus, 1513
Disease susceptibility
age of onset, 913
ankylosing spondylitis, 2054
antineutrophil cytoplasmic

antibodies, 1534
articular manifestations, 1051
brucellosis, 1051
corticotropin-releasing hormone, 913
genetics, 435, 1534
giant cell arteritis, 2019
haplotypes, 2019
heredity, 1885 (ab)
HLA, 1534
HLA-B*39, 1051
inflammatory bowel disease, 2054
interleukin 2, 435
nitric oxide synthase, 2019
polymorphism, 435, 2019
psoriatic arthritis, 1885 (ab)
rheumatoid arthritis, 435, 913
rheumatoid factor, 913
vasculitis, 1534
vertical disease transmission, 2054
Disorders of excessive somnolence
muscarinic receptors, 2406
Sjögren's syndrome, 2406
urological manifestations, 2406
Distress
fibromyalgia, 567
pain, 567
psychology, 567
tender points, 567
DNA
polymorphism, 1520
scleroderma, 1520
systemic sclerosis, 1520
transforming growth factor, 1520
DNA directed RNA polymerases
autoantibodies, 2392
HLA, 2392
immunogenetics, 2392
systemic sclerosis, 2392
Doppler
arthroscopy, 2170
synovitis, 2170
ultrasonography, 2170
Doxycycline
clinical trials, 41
metaanalysis, 2112
minocycline, 2112
randomized controlled trials, 2112
rheumatoid arthritis, 41, 2112
Drug contamination
eosinophilia myalgia syndrome, 89
five-hydroxytryptophan, 89
high performance liquid chromatography, 89
mass spectrometry, 89
Drug dose-response relationship
antirheumatic agents, 2517
genetics, 2517
juvenile rheumatoid arthritis, 829
nabumetone, 829
Drug hypersensitivity
systemic lupus erythematosus, 480
Drug induced abnormalities
See also Iatrogenic diseases
autoantibodies, 2725
biological therapy, 241
child, 1876 (ab)
disease modifying antirheumatic drugs, 241
etanercept, 2725, 2727
eye, 2727
pregnancy, 241
rheumatoid arthritis, 241, 2727
systemic lupus erythematosus, 1876 (ab)
Drug industry
American College of Rheumatology, 202
codes of ethics, 202
medical ethics, 202
Drug therapy
gout, 44
juvenile rheumatoid arthritis, 394
outcome and process assessment, 394
patient compliance, 44
polymyalgia rheumatica, 44
rheumatoid arthritis, 44
Drug toxicity
See also Drug induced abnormalities
adverse effects, 443
antimalarials, 1756
clinical trials data monitoring committees, 1883 (ab)
metaanalysis, 1883 (ab)
nonsteroidal antiinflammatory drugs, 2680
ophthalmologic monitoring, 1756
rheumatoid arthritis, 443
risk, 443
systemic lupus erythematosus, 1756
treatment outcome, 2680
vision screening, 1756
Drugs
acetaminophen, 2226
adalimumab, 232, 2563
anakinra, 225, 1877 (ab), 1878 (ab), 1881 (ab)
anti-osteoporosis agents, S68–31
anticoagulants, 897
antirheumatic agents, S68–26
aspirin, 2226
azithromycin, 2292
BAY 12-9566, 544
biological therapy, 241
carboplatin, 1341
colchicine, 2620
collagen-PVP, 256
combination drug therapy, 2666
corticosteroids, 1, 207, 622, 1017, 1871, 2365, 2673
cost-benefit analysis, S68–5
cyclooxygenase-2 inhibitors, 1888 (ab)
cyclophosphamide, 497, 1121, 1871
cyclosporine, 1889 (ab), 2027
D-penicillamine, 1616
D6S439, 2152
diclofenac, 2444
diphosphonates, 2673
disease modifying antirheumatic drugs, 241, 697, 2627, S67–51
doxycycline, 41, 2112
etanercept, 401, 691, 1127, 1356, 1864, 1888 (ab), 1897, 2287, 2315, 2506, 2725, 2727
etidronate, 430, 468, 474
fluvoxamine, 1124
gemcitabine, 1341
glucocorticoids, 1, 132, 2492
glucosamine, 523, 2512
gold, 1875 (ab), 1876 (ab)
gold sodium thiomalate, 1748
government regulation, S68–5
growth hormone, 2492
Health Economics in Rheumatology Conference, S68–5
hylan G-F, 1880 (ab)
ibuprofen, 2226
immunosuppressive agents, 1793
infliximab, 204, 407, 760, 941, 1127, 1356, 1394, 1624, 1657, 1876 (ab), 1880 (ab), 1882 (ab), 1883 (ab), 1884 (ab), 1885 (ab), 1888 (ab), 2287, 2315, 2557
irsogladine maleate, 2082
isoniazid, 1657
L-tryptophan, 628
leflunomide, 1182, 1725, 1886 (ab), 2572
lenercept, 680
LF 15-0195, 918
lidocaine, 594
lidocaine/prilocaine, 594
mesalazine, 1558
methotrexate, 1725, 1875 (ab), 1881 (ab), 1948, 2082, 2325
minocycline, 2112
mycophenolate mofetil, 1508
nabumetone, 829
nonsteroidal antiinflammatory drugs, 203, 792, 1888 (ab), 2201, 2234, 2241, 2680, S68–15
pamidronate, 2080
pentoxifylline, 2382
pramipexole, 2733
prednisone, 2127
quinacrine, 2330
rheumatology, S68–5
ribomunyl, 2027
risedronate, 1877 (ab), 1886 (ab)
rofecoxib, 421
rosmarinic acid, 1203
salicin, 1125
sildenafil, 2503
slow acting antirheumatic drugs, 1816
sodium oxybate, 1070
sulfasalazine, 404
tetracycline, 1888 (ab), 2085
thalidomide, 2627
valpromide, 208
yohimbe, 2503
Duodenum
ankylosing spondylitis, 2428
colitis, 2428
inflammation, 2428
nitric oxide, 2428
Durban
classification, 1857
ILAR, 1857
juvenile idiopathic arthritis, 1857
nomenclature, 1857
Dysgeusia
fibromyalgia, 1841
glossodynia, 1841
temporomandibular joint, 1841
xerostomia, 1841

E

Ear piercing
cartilage, 2716
relapsing polychondritis, 2716
trauma, 2716
Economic models
cost-benefit analysis, S68–21
Health Economics in Rheumatology Conference, S68–21
rheumatology, S68–21
Edema
dermatomyositis, 2722
Electrophoresis
diagnosis, 2540
immunoglobulin G, 2540
rheumatoid arthritis, 2540
sugars, 2540
Employment
fibromyalgia, 2045
health status, 2045

Enchondromatosis
hand, 1100
Sella turcica, 1100
Endothelial growth factors
angiopoietins, 260
rheumatoid arthritis, 260
Endothelium
hyperhomocysteinemia, 1400, 1479
platelet activation, 1479
systemic lupus erythematosus, 1400, 1479, 1963
von Willebrand factor, 1963
Enteric bacteria
etiology, 105
immune response, 105
spondyloarthropathy, 105
Enthesis
histology, 508
posterior tibial tendon dysfunction, 508
spondyloarthropathy, 508
Enzyme linked immunosorbent assay
autoantibodies, 1451, 2374
autoimmunity, 2374
diagnosis, 1451, 2374
rheumatoid arthritis, 1451
Eosinophilia myalgia syndrome
drug contamination, 89
five-hydroxytryptophan, 89
high performance liquid chromatography, 89
hypoalbuminemia, 628
hypoproteinemia, 628
L-tryptophan, 628
mass spectrometry, 89
Eosinophilic fasciitis
immunophenotyping, 1811
T lymphocytes, 1811
Epidemiology
alcohol drinking, 1215, 1222
Amish, 1835
amyloidosis, 948
ankylosing spondylitis, 1816, 2245
arthritis, 160, 2299, 2476
back pain, S67–26
body mass index, 2103
Bone and Joint Decade Conference, S67–26, S67–54, S67–56, S67–66
cardiovascular diseases, 1196
child, 2275, 2513
China, 1816, 2090, 2245
classification, 1665, 1666, 1668, 1671
Community Oriented Program for Control of Rheumatic Diseases, 2090, 2245
complications, 948
COPCORD, 2312
cross sectional studies, 160
depression, 2103
diagnosis, S67–26
disease activity, 1215
exercise, 2299, 2476
fibromyalgia, 1665, 1666, 1668, 1671, 1835
gout, 2245, 2312
Greece, 731, 1589, 2641
health status, S67–26
hyperuricemia, 2312
iatrogenic diseases, 1666, 1668
incidence, 731, 2460
India, 948
Indonesia, 2312, S67–54
jurisprudence, 1665, 1668, 1671
juvenile rheumatoid arthritis, 2275
macrophage activation syndrome, 2513
mortality, 1196
musculoskeletal diseases, 1589
musculoskeletal system, S67–56
nutrition, S67–66
osteoarthritis, 1196, 2103, S67–66
pain, 1666
prevalence, 1589, 1835
psoriatic arthritis, 2641
psychological stress, 2299, 2476
quality of life, 160
rheumatic diseases, 1589, 2090, 2245, S67–54
rheumatoid arthritis, 948, 1196, 2245, 2460, S67–66
risk factors, 2103
Russia, S67–56
self-medication, 2312
slow acting antirheumatic drugs, 1816
smoking, 1215, 1222
socioeconomic factors, 160
spondyloarthropathy, 2460
survival, 731
systemic lupus erythematosus, 731, 1215, 1222
treatment, 1816
treatment outcome, S67–26
Epitope
Ki antigen, 1208
Sjögren's syndrome, 1208
systemic lupus erythematosus, 1208
Epstein-Barr virus
rheumatoid arthritis, 1673
T lymphocytes, 1673
Errata
See Corrections
Erysipelas
child, 185
erythema, 185
familial Mediterranean fever, 185
genetics, 185
Erythema
child, 185
erysipelas, 185
familial Mediterranean fever, 185
genetics, 185
Estrogens
androgens, 1267, 2413, 2597
dehydroepiandrosterone, 2597
hormone replacement therapy, 1267
rheumatoid arthritis, 2597
Sjögren's syndrome, 1267, 2413
synovial fluid, 2597
xerophthalmia, 2413
Etanercept
adverse effects, 2506
aged, 691
ankylosing spondylitis, 1127, 1356
autoantibodies, 2725
biological therapy, 2315
consensus development conferences, 1356
dermatitis, 2506
drug induced abnormalities, 2725, 2727
eye, 2727
infertility, 1897
infliximab, 1127, 1356, 2287, 2315
juvenile idiopathic arthritis, 2506
juvenile rheumatoid arthritis, 401
macrophage activation syndrome, 401
psoriatic arthritis, 1888 (ab)
rheumatoid arthritis, 691, 2287, 2315, 2727
sarcoidosis, 1864
SpA Research Consortium of Canada, 1127, 1356
spondyloarthropathy, 1127
tumor necrosis factor receptors, 691
tumor necrosis factors, 1897
vasculitis, 2287
Ethnic groups
analgesics, 2201
arthroplasty, 1305
health services, 1305, 2201
nonsteroidal antiinflammatory drugs, 2201
osteoarthritis, 1305, 2201
Etidronate
bone and bones, 468
collagen, 468
cytokines, 474
osteoporosis, 474
rheumatoid arthritis, 430, 468, 474
Etiology
enteric bacteria, 105
immune response, 105
infection, 425
reactive arthritis, 425
rheumatoid arthritis, 425
spondyloarthropathy, 105
Exercise
arthritis, 2299, 2476
beer, 1036
epidemiology, 2299, 2476
gouty arthritis, 1036
knee, 1311
osteoarthritis, 1311, 2039
physiotherapy, 1311
psychological stress, 2299, 2476
randomized controlled trials, 1311
tai chi, 2039
uric acid, 1036
women, 2039
Exercise test
cardiovascular deconditioning, 1075
exercise tolerance, 1075
physical fitness, 1075
Exercise therapy
fibromyalgia, 1060, 1879 (ab)
oxygen, 1060
physical fitness, 1060
Exercise tolerance
cardiovascular deconditioning, 1075
exercise test, 1075
physical fitness, 1075
Experimental arthritis
adjuvants, 497
biological markers, 1561
bisphosphonates, 1280
cartilage erosion, 1561
cyclooxygenase-2, 1203
cyclophosphamide, 497
cytokines, 497
incadronate (YM175), 1280
inflammation, 1280
interleukin 6, 22
joint erosions, 1280
knockout mice, 22
matrix metalloproteinases, 211, 355, 1561
retinoic acid receptors, 211, 355
rheumatoid arthritis, 22, 211, 355, 1203
rosmarinic acid, 1203
tumor necrosis factor receptors, 22
urine, 1561
Extractable nuclear antigens
antinuclear antibodies, 736
connective tissue diseases, 736
Raynaud's phenomenon, 736
Eye
Behçet's disease, 1888 (ab)
drug induced abnormalities, 2727

etanercept, 2727
inflammation, 1888 (ab)
infliximab, 1888 (ab)
rheumatoid arthritis, 2727

F

Facial hemiatrophy
central nervous system, 1997
cerebrovascular circulation, 1997
scleroderma, 193, 1997
Sturge-Weber syndrome, 193
systemic sclerosis, 193
Factor V
anticardiolipin antibodies, 2385
lupus anticoagulant, 2385
thrombophilia, 2385
thrombosis, 2385
Familial Mediterranean fever
amyloidosis, 308, 313
apoptosis, 313
arthritis, 308
child, 185
colchicine, 2620
erysipelas, 185
erythema, 185
genetics, 185, 308, 2014
helper-inducer T lymphocytes, 2011
interferon-gamma, 2011
intravenous injections, 2620
juvenile arthritis, 2014
sex, 308
treatment failure, 2620
Families
camptodactyly, 1081
coxa vara, 1081
pericarditis, 1081
Family
antineutrophil cytoplasmic antibodies, 618
Churg-Strauss syndrome, 618
HLA, 618
Wegener's granulomatosis, 618
Family physician
juvenile rheumatoid arthritis, 2700
pediatrics, 2700
physician's practice patterns, 2700
Fas
apoptosis, 550
CD95 antigens, 550
chondrocytes, 550
Fatigue
breast implants, 2263
central nervous system lupus vasculitis, 283
fibromyalgia, 1070
pain, 1070, 2263
psychology, 283
silicone, 2263
sleep, 1070
sodium oxybate, 1070
systemic lupus erythematosus, 283
Fats
diet, 747
disease activity, 747
systemic lupus erythematosus, 747
vitamin C, 747
Fc gamma RIII
Fc-receptors, 1911
genetics, 1904
macrophages, 1911
natural killer cells, 1911
rheumatoid arthritis, 1904, 1911
Fc-receptors
Fc gamma RIII, 1911
macrophages, 1911
natural killer cells, 1911
rheumatoid arthritis, 1911
Felty's syndrome
rheumatoid arthritis, 404
sulfasalazine, 404
Femur head
osteoblasts, 348
osteonecrosis, 348
Ferritin
glycosylation, 1027
hemophagocytosis syndrome, 1027
macrophage activation, 1027
Ferrous sulfate
methotrexate, 1948
rheumatoid arthritis, 1948
Fever
inflammation, 1272
signs and symptoms, 1272
temporal arteritis, 1272
Fibrinolysis
blood coagulation factors, 783
osteonecrosis, 783
thrombophilia, 783
Fibroblasts
rheumatoid arthritis, 1680
synovial membrane, 1680
tumor necrosis factor receptors, 1680
tumor necrosis factors, 1680
Fibromyalgia
alternative medicine, 2088, 2257
Amish, 1835
beta-adrenergic receptors, 364
chronic fatigue syndrome, 804
classification, 1665, 1666, 1668, 1671
comorbidity, 1318
cost of illness, 804, 1886 (ab)
cyclic amp, 364
cytokines, 146
depression, 1318
diagnosis, 1887 (ab)
disability, 804, 1318, 1880 (ab)
distress, 567
dysgeusia, 1841
employment, 2045
epidemiology, 1665, 1666, 1668, 1671, 1835
exercise therapy, 1060, 1879 (ab)
fatigue, 1070
fluvoxamine, 1124
France, 1054
glossodynia, 1841
growth hormone, 809
health care costs, 1318
health status, 2045
hypoglycemia, 809
iatrogenic diseases, 1666, 1668
insulin-like growth factor-I, 809
interleukin, 146
jurisprudence, 1665, 1668, 1671
meditation, 2088, 2257
Medline, 151
nutritional status, 1884 (ab)
outcome and process assessment, 1054
oxygen, 1060
pain, 369, 567, 1054, 1070, 1666
pain measurement, 369
patient satisfaction, 1326
periodicals, 151
physical fitness, 1060
physician-patient relations, 1326
pramipexole, 2733
prevalence, 1835
psychology, 567
Qigong movement therapy, 2088, 2257
quality of life, 1054, 1879 (ab)
questionnaires, 1054, 1887 (ab)
rheumatoid arthritis, 369
skin, 146
sleep, 1070
sodium oxybate, 1070
spondyloarthropathy, 1879 (ab)
temporomandibular joint, 1841
tender points, 567
treatment, 154
tumor necrosis factor, 146
validation studies, 1054
women, 1880 (ab), 1886 (ab)
xerostomia, 1841
Fibrosis
connective tissue growth factor, 755
systemic sclerosis, 755
transforming growth factor, 755
Five-hydroxytryptophan
drug contamination, 89
eosinophilia myalgia syndrome, 89
high performance liquid chromatography, 89
mass spectrometry, 89
FK506
animal disease models, 2193
interleukin 1 beta, 2193
interleukin 6, 2193
rheumatoid arthritis, 2193
tumor necrosis factors, 2193
Fluvoxamine
fibromyalgia, 1124
Foot
gout, 863
hand, 671
magnetic resonance imaging, 671
orthotic devices, 2356
randomized controlled trials, 2356
rheumatoid arthritis, 671, 2356
Forefoot
arthrodesis, 1440
arthroplasty, 1440
metatarsophalangeal, 1440
rheumatoid arthritis, 1440
Fractures
Bone and Joint Decade Conference, S67–21
calcium, 1878 (ab)
diphosphonates, S67–21
hip, 1879 (ab)
osteoporosis, 1878 (ab), 1886 (ab), S67–21
preventive medicine, S67–21
quality of life, 1879 (ab)
risedronate, 1877 (ab), 1886 (ab)
risk, S67–21
treatment outcome, S67–21
France
Bone and Joint Decade Conference, S67–42
fibromyalgia, 1054
osteoporosis, S67–42
outcome and process assessment, 1054
pain, 1054
quality of life, 1054
questionnaires, 1054
spondyloarthropathy, S67–42
validation studies, 1054

G

G binding protein
autoantibodies, 993
guanosine, 993
systemic lupus erythematosus, 993

Gait
biomechanics, 529
knee, 529
osteoarthritis, 529
shoes, 529
Gastric antral vascular ectasia
Sjögren's syndrome, 1090
Gastrointestinal hemorrhage
adverse effects, 792
congestive heart failure, 792
nonsteroidal antiinflammatory drugs, 792
Gastrointestinal system
acetaminophen, 2226
adverse effects, 203
aspirin, 2226
hemorrhage, 2241
ibuprofen, 2226
nonsteroidal antiinflammatory drugs, 203, 2241
risk factors, 2241
Gemcitabine
antineoplastic agents, 1341
carboplatin, 1341
necrosis, 1341
scleroderma, 1341
Gene deletion
articular cartilage, 247
autoimmunity, 247
nitric oxide, 247
Gene expression regulation
cytokines, 1879 (ab)
gene expression regulation, 2330
matrix metalloproteinase, 2330
osteoarthritis, 1879 (ab)
prostaglandins, 1879 (ab)
quinacrine, 2330
transcription factors, 2330
Genes
parvovirus B19, 1907
rheumatoid arthritis, 1907
synovitis, 1907
Genetic predisposition to disease
ankylosing spondylitis, 102
autoimmune diseases, 102
Blacks, 60
Crohn's disease, 102, 305
microsatellite repeats, 60
mutation, 305
polymorphism, 60
promoter regions, 60
systemic lupus erythematosus, 60
Wegener's granulomatosis, 305
Genetics
amyloidosis, 308
ankle joint, 196
ankylosing spondylitis, 2182
antineutrophil cytoplasmic antibodies, 1534
antirheumatic agents, 2517
arthritis, 308
child, 185
disease susceptibility, 435, 1534
drug dose response relationship, 2517
erysipelas, 185
erythema, 185
familial Mediterranean fever, 185, 308, 2014
Fc gamma RIII, 1904
foot, 196
hemochromatosis, 196
HFE gene, 196
HLA, 1534
HLA antigens, 1298
HLA-B27, 2182
interleukin 2, 435
joint diseases, 196
juvenile ankylosing spondylitis, 2182
juvenile arthritis, 2014
North American Indians, 1887 (ab)
osteoarthritis, 1298
outcome and process assessment, 2638
polymorphism, 435
psoriasis, 2638
psoriatic arthritis, 1885 (ab), 2638
rheumatoid arthritis, 435, 1887 (ab), 1904
sex, 308
vasculitis, 1534
Genotype
angiotensin converting enzyme, 2705
juvenile rheumatoid arthritis, 2705
polymerase chain reaction, 2705
polymorphism, 2705
Giant cell arteritis
age of onset, 1548
amyloidosis, 2283
blindness, 625
disease susceptibility, 2019
haplotypes, 2019
HLA-DRB1*, 2729
ischemia, 2160
jaw abnormality, 2283
nitric oxide synthase, 2019
optic nerve diseases, 625
polymorphism, 2019, 2160
polymyalgia rheumatica, 2283, 2729
sex, 1119, 1548
Spain, 1548
temporal arteritis, 1548
vascular endothelial growth factor, 2160
Giant cells
ADAM8, 2033
hip replacement arthroplasty, 2033
osteoclasts, 2033
synovial membrane, 2033
Glomerulonephritis
biliary liver cirrhosis, 2710
D-penicillamine, 1616
Goodpasture syndrome, 1616
scleroderma, 1616
systemic sclerosis, 1616
vasculitis, 2710
Glossodynia
dysgeusia, 1841
fibromyalgia, 1841
temporomandibular joint, 1841
xerostomia, 1841
Glottis
corticosteroids, 1017
stenosis, 1017
treatment, 1017
Wegener's granulomatosis, 1017
Glucocorticoids
bisphosphonates, 132
calcium, 1, 132
corticosteroids, 1
cost-benefit analysis, 1, 132
growth, 2492
growth hormone, 2492
juvenile idiopathic arthritis, 2492
osteoporosis, 132
vitamin D, 1, 132
Glucosamine
Bone and Joint Decade Conference, S67–14
chondroitin sulfate, S67–14
diacerein, S67–14
knee, 523, 2512
osteoarthritis, 523, 2512, S67–14
pain, 523
topical administration, 2512
treatment outcome, S67–14
Glutathione transferase
autoimmune diseases, 276
metabolism, 276
systemic lupus erythematosus, 276
ultraviolet rays, 276
Glycoproteins
ankylosing spondylitis, 2729
antiphospholipid syndrome, 1875 (ab)
diagnosis, 2729
disease activity, 2729
T lymphocytes, 1875 (ab)
Glycosylation
ferritin, 1027
hemophagocytosis syndrome, 1027
macrophage activation, 1027
Gold
intramuscular, 1876 (ab)
rheumatoid arthritis, 1876 (ab)
Gold sodium thiomalate
rheumatoid arthritis, 1748
Goodpasture syndrome
D-penicillamine, 1616
glomerulonephritis, 1616
scleroderma, 1616
systemic sclerosis, 1616
Gottron's rash
arsenic poisoning, 415
Gout
ankylosing spondylitis, 2245
arthroscopy, 1868
cellulitis, 417
China, 2245
Community Oriented Program for Control of Rheumatic Diseases, 2245
drug therapy, 44
epidemiology, 2245
foot, 863
hyperuricemia, 2437
hypouricemia, 849
Indonesia, 2437
parenteral nutrition, 849
patient compliance, 44
polymyalgia rheumatica, 44
rheumatic diseases, 2245
rheumatoid arthritis, 44, 2245
self-medication, 2437
tophus, 1868
ultrasonography, 417
uric acid, 849
Gouty arthritis
beer, 1036
exercise, 1036
uric acid, 1036
Government regulation
cost-benefit analysis, S68–5
drugs, S68–5
Health Economics in Rheumatology Conference, S68–5
rheumatology, S68–5
Graduate medical education
rheumatology, 1882 (ab)
Granzyme B
cartilage, 1799
chondrocytes, 1799
perforins, 1799
remodeling, 1799
rheumatoid arthritis, 1799
Greece
epidemiology, 731, 1589, 2641
incidence, 731
musculoskeletal diseases, 1589
prevalence, 1589
psoriatic arthritis, 2641
rheumatic diseases, 1589
survival, 731
systemic lupus erythematosus, 731
Group psychotherapy
psychogical adaptation, 1011

quality of life, 1011
systemic lupus erythematosus, 1011
Growth
glucocorticoids, 2492
growth hormone, 2492
juvenile idiopathic arthritis, 2492
Growth hormone
fibromyalgia, 809
glucocorticoids, 2492
growth, 2492
hypoglycemia, 809
insulin-like growth factor-I, 809
juvenile idiopathic arthritis, 2492
GTP cyclohydrolase
argininosuccinate synthase, 652
nitric oxide, 652
tumor necrosis factors, 652
Guanosine
autoantibodies, 993
G binding protein, 993
systemic lupus erythematosus, 993
Guidelines
Bone and Joint Decade Conference, S67–38
cost of illness, S67–38
musculoskeletal diseases, S67–38

H

Hand
cirrhosis, 1628
enchondromatosis, 1100
foot, 671
Health Assessment Questionnaire, 1253
inflammation, 1628
ischemia, 1788
magnetic resonance imaging, 671
metaanalysis, 1788
outcome and process assessment, 1253
physician's practice patterns, 1464
rheumatoid arthritis, 671, 1464
Sella turcica, 1100
skin, 1253
surgery, 1464, 1788
sympathectomy, 1788
systemic sclerosis, 1253
Haplotypes
disease susceptibility, 2019
giant cell arteritis, 2019
nitric oxide synthase, 2019
polymorphism, 2019
Health Assessment Questionnaire
anakinra, 225
Arthritis Impact Measurement Scale, 379
cultural adaptation, 379
disability, 167
hand, 1253
interleukin receptors, 225
Medical Outcome Study SF-36, 379
methods, 379
outcome and process assessment, 1253, 1885 (ab)
quality of life, 225, 379
rheumatoid arthritis, 225
scleroderma, 1885 (ab)
skin, 1253
Stanford Health Assessment Questionnaire, 167
systemic sclerosis, 1253
Health care costs
comorbidity, 1318
depression, 1318
disability, 1318
fibromyalgia, 1318
Health care rationing
medical specialties, 1890
rheumatology, 1890
Health Economics in Rheumatology Conference
anti-osteoporosis agents, S68–31
antirheumatic agents, S68–26
cost of illness, S68–8
cost-benefit analysis, S68–1, S68–5, S68–15, S68–21, S68–23, S68–26, S68–31
decision support techniques, S68–23
disability, S68–8
drugs, S68–5
economic models, S68–21
government regulation, S68–5
health services accessibility, S68–12
introduction, S68–1
musculoskeletal diseases, S68–8
nonsteroidal antiinflammatory drugs, S68–15
osteoarthritis, S68–1, S68–26
osteoporosis, S68–1, S68–15, S68–31
outcome and process assessment, S68–15
patient satisfaction, S68–12
randomized controlled trials, S68–15
rheumatology, S68–5, S68–21, S68–23
Health policy
Bone and Joint Decade Conference, S67–6
musculoskeletal system, S67–6
World Health Organization, S67–6
Health resources
cost of illness, 1878 (ab)
systemic lupus erythematosus, 1878 (ab)
Health services
analgesics, 2201
arthroplasty, 1305
ethnic groups, 1305, 2201
nonsteroidal antiinflammatory drugs, 2201
osteoarthritis, 1305, 2201
Health services accessibility
Health Economics in Rheumatology Conference, S68–12
patient satisfaction, S68–12
Health services research
hospital emergency service, 1238
hospitalization, 1238
scleroderma, 1238
socioeconomic factors, 1238
systemic sclerosis, 1238
Health status
employment, 2045
fibromyalgia, 2045
infliximab, 941
juvenile rheumatoid arthritis, 1602
quality of life, 941, 1602
questionnaires, 1602
rheumatoid arthritis, 941
Health status indicators
OMERACT 6 conference, 873
patient participation, 873
rheumatoid arthritis, 873
Heart rate
autonomic nervous system, 74
baroreflex, 74
cardiovascular system, 74
Heat shock proteins
autoantibodies, 1875 (ab)
systemic lupus erythematosus, 1875 (ab)
Helper-inducer T lymphocytes
animal disease models, 918
autoimmunity, 918
cc chemokines, 2365
familial Mediterranean fever, 2011
interferon-gamma, 2011
LF 15-0195, 918
rheumatoid arthritis, 918
systemic lupus erythematosus, 2365
Hemochromatosis
aging, 121
ankle joint, 196
foot, 196
genetics, 196
HFE gene, 196
iron, 121
joint diseases, 196
mutation, 121
osteoarthritis, 121
Hemophagocytosis syndrome
ferritin, 1027
glycosylation, 1027
macrophage activation, 1027
Hemophilia
animal disease models, 339
blood, 339
cartilage, 339
proteoglycans, 339
Hemorrhage
gastrointestinal system, 2241
nonsteroidal antiinflammatory drugs, 2241
risk factors, 2241
Hepatitis
adult-onset Still's disease, 1624
hepatitis B virus, 1624
infliximab, 1624
Hepatitis B virus
adult-onset Still's disease, 1624
hepatitis, 1624
infliximab, 1624
Hepatitis C virus
antinuclear antibodies, 1473
autoantibodies, 1473
autoimmunity, 2005
cryoglobulinemia, 2005
cryoglobulins, 1473
HIV, 2005
interferon-alpha, 1775
mixed cryoglobulinemia, 1775
non-Hodgkin's lymphoma, 1775
rheumatoid arthritis, 455
rheumatoid factor, 455
ribavirin, 1775
systemic lupus erythematosus, 1473
Hepatocyte growth factor
adult onset Still's disease, 1093
liver failure, 1093
liver transplantation, 1093
Heredity
disease susceptibility, 1885 (ab)
psoriatic arthritis, 1885 (ab)
HFE gene
ankle joint, 196
foot, 196
genetics, 196
hemochromatosis, 196
joint diseases, 196
High performance liquid chromatography
drug contamination, 89
eosinophilia myalgia syndrome, 89
five-hydroxytryptophan, 89
mass spectrometry, 89
Hip
diabetes mellitus, 422

fractures, 1879 (ab)
knee, 2452
osteoarthritis, 2452
outcome and process assessment, 2452
patient satisfaction, 2452
quality of life, 1879 (ab)
WOMAC index, 2452
Hip replacement arthroplasty
ADAM8, 2033
giant cells, 2033
osteoclasts, 2033
synovial membrane, 2033
Histiocytic necrotizing lymphadenitis
rash, 857
systemic lupus erythematosus, 857
Histology
animal disease models, 2218
cartilage, 2218
enthesis, 508
osteoarthritis, 2218
posterior tibial tendon dysfunction, 508
spondyloarthropathy, 508
HIV
antiphospholipid antibodies, 214
antiphospholipid syndrome, 214
autoimmunity, 2005
cryoglobulinemia, 2005
hepatitis C virus, 2005
infection, 214
infliximab, 407
reactive arthritis, 407
rheumatoid arthritis, 2294
HLA
antineutrophil cytoplasmic antibodies, 618, 1534
autoantibodies, 2392
Churg-Strauss syndrome, 618
disease progression, 4
disease susceptibility, 1534
DNA directed RNA polymerases, 2392
family, 618
genetics, 1534
immunogenetics, 2392
psoriatic arthritis, 4
rheumatoid arthritis, 4
shared epitope, 4
systemic sclerosis, 2392
vasculitis, 1534
Wegener's granulomatosis, 618
HLA antigens
disease progression, 96
genetics, 1298
osteoarthritis, 1298
psoriatic arthritis, 96
shared epitope, 96
HLA-B*39
articular manifestations, 1051
brucellosis, 1051
disease susceptibility, 1051
HLA-B27
age of onset, 505
alleles, 2511, 2632
ankylosing spondylitis, 321, 518, 1120, 2182, 2511
back pain, 518
Brazil, 2511, 2632
Crohn's disease, 518
genetics, 2182
HLA-B7, 2632
inflammatory bowel disease, 518
juvenile ankylosing spondylitis, 2182
polymerase chain reaction, 321
polymorphism, 321
prognosis, 2632
psoriasis, 505
psoriatic arthritis, 505, 2508
reactive arthritis, 1291
sacroiliitis, 518
spondyloarthropathy, 1291, 2632
synovial membrane, 1291
Taiwan, 321
HLA-B7
alleles, 2632
Brazil, 2632
HLA-B27, 2632
prognosis, 2632
spondyloarthropathy, 2632
HLA-DM
polymorphism, 1485
systemic lupus erythematosus, 1485
HLA-DR antigens
autoantigens, 449
major histocompatibility complex, 449
rheumatoid arthritis, 449
T cell antigen receptors, 449
T lymphocytes, 449
HLA-DRB1*
giant cell arteritis, 2729
polymyalgia rheumatica, 2729
Homocysteine
lung, 298
scleroderma, 298
systemic sclerosis, 298
Homozygosity
D6S439, 2152
major histocompatibility complex, 2152
microsatellites, 2152
Sjögren's syndrome, 2152
Hormone replacement therapy
androgens, 1267
estrogens, 1267
radiography, 1456
randomized controlled trials, 1456
rheumatoid arthritis, 1456
Sjögren's syndrome, 1267
Hospital emergency service
health services research, 1238
hospitalization, 1238
scleroderma, 1238
socioeconomic factors, 1238
systemic sclerosis, 1238
Hospitalization
health services research, 1238
hospital emergency service, 1238
scleroderma, 1238
socioeconomic factors, 1238
systemic sclerosis, 1238
Humerus
bone and bones, 851
osteomyelitis, 851
shoulder pain, 851
tuberculosis, 851
Hyaluronan
cartilage, 2444
celecoxib, 2444
diclofenac, 2444
proteoglycans, 2444
Hyaluronic acid
matrix metalloproteinase-1, 1164
rheumatoid arthritis, 1164
Hydrarthrosis
arthritis, 2713
cytology, 2713
neoplasm metastasis, 2713
stomach, 2713
Hydroxypregnenolone
pregnenolone, 269
rheumatoid arthritis, 269
systemic lupus erythematosus, 269
Hylan G-F
intra-articular injection, 1880 (ab)
osteoarthritis, 1880 (ab)
Hyperhomocysteinemia
endothelium, 1400, 1479
platelet activation, 1479
systemic lupus erythematosus, 1400, 1479
Hypersensitivity
See also Drug hypersensitivity
Hypertension
blood pressure, 642
cardiovascular diseases, 642, 714
cost-benefit analysis, 714
osteoarthritis, 642, 714
pulmonary artery, 1881 (ab)
rheumatoid arthritis, 642, 714
systemic lupus erythematosus, 1881 (ab)
Hyperuricemia
COPCORD, 2312
epidemiology, 2312
gout, 2312, 2437
Indonesia, 2312, 2437
self-medication, 2312, 2437
Hypoalbuminemia
eosinophilia myalgia syndrome, 628
hypoproteinemia, 628
L-tryptophan, 628
Hypoglycemia
fibromyalgia, 809
growth hormone, 809
insulin-like growth factor-I, 809
Hypoproteinemia
eosinophilia myalgia syndrome, 628
hypoalbuminemia, 628
L-tryptophan, 628
Hypouricemia
gout, 849
parenteral nutrition, 849
uric acid, 849

I

Iatrogenic diseases
See also Drug induced abnormalities
classification, 1666, 1668
epidemiology, 1666, 1668
fibromyalgia, 1666, 1668
jurisprudence, 1668
lupus-like syndrome, 208
pain, 1666
systemic lupus erythematosus, 208
valpromide, 208
vasculitis, 208
Ibuprofen
acetaminophen, 2226
aspirin, 2226
gastrointestinal system, 2226
IgG receptors
immune complexes, 648
interleukin 10, 648
linkage, 926
polymorphism, 926
rheumatoid arthritis, 648, 926
tumor necrosis factors, 648
ILAR
classification, 1857
Durban, 1857
juvenile idiopathic arthritis, 1857
nomenclature, 1857
Immobilization
apoptosis, 559
articular cartilage, 559
protein 53, 559
Immune complexes
IgG receptors, 648
interleukin 10, 648
rheumatoid arthritis, 648
tumor necrosis factors, 648
Immune response
enteric bacteria, 105
etiology, 105

spondyloarthropathy, 105
Immune system
dermatomycosis, 1491
kynurenine, 1935
men, 2302
neopterin, 1935
onychomycosis, 1491
rheumatoid arthritis, 1935, 2302
sex hormones, 2302
systemic lupus erythematosus, 1491
tryptophan, 1935
Immunization
influenza, 2295
systemic lupus erythematosus, 2295
Immunogenetics
autoantibodies, 2392
DNA directed RNA polymerases, 2392
HLA, 2392
systemic sclerosis, 2392
Immunoglobulin G
diagnosis, 2540
electrophoresis, 2540
rheumatoid arthritis, 2540
sugars, 2540
Immunohistochemistry
atlantoaxial joint, 1420
bone and bones, 2319
cartilage, 1420
cervical vertebrae, 1420
ligament, 1420
NF-kappa B, 2319
RANKL, 2319
rheumatoid arthritis, 1420, 2319
tumor necrosis factor receptors, 2319
Immunology
diagnosis, 2535
predictive value of tests, 2535
rheumatoid arthritis, 2535
Immunophenotyping
eosinophilic fasciitis, 1811
T lymphocytes, 1811
Immunosuppression
mycophenolate mofetil, 1508
systemic lupus erythematosus, 1508
Immunosuppressive agents
angiography, 1793
Takayasu's arteritis, 1793
In situ hybridization
leukotriene B_4, 1712
rheumatoid arthritis, 1712
Incadronate (YM175)
bisphosphonates, 1280
experimental arthritis, 1280
inflammation, 1280
joint erosions, 1280
Incidence
epidemiology, 731, 2460
Greece, 731
rheumatoid arthritis, 2460
spondyloarthropathy, 2460
survival, 731
systemic lupus erythematosus, 731
Inclusion body myositis
classification, 1892
magnetic resonance imaging, 1892
polymyositis, 1892
India
amyloidosis, 948
complications, 948
epidemiology, 948
rheumatoid arthritis, 948
Indonesia
Bone and Joint Decade Conference, S67–54
COPCORD, 2312
epidemiology, 2312, S67–54
gout, 2312, 2437
hyperuricemia, 2312, 2437
rheumatic diseases, S67–54
self-medication, 2312, 2437
Infarction
diabetes mellitus, 1881 (ab)
ischemia, 634
kidney, 634
muscles, 1881 (ab)
pain, 634
systemic lupus erythematosus, 634
Infection
campylobacter, 459
etiology, 425
parvovirus B19, 2624
polymyalgia rheumatica, 2624
reactive arthritis, 425, 459
rheumatoid arthritis, 425, 459
seasons, 2624
Infertility
etanercept, 1897
tumor necrosis factors, 1897
Inflammation
adhesion molecules, 1611
ankylosing spondylitis, 2306, 2428
bisphosphonates, 1280
cardiovascular diseases, 1403
cirrhosis, 1628
colitis, 2306, 2428
defensins, 1719
diagnosis, 1900
duodenum, 2428
experimental arthritis, 1280
fever, 1272
hand, 1628
incadronate (YM175), 1280
insulin resistance, 1403
interleukin 2, 2147
joint erosions, 1280
joints, 1900, 2147
juvenile idiopathic arthritis, 1611, 1900
lymphocyte homing receptors, 1611
nitric oxide, 1173, 2428
peroxynitrous acid, 1173
psoriasis, 1900
rheumatoid arthritis, 1173, 1403, 1611, 1719
risk factors, 1403
signs and symptoms, 1272
spondyloarthropathy, 2306
synovial membrane, 1173
systemic sclerosis, 2147
T lymphocytes, 1611
temporal arteritis, 1272
YKL-40, 2147
Inflammatory bowel disease
ankylosing spondylitis, 518, 2054
back pain, 518
Crohn's disease, 518
disease susceptibility, 2054
HLA-B27, 518
sacroiliitis, 518
vertical disease transmission, 2054
Infliximab, 1884 (ab)
adult-onset Still's disease, 1624
adverse effects, 1888 (ab), 2557
ankylosing spondylitis, 1127, 1356
autoantibodies, 1882 (ab), 2557
Behçet's disease, 1888 (ab)
biological therapy, 2315
consensus development conferences, 1356
cost-benefit analysis, 1883 (ab)
etanercept, 1127, 1356, 2287, 2315
eye, 1888 (ab)
gold, 1876 (ab)
health status, 941
hepatitis, 1624
hepatitis B virus, 1624
HIV, 407
inflammation, 1888 (ab)
isoniazid, 1657
nitric oxide, 1885 (ab)
polymyalgia rheumatica, 760
psoriatic arthritis, 1880 (ab)
quality of life, 941
reactive arthritis, 407
recurrence, 760
relapsing polychondritis, 1394
rheumatic diseases, 1882 (ab)
rheumatoid arthritis, 941, 1394, 1657, 1876 (ab), 1882 (ab), 1883 (ab), 1885 (ab), 1888 (ab), 2287, 2315
SpA Research Consortium of Canada, 1127, 1356
spondyloarthropathy, 1127
treatment outcome, 1882 (ab)
tuberculosis, 1657
vasculitis, 2287
Influenza
immunization, 2295
systemic lupus erythematosus, 2295
Informed consent
patient satisfaction, 646, 815
randomized controlled trials, 646, 815
Insulin resistance
cardiovascular diseases, 1403
inflammation, 1403
rheumatoid arthritis, 1403
risk factors, 1403
Insulin-like growth factor-I
cartilage, 1565
chondrocytes, 1565
fibromyalgia, 809
growth hormone, 809
hypoglycemia, 809
oncogene proteins, 1565
osteoarthritis, 1565
Interferon-alpha
arthritis, 934
hepatitis C virus, 1775
interleukin 1 receptors, 934
mixed cryoglobulinemia, 1775
non-Hodgkin's lymphoma, 1775
osteoprotegerin, 934
ribavirin, 1775
tumor necrosis factor receptors, 934
Interferon-gamma
familial Mediterranean fever, 2011
helper-inducer T lymphocytes, 2011
Interleukin
cytokines, 146
fibromyalgia, 146
skin, 146
tumor necrosis factor, 146
Interleukin 1
osteogenesis, 2547
pathologic processes, 2547
rheumatoid arthritis, 2547
Interleukin 1 beta
animal disease models, 2193
FK506, 2193
interleukin 6, 2193
rheumatoid arthritis, 2193
tumor necrosis factors, 2193
Interleukin 1 receptors
arthritis, 934
interferon-alpha, 934
osteoprotegerin, 934
tumor necrosis factor receptors, 934
Interleukin 10
IgG receptors, 648

immune complexes, 648
rheumatoid arthritis, 648
tumor necrosis factors, 648
Interleukin 17
cyclooxygenase-2, 1879 (ab)
osteoarthritis, 1879 (ab)
Interleukin 18
adult onset Still's disease, 2422
cytokines, 2422
interleukin 2 receptors, 2422
Interleukin 2
disease susceptibility, 435
genetics, 435
inflammation, 2147
joints, 2147
polymorphism, 435
rheumatoid arthritis, 435
systemic sclerosis, 2147
YKL-40, 2147
Interleukin 2 receptors
adult onset Still's disease, 2422
cytokines, 2422
interleukin 18, 2422
Interleukin 6
animal disease models, 2193
experimental arthritis, 22
FK506, 2193
interleukin 1 beta, 2193
interleukin 6 receptors, 1426
knockout mice, 22
rheumatoid arthritis, 22, 1426, 2193
treatment, 1426
tumor necrosis factor receptors, 22
tumor necrosis factors, 2193
Interleukin 6 receptors
interleukin 6, 1426
rheumatoid arthritis, 1426
treatment, 1426
Interleukin 8
lung, 1524
oncogenes, 1524
scleroderma, 1524
systemic sclerosis, 1524
Interleukin receptors
anakinra, 225
Health Assessment Questionnaire, 225
quality of life, 225
rheumatoid arthritis, 225
Internet
medical specialties, 1887 (ab)
rheumatology, 1887 (ab)
Interstitial collagenase
See also Matrix metalloproteinase-1
Interstitial lung diseases
pulmonary hypertension, 2398
scleroderma, 2398
systemic sclerosis, 2398
Intra-articular injection
hylan G-F, 1880 (ab)
osteoarthritis, 1880 (ab)
Intramuscular injections
gold, 1875 (ab), 1876 (ab)
rheumatoid arthritis, 1875 (ab), 1876 (ab)
Intravenous injections
colchicine, 2620
familial Mediterranean fever, 2620
treatment failure, 2620
Iron
aging, 121
hemochromatosis, 121
mutation, 121
osteoarthritis, 121
Irsogladine maleate
methotrexate, 2082
rheumatoid arthritis, 2082
Ischemia
giant cell arteritis, 2160
hand, 1788
infarction, 634
kidney, 634
metaanalysis, 1788
pain, 634
polyarteritis nodosa, 1344
polymorphism, 2160
surgery, 1788
sympathectomy, 1788
systemic lupus erythematosus, 634
ultrasonography, 1344
vascular endothelial growth factor, 2160
Isoniazid
infliximab, 1657
rheumatoid arthritis, 1657
tuberculosis, 1657

J

Japan
Bone and Joint Decade Conference, S67–3, S67–47, S67–48
Japanese Rheumatism Friendship Association, S67–48
rheumatic diseases, S67–3
rheumatoid arthritis, S67–47
Japanese Rheumatism Friendship Association
Bone and Joint Decade Conference, S67–48
Japan, S67–48
rheumatoid arthritis, S67–48
Jaw abnormality
amyloidosis, 2283
giant cell arteritis, 2283
polymyalgia rheumatica, 2283
Joint diseases
ankle joint, 196
foot, 196
genetics, 196
hemochromatosis, 196
HFE gene, 196
Joint erosion
bone density, 2590
rheumatoid arthritis, 2590
sex, 2590
Joint erosions
bisphosphonates, 1280
disease progression, 905
experimental arthritis, 1280
incadronate (YM175), 1280
inflammation, 1280
longitudinal studies, 2582
magnetic resonance imaging, 1380
OMERACT 6 conference, 1102, 1108, 1380
outcome and process assessment, 705
prognosis, 705, 905, 2580, 2582
radiography, 705, 1102, 2580, 2582
randomized controlled trials, 1102, 1108
remission induction, 1102, 1108
rheumatoid arthritis, 705, 905, 1102, 1108, 1380, 2580, 2582
Joint instability
osteoarthritis, 799
osteoporosis, 799
Joints
diagnosis, 1900
inflammation, 1900, 2147
interleukin 2, 2147
juvenile idiopathic arthritis, 1900
psoriasis, 1900
systemic sclerosis, 2147
YKL-40, 2147
Journal article
pediatric rheumatic diseases, 597
publications, 597
Jurisprudence
arthritis, S67–36
Bone and Joint Decade Conference, S67–36
classification, 1665, 1668, 1671
disability, S67–36
epidemiology, 1665, 1668, 1671
fibromyalgia, 1665, 1668, 1671
iatrogenic diseases, 1668
United Kingdom, S67–36
Juvenile ankylosing spondylitis
ankylosing spondylitis, 2182
genetics, 2182
HLA-B27, 2182
Juvenile arthritis
familial Mediterranean fever, 2014
genetics, 2014
injections, 594
juvenile rheumatoid arthritis, 594
lidocaine, 594
lidocaine/prilocaine, 594
pain, 594
Juvenile chronic arthritis
juvenile rheumatoid arthritis, 579
mortality, 958
outcome and process assessment, 579
prognosis, 579
remission induction, 579
rheumatoid arthritis, 958
Juvenile dermatomyositis
central nervous system, 2059
vasculitis, 2059
Juvenile idiopathic arthritis
adhesion molecules, 1611
adverse effects, 2506
ankylosing spondylitis, S67–45
anti-cyclic citrullinated peptide, 825
Bone and Joint Decade Conference, S67–45
classification, 1663, 1857
dermatitis, 2506
diagnosis, 1900
Durban, 1857
etanercept, 2506
glucocorticoids, 2492
growth, 2492
growth hormone, 2492
ILAR, 1857
inflammation, 1611, 1900
joints, 1900
knee, 2720
lymphocyte homing receptors, 1611
nomenclature, 1857
pediatric rheumatic diseases, 1887 (ab)
psoriasis, 1900
rheumatoid arthritis, 1611, S67–45
rheumatoid factor, 825
rice bodies, 2720
T lymphocytes, 1611
Juvenile rheumatoid arthritis
See also Juvenile arthritis
See also Juvenile chronic arthritis
See also Juvenile idiopathic arthritis
angiotensin converting enzyme, 2705
arthritis, 1335
bone density, 179
calcaneus, 179
child, 1881 (ab), 2275
chronic disease, 179
classification, 1335

disability, 386, 832
drug dose-response relationship, 829
drug therapy, 394
epidemiology, 2275
etanercept, 401
family physician, 2700
genotype, 2705
health status, 1602
injections, 594
juvenile arthritis, 594
juvenile chronic arthritis, 579
lidocaine, 594
lidocaine/prilocaine, 594
macrophage activation syndrome, 401, 1885 (ab)
methotrexate, 1881 (ab)
nabumetone, 829
osteoporosis, 179
outcome and process assessment, 394, 579, 585
pain, 594
pediatric rheumatic diseases, 179
pediatrics, 2700
physician's practice patterns, 2700
polymerase chain reaction, 2705
polymorphism, 2705
prevalence, 1335
prognosis, 386, 579, 585
quality of life, 1602
questionnaires, 1602
radiography, 832
remission induction, 579
risk factors, 386
spondyloarthropathy, 1335
ultrasonography, 179

K

Kallikreins
central nervous system lupus vasculitis, 485
cerebrospinal fluid, 485
kininogens, 485
systemic lupus erythematosus, 485
Kaposi's sarcoma
corticosteroids, 622
Wegener's granulomatosis, 622
Kawasaki disease
metalloproteinases, 1884 (ab)
pathologic processes, 1884 (ab)
Keloid
nodules, 2500
scleroderma, 2500
systemic sclerosis, 2500
Ki antigen
epitope, 1208
Sjögren's syndrome, 1208
systemic lupus erythematosus, 1208
Kidney
autoantibodies, 1495
infarction, 634
ischemia, 634
pain, 634
systemic lupus erythematosus, 634, 1495
Kidney failure
systemic lupus erythematosus, 1227
thrombotic thrombocytopenic purpura, 1227
Kininogens
central nervous system lupus vasculitis, 485
cerebrospinal fluid, 485
kallikreins, 485
systemic lupus erythematosus, 485
Knee
biomechanics, 529
clinical trials, 329
cysts, 200, 1097, 1351
diagnosis, 908, 966, 1097
disability, 114
exercise, 1311
gait, 529
glucosamine, 523, 2512
hip, 2452
juvenile idiopathic arthritis, 2720
magnetic resonance imaging, 1097
musculoskeletal physiology, 2521
neuromuscular electrical stimulation, 1571
osteoarthritis, 114, 329, 523, 529, 534, 1311, 1571, 2452, 2512, 2521
outcome and process assessment, 2452
outcome assessment, 534
pain, 523, 534
patient satisfaction, 2452
physiotherapy, 1311
radiography, 329
randomized controlled trials, 1311
reproducibility of results, 534
rheumatoid arthritis, 908, 966, 1097, 1351
rice bodies, 2720
shoes, 529
soft tissue neoplasms, 200
synovial membrane, 1351
systemic lupus erythematosus, 1351
topical administration, 2512
treatment, 1571
ultrasonography, 908, 966
WOMAC index, 2452
Knee replacement
arthroplasty, 1822
disease progression, 1822
natural history, 1822
osteoarthritis, 1822
Knockout mice
experimental arthritis, 22
interleukin 6, 22
rheumatoid arthritis, 22
tumor necrosis factor receptors, 22
Kynurenine
immune system, 1935
neopterin, 1935
rheumatoid arthritis, 1935
tryptophan, 1935

L

L-tryptophan
eosinophilia myalgia syndrome, 628
hypoalbuminemia, 628
hypoproteinemia, 628
Lacrimal flow
Sjögren's syndrome, 206
xerostomia, 206
Lactoferrin
neutrophil granulocytes, 220
rheumatoid arthritis, 220
synovial fluid, 220
Lamin type B
blister, 1875 (ab)
systemic lupus erythematosus, 1875 (ab)
Laparotomy
diagnosis, 1621
purpura, 1621
vasculitis, 1621
LE cells
classification, 1880 (ab)
diagnosis, 1880 (ab)
systemic lupus erythematosus, 1880 (ab)
Leflunomide
clinical trials, 2572
metaanalyses, 1182
methotrexate, 1725
rheumatoid arthritis, 1182, 1725, 1886 (ab), 2572
treatment outcome, 1725, 1886 (ab), 2572
Lenercept
antibody formation, 680
randomized controlled trials, 680
rheumatoid arthritis, 680
tumor necrosis factor receptors, 680
Leukemia
temporal arteritis, 846
vasculitis, 846
Leukocytes
systemic lupus erythematosus, 1876 (ab)
Leukotriene B4
in situ hybridization, 1712
rheumatoid arthritis, 1712
LF 15-0195
animal disease models, 918
autoimmunity, 918
helper-inducer T lymphocytes, 918
rheumatoid arthritis, 918
Lidocaine
injections, 594
juvenile arthritis, 594
juvenile rheumatoid arthritis, 594
pain, 594
Lidocaine/prilocaine
injections, 594
juvenile arthritis, 594
juvenile rheumatoid arthritis, 594
pain, 594
Life tables
methotrexate, 2325
rheumatoid arthritis, 2325
Ligament
atlantoaxial joint, 1420
cartilage, 1420
cervical vertebrae, 1420
immunohistochemistry, 1420
rheumatoid arthritis, 1420
Linkage
IgG receptors, 926
polymorphism, 926
rheumatoid arthritis, 926
Lipid peroxidation
nitric oxide, 345
osteoarthritis, 345
rheumatoid arthritis, 345
synoviocytes, 345
Lithuania
Canada, 1882 (ab)
motor vehicles, 1882 (ab)
whiplash injuries, 1882 (ab)
Liver failure
adult onset Still's disease, 1093
hepatocyte growth factor, 1093
liver transplantation, 1093
Liver transplantation
adult onset Still's disease, 1093
hepatocyte growth factor, 1093
liver failure, 1093
Longitudinal studies
joint erosions, 2582
prognosis, 2582
radiography, 2582
rheumatoid arthritis, 2582
Low back pain
Bath Ankylosing Spondylitis Disease Activity Index, 1883 (ab)
diagnosis, 1883 (ab)
reproducibility of results, 1883 (ab)

Lower extremity
aged, 2689
disability, 2689
pain, 2689
quality of life, 2689
women, 2689
Lumbar vertebrae
acquired hyperostosis syndrome, 636
ankylosing spondylitis, 2732
diagnosis, 2732
range of motion, 2732
SAPHO, 636
Lung
homocysteine, 298
interleukin 8, 1524
oncogenes, 1524
rheumatoid arthritis, 1878 (ab)
scleroderma, 298, 1524
systemic sclerosis, 298, 1524
Lupus anticoagulant
anticardiolipin antibodies, 985, 2385
antiphospholipid antibodies, 723
antiphospholipid syndrome, 723
cerebrovascular disorders, 985
factor V, 2385
magnetic resonance imaging, 985
neurologic manifestations, 985
ROC curves, 723
systemic lupus erythematosus, 985
thrombophilia, 2385
thrombosis, 2385
Lupus anticoagulant inhibitor
See Lupus anticoagulant
Lupus nephritis
pentoxifylline, 2382
proteinuria, 2382
tumor necrosis factor receptors, 2382
Lupus-like syndrome
See also Iatrogenic diseases
Lymphocyte homing receptors
adhesion molecules, 1611
inflammation, 1611
juvenile idiopathic arthritis, 1611
rheumatoid arthritis, 1611
T lymphocytes, 1611

M

Macrophage activation
ferritin, 1027
glycosylation, 1027
hemophagocytosis syndrome, 1027
Macrophage activation syndrome
child, 2513
epidemiology, 2513
etanercept, 401
juvenile rheumatoid arthritis, 401, 1885 (ab)
Macrophages
Fc gamma RIII, 1911
Fc-receptors, 1911
monocytes, 2529
natural killer cells, 1911
nitric oxide, 2529
reverse transcriptase polymerase chain reaction, 2529
rheumatoid arthritis, 1911, 2529
Magnetic resonance imaging
Achilles tendon, 774
anticardiolipin antibodies, 985
arthritis, 774
cerebrovascular disorders, 985
classification, 1892
cysts, 1097
diagnosis, 1097
foot, 671
hand, 671
inclusion body myositis, 1892
joint erosions, 1380
knee, 1097
lupus anticoagulant, 985
neurologic manifestations, 985, 1983
OMERACT 6 conference, 1364, 1366, 1376, 1380, 1385, 1387
polymyositis, 1892
radiography, 1385
reproducibility of results, 1366, 1376, 1385
research design, 1364, 1387
rheumatoid arthritis, 671, 1097, 1364, 1366, 1376, 1380, 1385, 1387
systemic lupus erythematosus, 985, 1983
ultrasonography, 774
Major histocompatibility complex
alternative splicing, 2524
autoantigens, 449
autoimmune diseases, 2524
D6S439, 2152
HLA-DR antigens, 449
homozygosity, 2152
microsatellites, 2152
rheumatoid arthritis, 449, 2524
Sjögren's syndrome, 2152
T cell antigen receptors, 449
T lymphocytes, 449, 2524
Mannose binding lectin
autoantibodies, 740
complement, 740
polymorphism, 740
systemic lupus erythematosus, 740
Mass spectrometry
drug contamination, 89
eosinophilia myalgia syndrome, 89
five-hydroxytryptophan, 89
high performance liquid chromatography, 89
Matrix metalloproteinase
gene expression regulation, 2330
mepacrine, 2330
transcription factors, 2330
Matrix metalloproteinase-1
autoantigens, 1147
hyaluronic acid, 1164
rheumatoid arthritis, 1147, 1164
Matrix metalloproteinases
BAY 12-9566, 544
biological markers, 1561
cartilage, 544
cartilage erosion, 1561
collagen, 544
experimental arthritis, 211, 355, 1561
osteoarthritis, 544
remission induction, 10
retinoic acid receptors, 211, 355
rheumatoid arthritis, 10, 211, 355
synovial membrane, 10
tissue inhibitors of metalloproteinases, 10
urine, 1561
Medical ethics
American College of Rheumatology, 202
codes of ethics, 202
conflict of interest, 1661, 1851
disclosure, 1661, 1851
drug industry, 202
research support, 1661, 1851
Medical Outcome Study SF-36
Arthritis Impact Measurement Scale, 379
cultural adaptation, 379
Health Assessment Questionnaire, 379
methods, 379
quality of life, 379
Medical specialties
health care rationing, 1890
Internet, 1887 (ab)
rheumatology, 1887 (ab), 1890
Meditation
alternative medicine, 2088, 2257
fibromyalgia, 2088, 2257
Qigong movement therapy, 2088, 2257
Medline
fibromyalgia, 151
periodicals, 151
Meeting reports
Bone and Joint Decade Conference, S67–1-68
Canadian Rheumatology Association Meeting, 1874
Dunlop-Dottridge Lecture, 2003, 1851
Health Economics in Rheumatology Conference, S68–1–31
Knowledge Translation of Musculoskeletal Health Research, 575
OMERACT 6 conference, 639, 866, 1102, 1364, 1630
SpA Research Consortium of Canada, 1356
Memory disorders
aged, 1881 (ab)
bone density, 1881 (ab)
ultrasonography, 1881 (ab)
Men
immune system, 2302
rheumatoid arthritis, 2302, 2338
sex hormones, 2302, 2338
Meningitis
diagnosis, 2070
Wegener's granulomatosis, 2070
Mepacrine
See Quinacrine
Mesalazine
ankylosing spondylitis, 1558
treatment outcome, 1558
Metaanalysis
clinical trials data monitoring committees, 1883 (ab)
doxycycline, 2112
drug toxicity, 1883 (ab)
hand, 1788
ischemia, 1788
leflunomide, 1182
minocycline, 2112
randomized controlled trials, 2112
rheumatoid arthritis, 1182, 2112
surgery, 1788
sympathectomy, 1788
Metabolism
autoimmune diseases, 276
glutathione transferase, 276
systemic lupus erythematosus, 276
ultraviolet rays, 276
Metalloproteinases
Kawasaki disease, 1884 (ab)
pathologic processes, 1884 (ab)
Metatarsophalangeal
arthrodesis, 1440

arthroplasty, 1440
forefoot, 1440
rheumatoid arthritis, 1440
Methods
Arthritis Impact Measurement Scale, 379
cultural adaptation, 379
Health Assessment Questionnaire, 379
Medical Outcome Study SF-36, 379
quality of life, 379
Methotrexate
animal disease models, 2027
child, 1881 (ab)
cyclosporine, 2027
cytokines, 28
ferrous sulfate, 1948
irsogladine maleate, 2082
juvenile rheumatoid arthritis, 1881 (ab)
leflunomide, 1725
life tables, 2325
rheumatoid arthritis, 28, 1725, 1948, 2082, 2325
ribomunyl, 2027
systemic sclerosis, 1875 (ab)
treatment outcome, 1725
Micronucleus assay
chromosomes, 1244
Raynaud's phenomenon, 1244
systemic sclerosis, 1244
Microsatellite repeats
Blacks, 60
genetic predisposition to disease, 60
polymorphism, 60
promoter regions, 60
systemic lupus erythematosus, 60
Microsatellites
D6S439, 2152
homozygosity, 2152
major histocompatibility complex, 2152
Sjögren's syndrome, 2152
Minocycline
doxycycline, 2112
metaanalysis, 2112
randomized controlled trials, 2112
rheumatoid arthritis, 2112
Mitral valve insufficiency
aortic valve insufficiency, 1087
pediatric spondyloarthropathy, 1087
Mixed connective tissue disease
ribonuclear proteins, 998
RNA, 998
systemic lupus erythematosus, 998
Mixed cryoglobulinemia
hepatitis C virus, 1775
interferon-alpha, 1775
non-Hodgkin's lymphoma, 1775
ribavirin, 1775
Monoclonal antibodies
adalimumab, 2563
citrulline, 1696
cyclic peptides, 1696
disease modifying antirheumatic drugs, 2563
rheumatoid arthritis, 1696, 2563
tumor necrosis factor receptors, 2563
Monocytes
disease activity, 2023
macrophages, 2529
nitric oxide, 2529
reverse transcriptase polymerase chain reaction, 2529
Takayasu's arteritis, 2023
Morbidity
biological agents, S67–33
Bone and Joint Decade Conference, S67–10, S67–33
Chinese, 1513
disease modifying antirheumatic drugs, S67–10, S67–33
disease progression, 1513
mortality, 1513, S67–10, S67–33
rheumatoid arthritis, S67–10, S67–33
risk, 1513
systemic lupus erythematosus, 1513
Mortality
biological agents, S67–33
Bone and Joint Decade Conference, S67–10, S67–33, S67–51
cardiovascular diseases, 1196
Chinese, 1513
cost of illness, S67–51
disease activity, 1977
disease modifying antirheumatic drugs, S67–10, S67–33, S67–51
disease progression, 1513
epidemiology, 1196
juvenile chronic arthritis, 958
morbidity, 1513, S67–10, S67–33
osteoarthritis, 1196
prognosis, 1977
rheumatoid arthritis, 958, 1196, S67–10, S67–33, S67–51
rheumatoid factor, S67–51
risk, 1513
systemic lupus erythematosus, 1513, 1977
treatment outcome, S67–51
Motor vehicles
Canada, 1882 (ab)
Lithuania, 1882 (ab)
whiplash injuries, 1882 (ab)
Muscarinic receptors
disorders of excessive somnolence, 2406
Sjögren's syndrome, 2406
urological manifestations, 2406
Muscles
diabetes mellitus, 1881 (ab)
infarction, 1881 (ab)
myositis, 603
outcome and process assessment, 603
pediatric myositis, 603
treatment outcome, 603
Musculoskeletal diseases
Bone and Joint Decade Conference, S67–38
burden of illness, S67–4
cost of illness, S67–38, S68–8
disability, S68–8
epidemiology, 1589
Greece, 1589
guidelines, S67–38
Health Economics in Rheumatology Conference, S68–8
prevalence, 1589
rheumatic diseases, 1589
Musculoskeletal physiology
knee, 2521
osteoarthritis, 2521
Musculoskeletal system
arthritis, S67–62
Bone and Joint Decade Conference, S67–6, S67–56, S67–62
Cochrane collaboration, 575
epidemiology, S67–56
health policy, S67–6
osteoarthritis, S67–62
osteoporosis, S67–62
pain, 7, 139
physical examination, 1881 (ab)
psychology, 7
rheumatoid arthritis, 1191
rheumatoid nodule, 1191
Russia, S67–56
sick role, 7, 139
teaching, 1881 (ab)
ultrasonography, 1191
upper extremity, 7, 139
World Health Organization, S67–6
Mutation
aging, 121
Crohn's disease, 305
genetic predisposition to disease, 305
hemochromatosis, 121
iron, 121
osteoarthritis, 121
Wegener's granulomatosis, 305
Mycobacterium tuberculosis
chondrocalcinosis, 637
Mycophenolate mofetil
immunosuppression, 1508
systemic lupus erythematosus, 1508
Myocardial diseases
systemic lupus erythematosus, 288
Myositis
muscles, 603
outcome and process assessment, 603
pediatric myositis, 603
treatment outcome, 603

N

Nabumetone
drug dose-response relationship, 829
juvenile rheumatoid arthritis, 829
Natural history
arthroplasty, 1822
disease progression, 1822
knee replacement, 1822
osteoarthritis, 1822
Natural killer cells
cytotoxic T lymphocytes, 660
Fc gamma RIII, 1911
Fc-receptors, 1911
macrophages, 1911
rheumatoid arthritis, 660, 1911
synovial membrane, 660
Neck
outcome and process assessment, 2694
pain, 1124, 2694
patient care management, 2694
shoulder, 2694
upper extremity, 1124
Necrosis
antineoplastic agents, 1341
carboplatin, 1341
gemcitabine, 1341
scleroderma, 1341
Neoplasm metastasis
arthritis, 2713
cytology, 2713
hydrarthrosis, 2713
stomach, 2713
Neoplasms
autoantibodies, 1994
scleroderma, 1994
systemic sclerosis, 1994
Neopterin
immune system, 1935
kynurenine, 1935
rheumatoid arthritis, 1935

tryptophan, 1935
Neurologic manifestations
anticardiolipin antibodies, 985
cerebral blood flow, 2075
cerebrovascular circulation, 2075
cerebrovascular disorders, 985
cognition disorders, 1006
computed tomography, 2075
lupus anticoagulant, 985
magnetic resonance imaging, 985, 1983
questionnaires, 1006
systemic lupus erythematosus, 985, 1006, 1983, 2075
Neuromuscular electrical stimulation
knee, 1571
osteoarthritis, 1571
treatment outcome, 1571
Neuron specific enolase
disease activity, 2606
platelet activation, 2606
scleroderma, 2606
systemic sclerosis, 2606
Neuropathy
afferent neurons, 1552
Sjögren's syndrome, 1552
Newborn infant
cutaneous lupus, 1877 (ab)
systemic lupus erythematosus, 1877 (ab)
NF-kappa B
bone and bones, 2319
immunohistochemistry, 2319
RANKL, 2319
rheumatoid arthritis, 2319
tumor necrosis factor receptors, 2319
Nitric oxide
aggrecan, 326
ankylosing spondylitis, 2428
argininosuccinate synthase, 652
articular cartilage, 247
autoimmunity, 247
chondrocytes, 326
colitis, 2428
collagen, 326
duodenum, 2428
gene deletion, 247
GTP cyclohydrolase, 652
inflammation, 1173, 2428
infliximab, 1885 (ab)
lipid peroxidation, 345
macrophages, 2529
monocytes, 2529
osteoarthritis, 326, 345
peroxynitrous acid, 1173
reverse transcriptase polymerase chain reaction, 2529
rheumatoid arthritis, 345, 1173, 1885 (ab), 2529
synovial membrane, 1173
synoviocytes, 345
tumor necrosis factors, 652
Nitric oxide synthase
disease susceptibility, 2019
giant cell arteritis, 2019
haplotypes, 2019
polymorphism, 2019
Nodules
keloid, 2500
scleroderma, 2500
systemic sclerosis, 2500
Nomenclature
classification, 1857
Durban, 1857
ILAR, 1857
juvenile idiopathic arthritis, 1857
Non-Hodgkin's lymphoma
hepatitis C virus, 1775
interferon-alpha, 1775
mixed cryoglobulinemia, 1775
ribavirin, 1775
Nonsteroidal antiinflammatory drugs
adverse effects, 203, 792, 2234
congestive heart failure, 792
cost-benefit analysis, S68–15
cyclooxygenase-2 inhibitors, 1888 (ab)
gastrointestinal hemorrhage, 792
gastrointestinal system, 203, 2241
Health Economics in Rheumatology Conference, S68–15
hemorrhage, 2241
nonsteroidal antiinflammatory drugs, 2680
randomized controlled trials, S68–15
rheumatic diseases, 1888 (ab)
risk factors, 2241
Stevens-Johnson syndrome, 2234
treatment outcome, 2680
North American Indians
genetics, 1887 (ab)
rheumatoid arthritis, 1887 (ab)
Nuclear antigens
See also Extractable nuclear antigens
Nutrition
Bone and Joint Decade Conference, S67–66
epidemiology, S67–66
osteoarthritis, S67–66
rheumatoid arthritis, S67–66
Nutritional status
fibromyalgia, 1884 (ab)

O

Observer variation
classification, 2645
outcome and process assessment, 2645
psoriatic arthritis, 2645
radiography, 2645
OMERACT 6 conference
acknowledgments, 1655
classification, 1648
cost-benefit analysis, 886, 891
disease activity, 1110, 1112, 1115
health status indicators, 873
introduction, 866
joint erosions, 1102, 1108, 1380
magnetic resonance imaging, 1364, 1366, 1376, 1380, 1385, 1387
osteoarthritis, 1648
outcome and process assessment, 868, 877, 880, 1112, 1115, 1630, 1648
outcome assessment, 639, 1110
patient participation, 868, 873, 877, 880, 884
radiography, 1102, 1385
randomized controlled trials, 868, 880, 884, 1102, 1108, 1110, 1112, 1630, 1648
reference case, 886
reference standards, 891
remission induction, 1102, 1108
reproducibility of results, 1366, 1376, 1385
research design, 1364, 1387
rheumatoid arthritis, 868, 873, 877, 880, 884, 891, 1102, 1108, 1110, 1112, 1115, 1364, 1366, 1376, 1380, 1385, 1387
scleroderma, 1630
systemic sclerosis, 1630
Oncogene proteins
cartilage, 1565
chondrocytes, 1565
insulin-like growth factor-I, 1565
osteoarthritis, 1565
Oncogenes
interleukin 8, 1524
lung, 1524
scleroderma, 1524
systemic sclerosis, 1524
Onychomycosis
dermatomycosis, 1491
immune system, 1491
systemic lupus erythematosus, 1491
Ophthalmologic monitoring
antimalarials, 1756
drug toxicity, 1756
systemic lupus erythematosus, 1756
vision screening, 1756
Ophthalmological diagnostic techniques
antimalarials, 1876 (ab)
systemic lupus erythematosus, 1876 (ab)
Optic nerve diseases
blindness, 625
giant cell arteritis, 625
Orchitis
arthritis, 1347
bacterial infections, 1347
central nervous system, 1347
Whipple's disease, 1347
Organ systems
outcome and process assessment, 1955
systemic lupus erythematosus, 1955
Orthotic devices
foot, 2356
randomized controlled trials, 2356
rheumatoid arthritis, 2356
Osteoarthritis
adrenomedullin, 2553
aggrecan, 326
aging, 121
analgesics, 2201
angiogenesis, 2207
animal disease models, 1880 (ab), 2207, 2218
antirheumatic agents, S68–26
arthritis, S67–62
arthroplasty, 1305, 1822
avocado, 1825
BAY 12-9566, 544
biological markers, 910, 1043
biomechanics, 529
blood pressure, 642
body mass index, 2103
bone and bones, 910
Bone and Joint Decade Conference, S67–14, S67–62, S67–66
calcium pyrophosphate, 420
cardiovascular diseases, 36, 642, 714, 1196
cardiovascular system, 421
cartilage, 544, 910, 1565, 1825, 1880 (ab), 2207, 2218
cell communication, 1879 (ab)
cerebrovascular disorders, 36
chondrocytes, 326, 1565
chondroitin sulfate, S67–14
chondromodulin, 2207
classification, 1648
clinical trials, 329

collagen, 326, 544
cost-benefit analysis, 714, S68–1, S68–26
cyclooxygenase-2, 421, 1879 (ab)
cytokines, 1825, 1879 (ab)
depression, 2103
diacerein, S67–14
disability, 114
disease progression, 1043, 1822
epidemiology, 1196, 2103, S67–66
ethnic groups, 1305, 2201
exercise, 1311, 2039
gait, 529
gene expression regulation, 1879 (ab)
genetics, 1298
glucosamine, 523, 2512, S67–14
Health Economics in Rheumatology Conference, S68–1, S68–26
health services, 1305, 2201
hemochromatosis, 121
hip, 2452
histology, 2218
HLA antigens, 1298
hylan G-F, 1880 (ab)
hypertension, 642, 714
insulin-like growth factor-I, 1565
interleukin 17, 1879 (ab)
intra-articular injection, 1880 (ab)
iron, 121
joint instability, 799
knee, 114, 329, 523, 529, 534, 1311, 1571, 2452, 2512, 2521
knee replacement, 1822
lipid peroxidation, 345
matrix metalloproteinases, 544
mortality, 1196
musculoskeletal physiology, 2521
musculoskeletal system, S67–62
mutation, 121
natural history, 1822
neuromuscular electrical stimulation, 1571
nitric oxide, 326, 345
nonsteroidal antiinflammatory drugs, 2201
nutrition, S67–66
OMERACT 6 conference, 1648
oncogene proteins, 1565
osteocalcin, 1043
osteoporosis, 799, S67–62, S68–1
outcome and process assessment, 1648, 2452
outcome assessment, 534
pain, 523, 534
patient education, 1877 (ab)
patient satisfaction, 1656, 2452
physiotherapy, 1311
practice guidelines, 1846
prostaglandins, 1879 (ab)
quality of health care, 1886 (ab)
radiography, 329
randomized controlled trials, 1311, 1648
replacement arthroplasty, 1656
reproducibility of results, 534
rheumatoid arthritis, 345, 642, 714, 1196, 2553, S67–66
rheumatoid athritis, 36
risk, 36
risk factors, 2103
rofecoxib, 421
shoes, 529
soybeans, 1825
synovial fluid, 420
synoviocytes, 345
synovium, 2553
tai chi, 2039
thrombosis, 421
topical administration, 2512
transforming growth factor, 420
treatment, 1846
treatment outcome, 1571, S67–14
women, 2039

Osteoblasts
femur head, 348
osteonecrosis, 348

Osteocalcin
biological markers, 1043
disease progression, 1043
osteoarthritis, 1043

Osteoclasts
ADAM8, 2033
giant cells, 2033
hip replacement arthroplasty, 2033
synovial membrane, 2033

Osteogenesis
interleukin 1, 2547
pathologic processes, 2547
rheumatoid arthritis, 2547

Osteomyelitis
bone and bones, 851
humerus, 851
shoulder pain, 851
tuberculosis, 851

Osteonecrosis
blood coagulation factors, 783
femur head, 348
fibrinolysis, 783
osteoblasts, 348
thrombophilia, 783

Osteoporosis
ankylosing spondylitis, 779
anti-osteoporosis agents, S68–31
arthritis, S67–62
bisphosphonates, 132, 1883 (ab)
Bone and Joint Decade Conference, S67–21, S67–42, S67–62
bone density, 779, 2365, 2673
calcium, 132, 1878 (ab)
chemoprevention, 1884 (ab)
connective tissue diseases, 2673
corticosteroids, 2365, 2673
cost-benefit analysis, 132, S68–1, S68–15, S68–31
cytokines, 474
diagnosis, 1878 (ab)
diphosphonates, 2673, S67–21
etidronate, 474
fractures, 1878 (ab), 1886 (ab), S67–21
France, S67–42
glucocorticoids, 132
Health Economics in Rheumatology Conference, S68–1, S68–15, S68–31
joint instability, 799
musculoskeletal system, S67–62
osteoarthritis, 799, S67–62, S68–1
Osteoporosis Assessment Questionnaire, 1579
outcome and process assessment, S68–15
physician's practice patterns, 779
preventive medicine, S67–21
quality of life, 1579
rheumatic diseases, 1884 (ab)
rheumatoid arthritis, 474, S67–42
risedronate, 1886 (ab)
risk, S67–21
spinal fractures, 1579
spondyloarthropathy, S67–42
systemic lupus erythematosus, 1884 (ab), 2365
talus, 860
therapeutics, 779
tibia, 860
treatment, 779
treatment outcome, S67–21
vitamin D, 132

Osteoporosis Assessment Questionnaire
osteoporosis, 1579
quality of life, 1579
spinal fractures, 1579

Outcome and process assessment
ankylosing spondylitis, 764
classification, 1648, 2645
cost-benefit analysis, 1739, S68–15
disease activity, 1112, 1115, 1960, 1967
drug therapy, 394
fibromyalgia, 1054
France, 1054
genetics, 2638
hand, 1253
Health Assessment Questionnaire, 1253, 1885 (ab)
Health Economics in Rheumatology Conference, S68–15
hip, 2452
joint erosions, 705
juvenile chronic arthritis, 579
juvenile rheumatoid arthritis, 394, 579, 585
knee, 2452
muscles, 603
myositis, 603
neck, 2694
observer variation, 2645
OMERACT 6 conference, 868, 877, 880, 1112, 1115, 1630, 1648
organ systems, 1955
osteoarthritis, 1648, 2452
osteoporosis, S68–15
pain, 1054, 2694
patient care management, 2694
Patient Generated Index, 764
patient participation, 868, 877, 880
patient satisfaction, 2452
patient-physician relations, 1967
pediatric myositis, 603
prognosis, 579, 585, 705
psoriatic arthritis, 2638, 2645
quality of life, 1054
questionnaires, 764, 1054
radiography, 705, 2645
randomized controlled trials, 868, 880, 1112, 1630, 1648
remission induction, 579
reproducibility of results, 1739
rheumatoid arthritis, 705, 868, 877, 880, 1112, 1115, 1739
scleroderma, 1630, 1885 (ab)
shoulder, 2694
skin, 1253
systemic lupus erythematosus,

1955, 1960, 1967
systemic sclerosis, 1253, 1630
treatment outcome, 603
validation studies, 1054
WOMAC index, 2452
Outcome assessment
disease activity, 1110
knee, 534
Omeract 6, 639
OMERACT 6 conference, 1110
osteoarthritis, 534
pain, 534
randomized controlled trials, 1110
reproducibility of results, 534
rheumatoid arthritis, 1110
Oxygen
exercise therapy, 1060
fibromyalgia, 1060
physical fitness, 1060

P

Pain
aged, 2689
breast implants, 2263
disability, 2689
distress, 567
fatigue, 1070, 2263
fibromyalgia, 369, 567, 1054, 1070
France, 1054
glucosamine, 523
infarction, 634
injections, 594
ischemia, 634
juvenile arthritis, 594
juvenile rheumatoid arthritis, 594
kidney, 634
knee, 523, 534
lidocaine, 594
lidocaine/prilocaine, 594
lower extremity, 2689
musculoskeletal system, 7, 139
neck, 1124, 2694
osteoarthritis, 523, 534
outcome and process assessment, 1054, 2694
outcome assessment, 534
pain measurement, 369
patient care management, 2694
patient satisfaction, 1882 (ab)
psychology, 7, 567
quality of life, 1054, 2689
questionnaires, 1054
reproducibility of results, 534
rheumatic diseases, 1882 (ab)
rheumatoid arthritis, 369, 2718
shoulder, 2694
sick role, 7, 139
silicone, 2263
sleep, 1070
sodium oxybate, 1070
systemic lupus erythematosus, 634
tender points, 567
treatment outcome, 1882 (ab)
upper extremity, 7, 139, 1124
validation studies, 1054
women, 2689
wrist, 2718
Pain measurement
arthritis, 1584
fibromyalgia, 369
pain, 369
patient satisfaction, 1584
rheumatoid arthritis, 369, 1733
treatment outcome, 1733
Paleopathology
rheumatoid arthritis, 2095
spondyloarthropathy, 2095
tuberculosis, 2095
Pamidronate
randomized controlled trials, 2080
rheumatoid arthritis, 2080
Parenteral nutrition
gout, 849
hypouricemia, 849
uric acid, 849
Parvovirus B19
genes, 1907
infection, 2624
polymyalgia rheumatica, 2624
rheumatoid arthritis, 1907
seasons, 2624
synovitis, 1907
Pathologic processes
interleukin 1, 2547
Kawasaki disease, 1884 (ab)
metalloproteinases, 1884 (ab)
osteogenesis, 2547
rheumatoid arthritis, 2547
Patient acceptance of health care
cost of illness, 1886 (ab)
Patient care management
neck, 2694
outcome and process assessment, 2694
pain, 2694
shoulder, 2694
Patient compliance
drug therapy, 44
gout, 44
pharmaceutical preparations, 1887 (ab)
polymyalgia rheumatica, 44
rheumatic diseases, 1887 (ab)
rheumatoid arthritis, 44
Patient education
osteoarthritis, 1877 (ab)
Patient Generated Index
ankylosing spondylitis, 764
outcome and process assessment, 764
questionnaires, 764
Patient participation
health status indicators, 873
OMERACT 6 conference, 868, 873, 877, 880, 884
outcome and process assessment, 868, 877, 880
randomized controlled trials, 868, 880, 884
rheumatoid arthritis, 868, 873, 877, 880, 884
Patient satisfaction
arthritis, 1584
fibromyalgia, 1326
Health Economics in Rheumatology Conference, S68–12
health services accessibility, S68–12
hip, 2452
informed consent, 646, 815
knee, 2452
osteoarthritis, 1656, 2452
outcome and process assessment, 2452
pain, 1882 (ab)
pain measurement, 1584
physician-patient relations, 1326
randomized controlled trials, 646, 815
replacement arthroplasty, 1656
treatment outcome, 1882 (ab)
WOMAC index, 2452
Patient-physician relations
disease activity, 1967
outcome and process assessment, 1967
systemic lupus erythematosus, 1967
PD-1
rheumatoid arthritis, 1410
synovial fluid, 1410
T lymphocytes, 1410
Pediatric myositis
muscles, 603
myositis, 603
outcome and process assessment, 603
treatment outcome, 603
Pediatric rheumatic diseases
cutaneous lupus, 1877 (ab)
familial Mediterranean fever, 185, 2014
hyperuricemia, 841
journal article, 597
juvenile ankylosing spondylitis, 2182
juvenile arthritis, 2014
juvenile chronic arthritis, 579, 958
juvenile idiopathic arthritis, 825, 829, 1611, 1663, 1857, 1887 (ab), 1900, 2492, 2506, 2720, S67–45
juvenile rheumatoid arthritis, 179, 401, 579, 585, 1335, 1602, 1881 (ab), 1885 (ab), 2275, 2700, 2705
macrophage activation syndrome, 2513
myositis, 603
osteoporosis, 179
pediatric spondyloarthropathy, 1123
publications, 597
spondyloarthropathy, 1087
systemic lupus erythematosus, 1876 (ab)
systemic sclerosis, 2724
vasculitis, 1875 (ab)
Pediatric spondyloarthropathy
aortic valve insufficiency, 1087
arthritis, 1123
classification, 1123
mitral valve insufficiency, 1087
Pediatrics
family physician, 2700
juvenile rheumatoid arthritis, 2700
physician's practice patterns, 2700
Pentoxifylline
lupus nephritis, 2382
proteinuria, 2382
tumor necrosis factor receptors, 2382
Peptides
ankylosing spondylitis, 972
antigens, 972
cytotoxicity tests, 972
rheumatoid arthritis, 972
Perforins
cartilage, 1799
chondrocytes, 1799
granzyme B, 1799
remodeling, 1799
rheumatoid arthritis, 1799
Perfusion
myocardial diseases, 288
risk factors, 288
single photon emission computed tomography, 288
systemic lupus erythematosus, 288
Pericarditis
camptodactyly, 1081
coxa vara, 1081
families, 1081
Periodicals
fibromyalgia, 151
Medline, 151
Peripheral nervous system
pupil, 1231
scleroderma, 1231

substance P, 1231
systemic sclerosis, 1231
Peroxynitrous acid
inflammation, 1173
nitric oxide, 1173
rheumatoid arthritis, 1173
synovial membrane, 1173
Pharmaceutical preparations
patient compliance, 1887 (ab)
rheumatic diseases, 1887 (ab)
Physical examination
musculoskeletal system, 1881 (ab)
teaching, 1881 (ab)
Physical fitness
cardiovascular deconditioning, 1075
exercise test, 1075
exercise therapy, 1060
exercise tolerance, 1075
fibromyalgia, 1060
oxygen, 1060
Physician's practice patterns
ankylosing spondylitis, 779
bone density, 779
family physician, 2700
hands, 1464
juvenile rheumatoid arthritis, 2700
osteoporosis, 779
pediatrics, 2700
preventive medicine, 1940
rheumatoid arthritis, 1464, 1940
surgery, 1464
therapeutics, 779
treatment, 779
Physician-patient relations
fibromyalgia, 1326
patient satisfaction, 1326
Physiologic calcification
classification, 1029
reproducibility of results, 1029
shoulder, 1029
tendinitis, 1029
Physiotherapy
exercise, 1311
knee, 1311
osteoarthritis, 1311
randomized controlled trials, 1311
Platelet activation
disease activity, 2606
endothelium, 1479
hyperhomocysteinemia, 1479
neuron specific enolase, 2606
scleroderma, 2606
systemic lupus erythematosus, 1479
systemic sclerosis, 2606
Polyarteritis nodosa
ischemia, 1344
temporal arteritis, 2165
ultrasonography, 1344
vasculitis, 2165
Wegener's granulomatosis, 2165
Polyarthritis
antibodies, 1691
citrulline, 1691
cyclic peptides, 1691
diagnosis, 902, 1691
prognosis, 1691
rheumatoid arthritis, 902, 1691
Polymerase chain reaction
angiotensin converting enzyme, 2705
ankylosing spondylitis, 321
genotype, 2705
HLA-B27, 321
juvenile rheumatoid arthritis, 2705
polymorphism, 321, 2705
Taiwan, 321
Polymorphism
angiotensin converting enzyme, 2705
ankylosing spondylitis, 321
autoantibodies, 740
Blacks, 60
chemokine receptors, 1541, 1770
chemokines, 1541
complement, 740
disease susceptibility, 435, 2019
DNA, 1520
genetic predisposition to disease, 60
genetics, 435
genotype, 2705
giant cell arteritis, 2019, 2160
haplotypes, 2019
HLA-B27, 321
HLA-DM, 1485
IgG receptors, 926
interleukin 2, 435
ischemia, 2160
juvenile rheumatoid arthritis, 2705
linkage, 926
mannose binding lectin, 740
microsatellite repeats, 60
nitric oxide synthase, 2019
polymerase chain reaction, 321, 2705
promoter regions, 60
rheumatoid arthritis, 435, 438, 926, 1406
scleroderma, 1520
systemic lupus erythematosus, 60, 740, 1485, 1770
systemic sclerosis, 1520
Taiwan, 321
transforming growth factor, 1520
tumor necrosis factor receptors, 438
tumor necrosis factors, 1406
vascular endothelial growth factor, 2160
Wegener's granulomatosis, 1541
Polymorphonuclear leukocytes
adalimumab, 232
reactive oxygen species, 232
rheumatoid arthritis, 232
Polymyalgia rheumatica
amyloidosis, 2283
auscultation, 191
drug therapy, 44
giant cell arteritis, 2283, 2729
gout, 44
HLA-DRB1*, 2729
infection, 2624
infliximab, 760
jaw abnormality, 2283
parvovirus B19, 2624
patient compliance, 44
recurrence, 760
rheumatoid arthritis, 44
seasons, 2624
temporal arteritis, 191
Polymyositis
aldolase, 2077
classification, 1892
creatine kinase, 2077
dermatomyositis, 2077
inclusion body myositis, 1892
magnetic resonance imaging, 1892
Posterior tibial tendon dysfunction
enthesis, 508
histology, 508
spondyloarthropathy, 508
Practice guidelines
osteoarthritis, 1846
treatment, 1846
Pramipexole
fibromyalgia, 2733
Predictive value of tests
classification, 720
diagnosis, 2535
immunology, 2535
Raynaud's phenomenon, 720
rheumatoid arthritis, 2535
thermography, 720
Prednisone
anticardiolipin antibodies, 2127
pregnancy, 2127
systemic lupus erythematosus, 2127
Pregnancy
anticardiolipin antibodies, 2127
biological therapy, 241
disease modifying antirheumatic drugs, 241
drug induced abnormalities, 241
prednisone, 2127
rheumatoid arthritis, 241
systemic lupus erythematosus, 2127
Pregnenolone
hydroxypregnenolone, 269
rheumatoid arthritis, 269
systemic lupus erythematosus, 269
Prevalence
Amish, 1835
arthritis, 126, 1335
classification, 1335
epidemiology, 1589, 1835
fibromyalgia, 1835
Greece, 1589
juvenile rheumatoid arthritis, 1335
musculoskeletal diseases, 1589
Quebec, 126
rheumatic diseases, 1589
spondyloarthropathy, 1335
Preventive medicine
Arthritis Foundation, S67–32
Bone and Joint Decade Conference, S67–21, S67–32, S67–41
diphosphonates, S67–21
fractures, S67–21
osteoporosis, S67–21
physician's practice patterns, 1940
rheumatoid arthritis, 1940
risk, S67–21
Sweden, S67–41
treatment outcome, S67–21
United States of America, S67–32
Prognosis
alleles, 2632
ankylosing spondylitis, 316, 2186
antibodies, 1691
Brazil, 2632
citrulline, 1691
classification, 1022
cyclic peptides, 1691
diagnosis, 1691
disability, 386, 2186, 2344
disease activity, 1977
disease progression, 905
HLA-B27, 2632
HLA-B7, 2632
joint erosions, 705, 905, 2580, 2582
juvenile chronic arthritis, 579
juvenile rheumatoid arthritis, 386, 579, 585
longitudinal studies, 2582
mortality, 1977
outcome and process assessment, 579, 585, 705
polyarthritis, 1691

psoriatic arthritis, 1022
radiography, 705, 2344, 2580, 2582
radiology, 316, 1022
remission induction, 579
rheumatoid arthritis, 705, 905, 1691, 2344, 2580, 2582
risk factors, 386
spondyloarthropathy, 2632
systemic lupus erythematosus, 1977
Prolactin
disease activity, 2140
systemic lupus erythematosus, 2140
Systemic Lupus Erythematosus Disease Activity Index, 2140
Promoter regions
Blacks, 60
genetic predisposition to disease, 60
microsatellite repeats, 60
polymorphism, 60
systemic lupus erythematosus, 60
Prostaglandins
cell communication, 1879 (ab)
cytokines, 1879 (ab)
gene expression regulation, 1879 (ab)
osteoarthritis, 1879 (ab)
Prosthesis related infections
replacement arthroplasty, 1888 (ab)
Protein 53
apoptosis, 559
articular cartilage, 559
immobilization, 559
Proteinases
antineutrophil cytoplasmic antibodies, 2064
rheumatoid arthritis, 2064
rheumatoid factor, 2064
Wegener's granulomatosis, 2064
Proteoglycans
animal disease models, 339
blood, 339
cartilage, 339, 2444
celecoxib, 2444
diclofenac, 2444
hemophilia, 339
hyaluronan, 2444
Psoriasis
age of onset, 505
diagnosis, 1900
genetics, 2638
HLA-B27, 505
inflammation, 1900
joints, 1900
juvenile idiopathic arthritis, 1900
outcome and process assessment, 2638
psoriatic arthritis, 505, 2638
Psoriatic arthritis
age of onset, 505
classification, 1022, 2645
disease progression, 4, 96
disease susceptibility, 1885 (ab)
epidemiology, 2641
etanercept, 1888 (ab)
genetics, 1885 (ab)
Greece, 2641
heredity, 1885 (ab)
HLA, 4
HLA antigens, 96
HLA-B27, 505, 2508
infliximab, 1880 (ab)
observer variation, 2645
outcome and process assessment, 2645
prognosis, 1022
psoriasis, 505
radiography, 2645
radiology, 1022
rheumatoid arthritis, 4
shared epitope, 4, 96
Psychological adaptation
group psychotherapy, 1011
quality of life, 1011
systemic lupus erythematosus, 1011
Psychological stress
arthritis, 2299, 2476
epidemiology, 2299, 2476
exercise, 2299
psychological stress, 2476
Psychology
central nervous system lupus vasculitis, 283
distress, 567
fatigue, 283
fibromyalgia, 567
musculoskeletal system, 7
pain, 7, 567
sick role, 7
systemic lupus erythematosus, 283
tender points, 567
upper extremity, 7
Publications
journal article, 597
pediatric rheumatic diseases, 597
Pulmonary artery
hypertension, 1881 (ab)
systemic lupus erythematosus, 1881 (ab)
Pulmonary fibrosis
cyclophosphamide, 1121
systemic sclerosis, 1121
treatment, 1121
Pulmonary hypertension
interstitial lung diseases, 2398
scleroderma, 2398
systemic sclerosis, 2398
Pupil
peripheral nervous system, 1231
scleroderma, 1231
substance P, 1231
systemic sclerosis, 1231
Purpura
diagnosis, 1621
laparotomy, 1621
vasculitis, 1621

Q

Qigong movement therapy
alternative medicine, 2088, 2257
fibromyalgia, 2088, 2257
meditation, 2088, 2257
Quality of health care
osteoarthritis, 1886 (ab)
rheumatoid arthritis, 1883 (ab)
Quality of life
age of onset, 952
aged, 2689
anakinra, 225
arthritis, 160
Arthritis Impact Measurement Scale, 379
cross sectional studies, 160
cultural adaptation, 379
depression, 952
disability, 952, 2689
epidemiology, 160
fibromyalgia, 1054, 1879 (ab)
fractures, 1879 (ab)
France, 1054
group psychotherapy, 1011
Health Assessment Questionnaire, 225, 379
health status, 941, 1602
hip, 1879 (ab)
infliximab, 941
interleukin receptors, 225
juvenile rheumatoid arthritis, 1602
lower extremity, 2689
Medical Outcome Study SF-36, 379
methods, 379
osteoporosis, 1579
Osteoporosis Assessment Questionnaire, 1579
outcome and process assessment, 1054
pain, 1054, 2689
psychological adaptation, 1011
questionnaires, 1054, 1602
rheumatic diseases, 2268
rheumatoid arthritis, 225, 941, 952
Singapore, 2268
socioeconomic factors, 160
spinal fractures, 1579
spondyloarthropathy, 1879 (ab)
systemic lupus erythematosus, 1011
validation studies, 1054
women, 2689
Quebec
arthritis, 126
prevalence, 126
Questionnaires
ankylosing spondylitis, 764
cognition disorders, 1006
Compliance-Questionnaire-Rheumatology, 2469
cost of illness, 2485
diagnosis, 1887 (ab)
fibromyalgia, 1054, 1887 (ab)
France, 1054
health status, 1602
juvenile rheumatoid arthritis, 1602
neurologic manifestations, 1006
outcome and process assessment, 764, 1054
pain, 1054
Patient Generated Index, 764
quality of life, 1054, 1602
rheumatoid arthritis, 2485
SLICC/ACR Damage Index, 292
systemic lupus erythematosus, 1006
validation studies, 1054
WOMAC index, 2452
Quinacrine
gene expression regulation, 2330
matrix metalloproteinase, 2330

R

Radiography
body mass index, 2350
classification, 2645
clinical trials, 329
computer assisted image processing, 238
diagnostic imaging, 238
disability, 832, 2344
hormone replacement therapy, 1456
joint erosions, 705, 1102, 2580, 2582
juvenile rheumatoid arthritis, 832
knee, 329
longitudinal studies, 2582
magnetic resonance imaging, 1385
observer variation, 2645
OMERACT 6 conference, 1102, 1385
osteoarthritis, 329
outcome and process assessment, 705, 2645
prognosis, 705, 2344, 2580, 2582

psoriatic arthritis, 2645
randomized controlled trials, 1102, 1456
remission induction, 1102
reproducibility of results, 238, 1385
rheumatoid arthritis, 238, 705, 1102, 1385, 1456, 2344, 2350, 2580, 2582
shared epitope, 2350
Radiology
ankylosing spondylitis, 316
classification, 1022
prognosis, 316, 1022
psoriatic arthritis, 1022
Radius
bursa, 1626
dactylitis, 1626
thumb, 1626
Randomized controlled trials
antibody formation, 680
bias, 979
classification, 1135, 1138, 1648
cost-benefit analysis, S68–15
disease activity, 1110, 1112
doxycycline, 2112
exercise, 1311
foot, 2356
Health Economics in Rheumatology Conference, S68–15
hormone replacement therapy, 1456
informed consent, 646, 815
joint erosions, 1102, 1108
knee, 1311
lenercept, 680
metaanalysis, 2112
minocycline, 2112
nonsteroidal antiinflammatory drugs, S68–15
OMERACT 6 conference, 868, 880, 884, 1102, 1108, 1110, 1112, 1630, 1648
orthotic devices, 2356
osteoarthritis, 1311, 1648
outcome and process assessment, 868, 880, 1112, 1630, 1648
outcome assessment, 1110
pamidronate, 2080
patient participation, 868, 880, 884
patient satisfaction, 646, 815
physiotherapy, 1311
radiography, 1102, 1456
regression analysis, 465
remission induction, 1102, 1108
research design, 979
rheumatoid arthritis, 465, 680, 868, 880, 884, 1102, 1108, 1110, 1112, 1135, 1138, 1456, 2080, 2112, 2356
scleroderma, 1630
systemic lupus erythematosus, 979
systemic sclerosis, 1630
Tripterygium wilfordii, 465
tumor necrosis factor receptors, 680
Range of motion
ankylosing spondylitis, 2732
diagnosis, 2732
lumbar vertebrae, 2732
RANKL
bone and bones, 2319
immunohistochemistry, 2319
NF-kappa B, 2319
rheumatoid arthritis, 2319
tumor necrosis factor receptors, 2319
Rasch analysis
SLICC/ACR Damage Index, 292
systemic lupus erythematosus, 292
weightings, 292
Rash
histiocytic necrotizing lymphadenitis, 857
systemic lupus erythematosus, 857
Raynaud's phenomenon
antinuclear antibodies, 736
chromosomes, 1244
classification, 720
connective tissue diseases, 736
CREST syndrome, 2503
extractable nuclear antigens, 736
impotence, 2503
micronucleus assay, 1244
predictive value of tests, 720
sildenafil, 2503
systemic sclerosis, 1244
thermography, 720
yohimbine, 2503
Reactive arthritis
brucellosis, 2666
campylobacter, 459
combination drug therapy, 2666
etiology, 425
HIV, 407
HLA-B27, 1291
infection, 425, 459
infliximab, 407
rheumatoid arthritis, 425, 459
spondyloarthropathy, 1291
synovial membrane, 1291
treatment, 2666
Reactive oxygen species
adalimumab, 232
polymorphonuclear leukocytes, 232
rheumatoid arthritis, 232
Recurrence
infliximab, 760
polymyalgia rheumatica, 760
remission induction, 80
treatment, 80
vasculitis, 80
Wegener's granulomatosis, 80
Reference case
cost-benefit analysis, 886
OMERACT 6 conference, 886
Reference standards
cost-benefit analysis, 891
OMERACT 6 conference, 891
rheumatoid arthritis, 891
Regression analysis
randomized controlled trials, 465
rheumatoid arthritis, 465
Tripterygium wilfordii, 465
Relapsing polychondritis
cartilage, 2716
ear piercing, 2716
infliximab, 1394
rheumatoid arthritis, 1394
trauma, 2716
Remission induction
See also Spontaneous remission
joint erosions, 1102, 1108
juvenile chronic arthritis, 579
juvenile rheumatoid arthritis, 579
matrix metalloproteinases, 10
OMERACT 6 conference, 1102, 1108
outcome and process assessment, 579
prognosis, 579
radiography, 1102
randomized controlled trials, 1102, 1108
recurrence, 80
rheumatoid arthritis, 10, 1102, 1108
synovial membrane, 10
systemic lupus erythematosus, 1880 (ab)
tissue inhibitors of metalloproteinases, 10
treatment, 80
vasculitis, 80
Wegener's granulomatosis, 80
Remodeling
cartilage, 1799
chondrocytes, 1799
granzyme B, 1799
perforins, 1799
rheumatoid arthritis, 1799
Replacement arthroplasty
osteoarthritis, 1656
patient satisfaction, 1656
prosthesis related infections, 1888 (ab)
Reproducibility of results
Bath Ankylosing Spondylitis Disease Activity Index, 1883 (ab)
classification, 1029
computer assisted image processing, 238
cost-benefit analysis, 1739
diagnosis, 1883 (ab)
diagnostic imaging, 238
knee, 534
low back pain, 1883 (ab)
magnetic resonance imaging, 1366, 1376, 1385
OMERACT 6 conference, 1366, 1376, 1385
osteoarthritis, 534
outcome and process assessment, 1739
outcome assessment, 534
pain, 534
physiologic calcification, 1029
radiography, 238, 1385
rheumatoid arthritis, 238, 1366, 1376, 1385, 1739
shoulder, 1029
tendinitis, 1029
Research design
bias, 979
magnetic resonance imaging, 1364, 1387
OMERACT 6 conference, 1364, 1387
randomized controlled trials, 979
rheumatoid arthritis, 1364, 1387
systemic lupus erythematosus, 979
Research support
conflict of interest, 1661
disclosure, 1661
medical ethics, 1661
Respiratory system
antineutrophil cytoplasmic antibodies, 2420
Wegener's granulomatosis, 2420
Retinoic acid receptors
experimental arthritis, 211, 355
matrix metalloproteinases, 211, 355
rheumatoid arthritis, 211, 355
Reverse transcriptase polymerase chain reaction
macrophages, 2529
monocytes, 2529
nitric oxide, 2529
rheumatoid arthritis, 2529
Rheumatic diseases
ankylosing spondylitis, 2245
arthritis, S67–59

Arthritis and Rheumatism International, S67–59
autoantibodies, 1882 (ab)
Bone and Joint Decade Conference, S67–3, S67–54, S67–59, S67–65
Canadian Database of Osteoporosis and Osteopenia, 2308
Canadian Osteoarthritis Rx Program, 2308
chemoprevention, 1884 (ab)
China, 2090, 2245
Community Oriented Program for Control of Rheumatic Diseases, 2090, 2245, 2252
Compliance-Questionnaire-Rheumatology, 2469
Consortium of Rheumatology Researchers of North America, 2308
cyclooxygenase-2 inhibitors, 1888 (ab)
data collection, 2308
epidemiology, 1589, 2090, 2245, S67–54
gout, 2245
Greece, 1589
Indonesia, S67–54
infliximab, 1882 (ab)
Japan, S67–3
musculoskeletal diseases, 1589
nonsteroidal antiinflammatory drugs, 1888 (ab)
osteoporosis, 1884 (ab)
pain, 1882 (ab)
patient compliance, 1887 (ab)
pharmaceutical preparations, 1887 (ab)
prevalence, 1589
quality of life, 2268
rheumatoid arthritis, 2245, 2469
Singapore, 2268
treatment outcome, 1882 (ab)
Vietnam, 2252
Rheumatoid arthritis
adalimumab, 232, 2563
adhesion molecules, 1611
adrenomedullin, 2553
adverse effects, 443, 1888 (ab)
age of onset, 913, 952
alternative splicing, 2524
amyloidosis, 948
anakinra, 225, 1877 (ab), 1878 (ab), 1881 (ab)
androgens, 2597
angiopoietins, 260
animal disease models, 918, 2193
ankle, 1951
ankylosing spondylitis, 972, 2245, S67–45
antibodies, 1691
antibody formation, 680
antigens, 972
antineutrophil cytoplasmic antibodies, 2064
arthrodesis, 1440
arthroplasty, 1440
atlantoaxial joint, 1420
autoantibodies, 1451, 1884 (ab), 1885 (ab)
autoantigens, 449, 1147
autoimmune diseases, 2524
autoimmunity, 918
biological agents, S67–33
biological therapy, 241, 256, 2315
blood pressure, 642
body mass index, 2350
bone and bones, 468, 2319
Bone and Joint Decade Conference, S67–10, S67–33, S67–45, S67–48, S67–51, S67–66
bone density, 2590
bursitis, 1354
campylobacter, 459
cardiovascular diseases, 36, 642, 714, 1196, 1403
cartilage, 1420, 1799
cerebrovascular disorders, 36
cervical vertebrae, 1420
chemokine receptors, 1928
chemokines, 1918
China, 2245
chondrocytes, 1799
citrulline, 1691, 1696
classification, 1135, 1138
clinical trials, 41, 2572
cohort studies, 697
collagen, 468
collagen-PVP, 256
Community Oriented Program for Control of Rheumatic Diseases, 2245
comorbidity, 1436
complementary therapies, 1883 (ab)
Compliance-Questionnaire-Rheumatology, 2469
complications, 948
computer assisted image processing, 238
controlled clinical trial, 2123
corticotropin-releasing hormone, 913
cost of illness, 2485, S67–51
cost-benefit analysis, 714, 891, 1739, 1883 (ab)
cyclic peptides, 1691, 1696
cyclooxygenase-2, 1203
cyclosporine, 1889 (ab)
cysts, 1097, 1351
cytokines, 28, 474, 1157, 1928
cytotoxic T lymphocytes, 660
cytotoxicity tests, 972
defensins, 1719
dehyroepiandrosterone, 2597
depression, 952
diagnosis, 902, 908, 966, 1097, 1354, 1393, 1451, 1691, 2535, 2540
diagnostic imaging, 238
disability, 952, 1881 (ab), 2344
disease activity, 1110, 1112, 1115
disease duration, 1885 (ab)
disease modifying antirheumatic drugs, 241, 697, 2563, S67–10, S67–33, S67–51
disease progression, 4, 905
disease susceptibility, 435, 913
doxycycline, 41, 2112
drug induced abnormalities, 241, 2724
drug therapy, 44
drug toxicity, 443
electrophoresis, 2540
endothelial growth factors, 260
enzyme linked immunosorbent assay, 1451
epidemiology, 948, 1196, 2245, 2460, S67–66
Epstein-Barr virus, 1673
estrogens, 2597
etanercept, 2287, 2315
etidronate, 430, 468, 474
etiology, 425
experimental arthritis, 22, 211, 355, 1203
Fc gamma RIII, 1904, 1911
Fc-receptors, 1911
Felty's syndrome, 404
ferrous sulfate, 1948
fibroblasts, 1680
fibromyalgia, 369
FK506, 2193
foot, 671, 2356
forefoot, 1440
France, S67–42
genes, 1907
genetics, 435, 1887 (ab), 1904
gold, 1875 (ab), 1876 (ab)
gold sodium thiomalate, 1748
gout, 44, 2245
granzyme B, 1799
hand, 671
hands, 1464
Health Assessment Questionnaire, 225
health status, 941
health status indicators, 873
helper-inducer T lymphocytes, 918
hepatitis C virus, 455
HIV, 2294
HLA, 4
HLA-DR antigens, 449
hormone replacement therapy, 1456
hyaluronic acid, 1164
hydroxypregnenolone, 269
hypertension, 642, 714
IgG receptors, 648, 926
immune complexes, 648
immune system, 1935, 2302
immunoglobulin G, 2540
immunohistochemistry, 1420, 2319
immunology, 2535
in situ hybridization, 1712
incidence, 2460
India, 948
infection, 425, 459
inflammation, 1173, 1403, 1611, 1719
infliximab, 941, 1657, 1876 (ab), 1882 (ab), 1883 (ab), 1885 (ab), 1888 (ab), 2287, 2315
insulin resistance, 1403
interleukin 1, 2547
interleukin 1 beta, 2193
interleukin 2, 435
interleukin 6, 22, 1426, 2193
interleukin 6 receptors, 1426
interleukin 10, 648
interleukin receptors, 225
intramuscular, 1876 (ab)
intramuscular injections, 1875 (ab)
irsogladine maleate, 2082
isoniazid, 1657
Japan, S67–47, S67–48
joint erosions, 705, 905, 1102, 1108, 1380, 2580, 2582, 2590
juvenile chronic arthritis, 958
juvenile idiopathic arthritis, 1611, S67–45
knee, 908, 966, 1097, 1351
knockout mice, 22
kynurenine, 1935
lactoferrin, 220
leflunomide, 1182, 1725, 1886 (ab), 2572
lenercept, 680
leukotriene B_4, 1712
LF 15-0195, 918
life tables, 2325
ligament, 1420
linkage, 926
lipid peroxidation, 345
longitudinal studies, 2582
lung, 1878 (ab)
lymphocyte homing receptors, 1611
macrophages, 1911
magnetic resonance imaging,

671, 1097, 1364, 1366, 1376, 1380, 1385, 1387
major histocompatibility complex, 449, 2524
matrix metalloproteinase-1, 1147, 1164
matrix metalloproteinases, 10, 211, 355
men, 2302, 2338
metaanalyses, 1182
metaanalysis, 2112
metatarsophalangeal, 1440
methotrexate, 28, 1725, 1948, 2082, 2325
minocycline, 2112
monoclonal antibodies, 1696, 2563
morbidity, S67–10, S67–33
mortality, 958, 1196, S67–10, S67–33, S67–51
musculoskeletal system, 1191
natural killer cells, 660, 1911
neopterin, 1935
neutrophil granulocytes, 220
NF-kappa B, 2319
nitric oxide, 345, 1173, 1885 (ab)
North American Indians, 1887 (ab)
nutrition, S67–66
OMERACT 6 conference, 868, 873, 877, 880, 884, 891, 1102, 1108, 1110, 1112, 1115, 1364, 1366, 1376, 1380, 1385, 1387
orthotic devices, 2356
osteoarthritis, 36, 345, 642, 714, 1196, 2553, S67–66
osteogenesis, 2547
osteoporosis, 474, S67–42
outcome and process assessment, 705, 868, 877, 880, 1112, 1115, 1739
outcome assessment, 1110
pain, 369, 2718
pain measurement, 369, 1733
paleopathology, 2095
pamidronate, 2080
parvovirus B19, 1907
pathologic processes, 2547
patient compliance, 44
patient participation, 868, 873, 877, 880, 884
PD-1, 1410
peptides, 972
perforins, 1799
peroxynitrous acid, 1173
physician's practice patterns, 1464, 1940
polyarthritis, 902, 1691
polymorphism, 435, 438, 926, 1406
polymorphonuclear leukocytes, 232
polymyalgia rheumatica, 44
predictive value of tests, 2535
pregnancy, 241
pregnenolone, 269
preventive medicine, 1940
prognosis, 705, 905, 1691, 2344, 2580, 2582
proteinases, 2064
psoriatic arthritis, 4
quality of health care, 1883 (ab)
quality of life, 225, 941, 952
questionnaires, 2485
radiography, 238, 705, 1102, 1385, 1456, 2344, 2350, 2580
randomized controlled trials, 465, 680, 868, 880, 884, 1102, 1108, 1110, 1112, 1135, 1138, 1456, 2080, 2112, 2356
RANKL, 2319
reactive arthritis, 425, 459
reactive oxygen species, 232
reference standards, 891
regression analysis, 465
relapsing polychondritis, 1394
remission induction, 10, 1102, 1108
remodeling, 1799
reproducibility of results, 238, 1366, 1376, 1385, 1739
research design, 1364, 1387
retinoic acid receptors, 211, 355
rheumatic diseases, 2245, 2469
rheumatoid arthritis, 1394
rheumatoid factor, 455, 913, 1393, 2064, S67–51
rheumatoid nodule, 1191
risk, 36, 443
risk assessment, 1397, 1436
risk factors, 1403
rosmarinic acid, 1203
scleritis, 1889 (ab)
self-evaluation programs, 1130, 1133
sex, 2590
sex hormones, 2302, 2338
shared epitope, 4, 2350
smoking, 1877 (ab)
spondyloarthropathy, 2095, 2460, S67–42
sugars, 2540
sulfasalazine, 404
surgery, 1464
synovial fluid, 220, 1410, 1928, 2597
synovial membrane, 10, 660, 1173, 1351, 1354, 1680
synoviocytes, 345
synovitis, 1907, 1951
synovium, 2553
systemic lupus erythematosus, 269, 1351
T cell antigen receptors, 449
T lymphocytes, 449, 1157, 1410, 1611, 1673, 1918, 2524
tendons, 1951
tetracycline, 1888 (ab), 2085
tissue inhibitors of metalloproteinases, 10
treatment, 1426
treatment cessation, 697
treatment outcome, 1725, 1733, 1882 (ab), 1886 (ab), 2572, S67–51
Tripterygium wilfordii, 465
tryptophan, 1935
tuberculosis, 1397, 1436, 1657, 2095
tumor necrosis factor receptors, 22, 438, 680, 1680, 2123, 2319, 2563
tumor necrosis factors, 648, 1406, 1680, 2193
ultrasonography, 908, 966, 1191
vasculitis, 2287
vimentin, 1884 (ab)
weather, 2728
Wegener's granulomatosis, 2064
wrist, 2718

Rheumatoid factor
age of onset, 913
anti-cyclic citrullinated peptide, 825
antineutrophil cytoplasmic antibodies, 2064
Bone and Joint Decade Conference, S67–51
corticotropin-releasing hormone, 913
cost of illness, S67–51
diagnosis, 1393
disease modifying antirheumatic drugs, S67–51
disease susceptibility, 913
hepatitis C virus, 455
juvenile idiopathic arthritis, 825
mortality, S67–51
proteinases, 2064
rheumatoid arthritis, 455, 913, 1393, 2064, S67–51
treatment outcome, S67–51
Wegener's granulomatosis, 2064

Rheumatoid nodule
musculoskeletal system, 1191
rheumatoid arthritis, 1191
ultrasonography, 1191

Rheumatology
antiphospholipid syndrome, 1893
classification, 1893
cost-benefit analysis, S68–5, S68–21, S68–23
decision support techniques, S68–23
drugs, S68–5
economic models, S68–21
government regulation, S68–5
graduate medical education, 1882 (ab)
health care rationing, 1890
Health Economics in Rheumatology Conference, S68–5, S68–21, S68–23
Internet, 1887 (ab)
medical specialties, 1887 (ab), 1890

Ribavirin
hepatitis C virus, 1775
interferon-alpha, 1775
mixed cryoglobulinemia, 1775
non-Hodgkin's lymphoma, 1775

Ribomunyl
animal disease models, 2027
cyclosporine, 2027
methotrexate, 2027

Ribonuclear proteins
mixed connective tissue disease, 998
RNA, 998
systemic lupus erythematosus, 998

Rice bodies
juvenile idiopathic arthritis, 2720
knee, 2720

Risedronate
fractures, 1877 (ab), 1886 (ab)
osteoporosis, 1886 (ab)

Risk
adverse effects, 443
Bone and Joint Decade Conference, S67–21
breast neoplasms, 1505
cardiovascular diseases, 36
cerebrovascular disorders, 36
Chinese, 1513
diphosphonates, S67–21
disease progression, 1513
drug toxicity, 443
fractures, S67–21
morbidity, 1513
mortality, 1513
osteoarthritis, 36
osteoporosis, S67–21
preventive medicine, S67–21
rheumatoid arthritis, 36, 443
systemic lupus erythematosus, 1505, 1513
treatment outcome, S67–21

Risk assessment
comorbidity, 1436

rheumatoid arthritis, 1397, 1436
tuberculosis, 1397, 1436
Risk factors
body mass index, 2103
breast neoplasms, 1876 (ab)
cardiovascular diseases, 493, 1403
depression, 2103
diagnosis, 493
disability, 386
epidemiology, 2103
gastrointestinal system, 2241
hemorrhage, 2241
inflammation, 1403
insulin resistance, 1403
juvenile rheumatoid arthritis, 386
myocardial diseases, 288
nonsteroidal antiinflammatory drugs, 2241
osteoarthritis, 2103
perfusion, 288
prognosis, 386
rheumatoid arthritis, 1403
single photon emission computed tomography, 288
systemic lupus erythematosus, 288, 493, 1876 (ab)
RNA
mixed connective tissue disease, 998
ribonuclear proteins, 998
systemic lupus erythematosus, 998
ROC curves
antiphospholipid antibodies, 723
antiphospholipid syndrome, 723
lupus anticoagulant, 723
Rofecoxib
cardiovascular system, 421
cyclooxygenase-2, 421
osteoarthritis, 421
thrombosis, 421
Rosmarinic acid
cyclooxygenase-2, 1203
experimental arthritis, 1203
rheumatoid arthritis, 1203
Russia
Bone and Joint Decade Conference, S67–56
musculoskeletal system, S67–56

S

Sacroiliitis
ankylosing spondylitis, 518
back pain, 518
Crohn's disease, 518
HLA-B27, 518
inflammatory bowel disease, 518
Salicin
arthritis, 1125
SAPHO
acquired hyperostosis syndrome, 636
lumbar vertebrae, 636
Sarcoidosis
etanercept, 1864
Scleritis
cyclosporine, 1889 (ab)
rheumatoid arthritis, 1889 (ab)
Scleroderma
See also Circumscribed scleroderma
See also Systemic sclerosis
angiogenesis, 1529
antineoplastic agents, 1341
autoantibodies, 1248, 1994, 2725
brain, 2724
calcification, 2724
capillaries, 1529
carboplatin, 1341
central nervous system, 1997
cerebrovascular circulation, 1997
connective tissue diseases, 1248
D-penicillamine, 1616
depression, 1782
disease activity, 2606
DNA, 1520
drug induced abnormalities, 2725
etanercept, 2725
facial hemiatrophy, 193, 1997
gemcitabine, 1341
glomerulonephritis, 1616
Goodpasture syndrome, 1616
Health Assessment Questionnaire, 1885 (ab)
health services research, 1238
homocysteine, 298
hospital emergency service, 1238
hospitalization, 1238
interleukin 8, 1524
interstitial lung diseases, 2398
keloid, 2500
lung, 298, 1524
necrosis, 1341
neoplasms, 1994
neuron specific enolase, 2606
nodules, 2500
OMERACT 6 conference, 1630
oncogenes, 1524
outcome and process assessment, 1630, 1885 (ab)
peripheral nervous system, 1231
platelet activation, 2606
polymorphism, 1520
pulmonary hypertension, 2398
pupil, 1231
randomized controlled trials, 1630
socioeconomic factors, 1238
Sturge-Weber syndrome, 193
substance P, 1231
systemic sclerosis, 193, 298, 1231, 1238, 1520, 1524, 1529, 1616, 1630, 1994, 2398, 2500, 2606, 2724
transforming growth factor, 1520
vascular endothelial growth factor, 1529
Seasons
infection, 2624
parvovirus B19, 2624
polymyalgia rheumatica, 2624
Self-evaluation programs
rheumatoid arthritis, 1130, 1133
Self-medication
COPCORD, 2312
epidemiology, 2312
gout, 2312, 2437
hyperuricemia, 2312, 2437
Indonesia, 2312, 2437
Sella turcica
enchondromatosis, 1100
hand, 1100
Sepsis
spine, 632
Streptococcus oralis, 632
Sex
age of onset, 1548
bone density, 2590
giant cell arteritis, 1119, 1548
joint erosions, 2590
rheumatoid arthritis, 2590
Spain, 1548
temporal arteritis, 1548
Sex hormones
immune system, 2302
men, 2302, 2338
rheumatoid arthritis, 2302, 2338
Shared epitope
body mass index, 2350
disease progression, 4, 96
HLA, 4
HLA antigens, 96
psoriatic arthritis, 4, 96
radiography, 2350
rheumatoid arthritis, 4, 2350
Shoes
biomechanics, 529
gait, 529
knee, 529
osteoarthritis, 529
Shoulder
classification, 1029
neck, 2694
outcome and process assessment, 2694
pain, 2694
patient care management, 2694
physiologic calcification, 1029
reproducibility of results, 1029
tendinitis, 1029
Shoulder pain
bone and bones, 851
humerus, 851
osteomyelitis, 851
tuberculosis, 851
Sicca
signs and symptoms, 1259
Sjögren's syndrome, 1259
Sick role
musculoskeletal system, 7, 139
pain, 7, 139
psychology, 7
upper extremity, 7, 139
Signs and symptoms
anticoagulants, 897
antiphospholipid syndrome, 897
fever, 1272
inflammation, 1272
sicca, 1259
Sjögren's syndrome, 1259
temporal arteritis, 1272
Sildenafil
CREST syndrome, 2503
impotence, 2503
Raynaud's phenomenon, 2503
Silicone
breast implants, 2092, 2263
fatigue, 2263
pain, 2263
Singapore
quality of life, 2268
rheumatic diseases, 2268
Single photon emission computed tomography
myocardial diseases, 288
perfusion, 288
risk factors, 288
systemic lupus erythematosus, 288
Single stranded DNA
antinuclear antibodies, 1761
disease activity, 1761
systemic lupus erythematosus, 1761
Sjögren's syndrome
afferent neurons, 1552
alpha-fodrin, 2157
androgens, 1267, 2413
anti-endomysial assay, 2613
autoantibodies, 2157
autonomic nervous system, 2296
celiac disease, 2613
classification, 2157
D6S439, 2152
diagnosis, 2613

disorders of excessive somnolence, 2406
epitope, 1208
estrogens, 1267, 2413
gastric antral vascular ectasia, 1090
homozygosity, 2152
hormone replacement therapy, 1267
Ki antigen, 1208
lacrimal flow, 206
major histocompatibility complex, 2152
microsatellites, 2152
muscarinic receptors, 2406
neuropathy, 1552
sicca, 1259
signs and symptoms, 1259
systemic lupus erythematosus, 1208
tissue transglutaminases, 2613
urological manifestations, 2406
xerostomia, 206

Skin
cytokines, 146
fibromyalgia, 146
hand, 1253
Health Assessment Questionnaire, 1253
interleukin, 146
outcome and process assessment, 1253
systemic sclerosis, 1253
tumor necrosis factor, 146

Sleep
fatigue, 1070
fibromyalgia, 1070
pain, 1070
sodium oxybate, 1070

SLICC/ACR Damage Index
Rasch analysis, 292
systemic lupus erythematosus, 292
weightings, 292

Slow acting antirheumatic drugs
ankylosing spondylitis, 1816
China, 1816
epidemiology, 1816
treatment, 1816

Smoking
alcohol drinking, 1215, 1222
disease activity, 1215
epidemiology, 1215, 1222
systemic lupus erythematosus, 1215, 1222

Socioeconomic factors
arthritis, 160
cross sectional studies, 160
epidemiology, 160
health services research, 1238
hospital emergency service, 1238
hospitalization, 1238
quality of life, 160
scleroderma, 1238
systemic sclerosis, 1238

Sodium oxybate
fatigue, 1070
fibromyalgia, 1070
pain, 1070
sleep, 1070

Soft tissue neoplasms
cysts, 200
knee, 200

Somatomedins
See also Insulin-like growth factor-I

Soybeans
avocado, 1825
cartilage, 1825
cytokines, 1825
osteoarthritis, 1825

SpA Research Consortium of Canada
ankylosing spondylitis, 1127, 1356
consensus development conferences, 1356
etanercept, 1127, 1356
infliximab, 1127, 1356
spondyloarthropathy, 1127

Spain
age of onset, 1548
giant cell arteritis, 1548
sex, 1548
temporal arteritis, 1548

Spinal fractures
osteoporosis, 1579
Osteoporosis Assessment Questionnaire, 1579
quality of life, 1579

Spinal injections
central nervous system, 207
corticosteroids, 207
systemic lupus erythematosus, 207

Spine
sepsis, 632
Streptococcus oralis, 632

Spondyloarthropathy
alleles, 2632
ankylosing spondylitis, 1127, 2306
arthritis, 1335
Bone and Joint Decade Conference, S67–42
Brazil, 2632
classification, 1335
colitis, 2306
enteric bacteria, 105
enthesis, 508
epidemiology, 2460
etanercept, 1127
etiology, 105
fibromyalgia, 1879 (ab)
France, S67–42
histology, 508
HLA-B27, 1291, 2632
HLA-B7, 2632
immune response, 105
incidence, 2460
inflammation, 2306
infliximab, 1127
juvenile rheumatoid arthritis, 1335
osteoporosis, S67–42
paleopathology, 2095
posterior tibial tendon dysfunction, 508
prevalence, 1335
prognosis, 2632
quality of life, 1879 (ab)
reactive arthritis, 1291
rheumatoid arthritis, 2095, 2460, S67–42
SpA Research Consortium of Canada, 1127
synovial membrane, 1291
tarsal joints, 630
tuberculosis, 2095

Staining and labelling
Alizarin red, 1032
calcium pyrophosphate dihydrate crystal deposition, 1032
diagnosis, 1032

Stanford Health Assessment Questionnaire
disability, 167
Health Assessment Questionnaire, 167

Stenosis
corticosteroids, 1017
glottis, 1017
treatment, 1017
Wegener's granulomatosis, 1017

Stevens-Johnson syndrome
adverse effects, 2234
nonsteroidal antiinflammatory drugs, 2234

Stomach
arthritis, 2713
cytology, 2713
hydrarthrosis, 2713
neoplasm metastasis, 2713

Streptococcus oralis
sepsis, 632
spine, 632

Substance P
peripheral nervous system, 1231
pupil, 1231
scleroderma, 1231
systemic sclerosis, 1231

Sugars
diagnosis, 2540
electrophoresis, 2540
immunoglobulin G, 2540
rheumatoid arthritis, 2540

Sulfasalazine
anterior uveitis, 1277
Felty's syndrome, 404
rheumatoid arthritis, 404
treatment, 1277

Surgery
hand, 1788
hands, 1464
ischemia, 1788
metaanalysis, 1788
physician's practice patterns, 1464
rheumatoid arthritis, 1464
sympathectomy, 1788

Survival
epidemiology, 731
Greece, 731
incidence, 731
systemic lupus erythematosus, 731

Sweden
Bone and Joint Decade Conference, S67–41
preventive medicine, S67–41

Sympathectomy
hand, 1788
ischemia, 1788
metaanalysis, 1788
surgery, 1788

2759 fluid
androgens, 2597
calcium pyrophosphate, 420
chemokine receptors, 1928
cytokines, 1928
dehyroepiandrosterone, 2597
estrogens, 2597
lactoferrin, 220
neutrophil granulocytes, 220
osteoarthritis, 420
PD-1, 1410
rheumatoid arthritis, 220, 1410, 1928, 2597
T lymphocytes, 1410
transforming growth factor, 420

Synovial membrane
ADAM8, 2033
bursitis, 1354
cysts, 1351
cytotoxic T lymphocytes, 660
diagnosis, 1354
fibroblasts, 1680
giant cells, 2033
hip replacement arthroplasty, 2033
HLA-B27, 1291
inflammation, 1173
knee, 1351
matrix metalloproteinases, 10
natural killer cells, 660
nitric oxide, 1173
osteoclasts, 2033
peroxynitrous acid, 1173
reactive arthritis, 1291
remission induction, 10
rheumatoid arthritis, 10, 660, 1173, 1351, 1354, 1680
spondyloarthropathy, 1291

systemic lupus erythematosus, 1351
tissue inhibitors of metalloproteinases, 10
tumor necrosis factor receptors, 1680
tumor necrosis factors, 1680
Synoviocytes
lipid peroxidation, 345
nitric oxide, 345
osteoarthritis, 345
rheumatoid arthritis, 345
Synovitis
ankle, 1951
arthroscopy, 2170
Doppler, 2170
genes, 1907
parvovirus B19, 1907
rheumatoid arthritis, 1907, 1951
tendons, 1951
ultrasonography, 2170
Synovium
adrenomedullin, 2553
osteoarthritis, 2553
rheumatoid arthritis, 2553
Systemic lupus erythematosus
See also Central nervous system lupus vasculitis
adhesion molecules, 2133
agammaglobulinemia, 412
alcohol drinking, 1215, 1222
anticardiolipin antibodies, 985, 2127
antimalarials, 1756, 1876 (ab)
antinuclear antibodies, 1473, 1761
autoantibodies, 740, 993, 1473, 1495, 1875 (ab)
autoimmune diseases, 276
B lymphocytes, 412
bias, 979
Blacks, 60
blister, 1875 (ab)
bone density, 2365
breast neoplasms, 1505, 1876 (ab)
British Isles Lupus Assessment Group index, 2133
cardiovascular diseases, 493, 899
cc chemokines, 2365
central nervous system, 207
central nervous system lupus vasculitis, 283, 485
cerebral blood flow, 2075
cerebrospinal fluid, 485
cerebrovascular circulation, 2075
cerebrovascular disorders, 985
chemokine receptors, 1770
Chinese, 1513
classification, 1880 (ab)
cognition disorders, 1006
common variable immunodeficiency, 412
complement, 740
computed tomography, 2075
corticosteroids, 207, 1871, 2365
cost of illness, 1878 (ab)
cryoglobulins, 1473
cutaneous lupus, 1877 (ab)
cyclophosphamide, 1871
cysts, 1351
cytokines, 2133
demyelinating diseases, 1871
dermatomycosis, 1491
diagnosis, 493, 1880 (ab)
diagnostic tests, 899
diet, 747
disease activity, 747, 1215, 1761, 1960, 1967, 1977, 2133, 2140
disease progression, 1513
drug hypersensitivity, 480
drug toxicity, 1756
endothelium, 1400, 1479, 1963
epidemiology, 731, 1215, 1222
epitope, 1208
fatigue, 283
fats, 747
G binding protein, 993
genetic predisposition to disease, 60
glutathione transferase, 276
Greece, 731
group psychotherapy, 1011
guanosine, 993
health resources, 1878 (ab)
heat shock proteins, 1875 (ab)
helper-inducer T lymphocytes, 2365
hepatitis C virus, 1473
histiocytic necrotizing lymphadenitis, 857
HLA-DM, 1485
hydroxypregnenolone, 269
hyperhomocysteinemia, 1400, 1479
hypertension, 1881 (ab)
iatrogenic diseases, 208
immune system, 1491
immunization, 2295
immunosuppression, 1508
incidence, 731
infarction, 634
influenza, 2295
ischemia, 634
kallikreins, 485
Ki antigen, 1208
kidney, 634, 1495
kidney failure, 1227
kininogens, 485
knee, 1351
lamin type B, 1875 (ab)
LE cells, 1880 (ab)
leukocytes, 1876 (ab)
lupus coagulant, 985
lupus-like syndrome, 208
magnetic resonance imaging, 985, 1983
mannose binding lectin, 740
metabolism, 276
microsatellite repeats, 60
mixed connective tissue disease, 998
morbidity, 1513
mortality, 1513, 1977
mycophenolate mofetil, 1508
myocardial diseases, 288
neurologic manifestations, 985, 1006, 1983, 2075
newborn infant, 1877 (ab)
onychomycosis, 1491
ophthalmologic monitoring, 1756
ophthalmological diagnostic techniques, 1876 (ab)
organ systems, 1955
osteoporosis, 1884 (ab), 2365
outcome and process assessment, 1955, 1960, 1967
pain, 634
patient-physician relations, 1967
perfusion, 288
platelet activation, 1479
polymorphism, 60, 740, 1485, 1770
prednisone, 2127
pregnancy, 2127
pregnenolone, 269
prognosis, 1977
prolactin, 2140
promoter regions, 60
psychological adaptation, 1011
psychology, 283
pulmonary artery, 1881 (ab)
quality of life, 1011
questionnaires, 1006
randomized controlled trials, 979
Rasch analysis, 292
rash, 857
remission induction, 1880 (ab)
research design, 979
rheumatoid arthritis, 269, 1351
ribonuclear proteins, 998
risk, 1505, 1513
risk factors, 288, 493, 1876 (ab)
RNA, 998
single photon emission computed tomography, 288
single stranded DNA, 1761
Sjögren's syndrome, 1208
SLICC/ACR Damage Index, 292
smoking, 1215, 1222
spinal injections, 207
survival, 731
synovial membrane, 1351
Systemic Lupus Erythematosus Disease Activity Index, 2140
thrombotic thrombocytopenic purpura, 1227
ultraviolet rays, 276
valpromide, 208
vasculitis, 208
vision screening, 1756
vitamin C, 747
von Willebrand factor, 1963
weightings, 292
Systemic Lupus Erythematosus Disease Activity Index
disease activity, 2140
prolactin, 2140
systemic lupus erythematosus, 2140
Systemic sclerosis
See also Scleroderma
angiogenesis, 1529
antineutrophil cytoplasmic antibodies, 2078
apoptosis, 1886 (ab)
autoantibodies, 1994, 2392
brain, 2724
c-telopeptide, 68
calcification, 2724
capillaries, 1529
chromosomes, 1244
collagen type I, 68
connective tissue growth factor, 755
cyclophosphamide, 1121
D-penicillamine, 1616
disease activity, 2606
DNA, 1520
DNA directed RNA polymerases, 2392
facial hemiatrophy, 193
fibrosis, 755
glomerulonephritis, 1616
Goodpasture syndrome, 1616
hand, 1253
Health Assessment Questionnaire, 1253
health services research, 1238
HLA, 2392
homocysteine, 298
hospital emergency service, 1238
hospitalization, 1238
immunogenetics, 2392
inflammation, 2147
interleukin 2, 2147
interleukin 8, 1524
interstitial lung diseases, 2398

joints, 2147
keloid, 2500
lung, 298, 1524
methotrexate, 1875 (ab)
micronucleus assay, 1244
neoplasms, 1994
neuron specific enolase, 2606
nodules, 2500
OMERACT 6 conference, 1630
oncogenes, 1524
outcome and process assessment, 1253, 1630
peripheral nervous system, 1231
platelet activation, 2606
polymorphism, 1520
pulmonary fibrosis, 1121
pulmonary hypertension, 2398
pupil, 1231
randomized controlled trials, 1630
Raynaud's phenomenon, 1244
scleroderma, 193, 298, 1231, 1238, 1520, 1524, 1529, 1616, 1630, 1994, 2398, 2500, 2606, 2724
skin, 1253
socioeconomic factors, 1238
Sturge-Weber syndrome, 193
substance P, 1231
transforming growth factor, 755, 1520
treatment, 1121
vascular endothelial growth factor, 1529
YKL-40, 2147

T

T cell antigen receptors
autoantigens, 449
HLA-DR antigens, 449
major histocompatibility complex, 449
rheumatoid arthritis, 449
T lymphocytes, 449
T lymphocytes
See also Cytotoxic T lymphocytes
adhesion molecules, 1611
alternative splicing, 2524
antiphospholipid syndrome, 1875 (ab)
autoantigens, 449
autoimmune diseases, 2524
chemokines, 1918
cytokines, 1157
eosinophilic fasciitis, 1811
Epstein-Barr virus, 1673
glycoproteins, 1875 (ab)
HLA-DR antigens, 449
immunophenotyping, 1811
inflammation, 1611
juvenile idiopathic arthritis, 1611
lymphocyte homing receptors, 1611
major histocompatibility complex, 449, 2524
PD-1, 1410
rheumatoid arthritis, 449, 1157, 1410, 1611, 1673, 1918, 2524
synovial fluid, 1410
T cell antigen receptors, 449
Tai chi
exercise, 2039
osteoarthritis, 2039
women, 2039
Taiwan
ankylosing spondylitis, 321
HLA-B27, 321
polymerase chain reaction, 321
polymorphism, 321
Takayasu's arteritis
angiography, 1793
aortitis, 2508
disease activity, 2023
immunosuppressive agents, 1793
monocytes, 2023
Talus
osteoporosis, 860
tibia, 860
Tarsal joints
spondyloarthropathy, 630
Teaching
musculoskeletal system, 1881 (ab)
physical examination, 1881 (ab)
Temporal arteritis
age of onset, 1548
auscultation, 191
diagnosis, 2177
fever, 1272
giant cell arteritis, 1548
inflammation, 1272
leukemia, 846
polyarteritis nodosa, 2165
polymyalgia rheumatica, 191
sex, 1548
signs and symptoms, 1272
Spain, 1548
ultrasonography, 2177
vasculitis, 846, 2165
Wegener's granulomatosis, 2165
Temporomandibular joint
dysgeusia, 1841
fibromyalgia, 1841
glossodynia, 1841
xerostomia, 1841
Tender points
distress, 567
fibromyalgia, 567
pain, 567
psychology, 567
Tendinitis
anserine, 352
bursitis, 352
classification, 1029
diabetes mellitus, 352
physiologic calcification, 1029
reproducibility of results, 1029
shoulder, 1029
ultrasonography, 352
Tendons
ankle, 1951
rheumatoid arthritis, 1951
synovitis, 1951
Tetracycline
rheumatoid arthritis, 1888 (ab), 2085
Thalidomide
ankylosing spondylitis, 2627
disease modifying antirheumatic drugs, 2627
tumor necrosis factor receptors, 2627
The Canadian Database of Osteoporosis and Osteopenia
Canadian Osteoarthritis Rx Program, 2308
Consortium of Rheumatology Researchers of North America, 2308
data collection, 2308
rheumatic diseases, 2308
Therapeutics
ankylosing spondylitis, 779
bone density, 779
osteoporosis, 779
physician's practice patterns, 779
treatment, 779
Thermography
classification, 720
predictive value of tests, 720
Raynaud's phenomenon, 720
Thrombin
annexin V, 1990
antiphospholipid antibodies, 1990
Thrombophilia
anticardiolipin antibodies, 2385
blood coagulation factors, 783
factor V, 2385
fibrinolysis, 783
lupus anticoagulant, 2385
osteonecrosis, 783
thrombosis, 2385
Thrombosis
anticardiolipin antibodies, 2385
cardiovascular system, 421
cyclooxygenase-2, 421
diagnostic tests, 1877 (ab)
factor V, 2385
lupus anticoagulant, 2385
osteoarthritis, 421
rofecoxib, 421
thrombophilia, 2385
Thrombotic thrombocytopenic purpura
kidney failure, 1227
systemic lupus erythematosus, 1227
Thromboxane A2
antiphospholipid antibodies, 55
antiphospholipid syndrome, 55
blood platelets, 55
Thumb
bursa, 1626
dactylitis, 1626
radius, 1626
Tibia
osteoporosis, 860
talus, 860
Tissue inhibitors of metalloproteinases
matrix metalloproteinases, 10
remission induction, 10
rheumatoid arthritis, 10
synovial membrane, 10
Tissue transglutaminases
anti-endomysial assay, 2613
celiac disease, 2613
diagnosis, 2613
Sjögren's syndrome, 2613
Tophus
arthroscopy, 1868
gout, 1868
Transforming growth factor
calcium pyrophosphate, 420
connective tissue growth factor, 755
DNA, 1520
fibrosis, 755
osteoarthritis, 420
polymorphism, 1520
scleroderma, 1520
synovial fluid, 420
systemic sclerosis, 755, 1520
Trauma
cartilage, 2716
ear piercing, 2716
relapsing polychondritis, 2716
Treatment
ankylosing spondylitis, 779, 1816
anterior uveitis, 1277
bone density, 779
brucellosis, 2666
China, 1816
combination drug therapy, 2666
corticosteroids, 1017
cyclophosphamide, 1121
epidemiology, 1816
fibromyalgia, 154
glottis, 1017

interleukin 6, 1426
interleukin 6 receptors, 1426
osteoarthritis, 1846
osteoporosis, 779
physician's practice patterns, 779
practice guidelines, 1846
pulmonary fibrosis, 1121
reactive arthritis, 2666
recurrence, 80
remission induction, 80
rheumatoid arthritis, 1426
slow acting antirheumatic drugs, 1816
stenosis, 1017
sulfasalazine, 1277
systemic sclerosis, 1121
therapeutics, 779
vasculitis, 80
Wegener's granulomatosis, 80, 1017
Treatment cessation
cohort studies, 697
disease modifying antirheumatic drugs, 697
rheumatoid arthritis, 697
Treatment failure
ankylosing spondylitis, 204
colchicine, 2620
familial Mediterranean fever, 2620
infliximab, 204
intravenous injections, 2620
Treatment outcome
ankylosing spondylitis, 1558
back pain, S67–26
Bone and Joint Decade Conference, S67–14, S67–21, S67–26, S67–51
clinical trials, 2572
cost of illness, S67–51
diacerein, S67–14
diagnosis, S67–26
diphosphonates, S67–21
disease modifying antirheumatic drugs, S67–51
drug toxicity, 2680
epidemiology, S67–26
fractures, S67–21
glucosamine, S67–14
health status, S67–26
infliximab, 1882 (ab)
knee, 1571
leflunomide, 1725, 1886 (ab), 2572
mesalazine, 1558
methotrexate, 1725
mortality, S67–51
muscles, 603
myositis, 603
neuromuscular electrical stimulation, 1571
nonsteroidal antiinflammatory drugs, 2680
osteoarthritis, 1571, S67–14
osteoporosis, S67–21
outcome and process assessment, 603
pain, 1882 (ab)
pain measurement, 1733
patient satisfaction, 1882 (ab)
pediatric myositis, 603
preventive medicine, S67–21
rheumatic diseases, 1882 (ab)
rheumatoid arthritis, 1725, 1733, 1882 (ab), 1886 (ab), 2572, S67–51
rheumatoid factor, S67–51
risk, S67–21
Tripterygium wilfordii
randomized controlled trials, 465
regression analysis, 465
rheumatoid arthritis, 465
Tryptophan
immune system, 1935
kynurenine, 1935
neopterin, 1935
rheumatoid arthritis, 1935
Tuberculosis
bone and bones, 851
comorbidity, 1436
humerus, 851
infliximab, 1657
isoniazid, 1657
osteomyelitis, 851
paleopathology, 2095
rheumatoid arthritis, 1397, 1436, 1657, 2095
risk assessment, 1397, 1436
shoulder pain, 851
spondyloarthropathy, 2095
Tumor necrosis factor receptors
adalimumab, 2563
ankylosing spondylitis, 2627
arthritis, 934
bone and bones, 2319
controlled clinical trial, 2123
disease modifying antirheumatic drugs, 2563, 2627
experimental arthritis, 22
fibroblasts, 1680
immunohistochemistry, 2319
interferon-alpha, 934
interleukin 1 receptors, 934
interleukin 6, 22
knockout mice, 22
lupus nephritis, 2382
monoclonal antibodies, 2563
NF-kappa B, 2319
osteoprotegerin, 934
pentoxifylline, 2382
polymorphism, 438
proteinuria, 2382
RANKL, 2319
rheumatoid arthritis, 22, 438, 1680, 2123, 2319, 2563
synovial membrane, 1680
thalidomide, 2627
tumor necrosis factors, 1680
Tumor necrosis factors
aged, 691
animal disease models, 2193
antibody formation, 680
argininosuccinate synthase, 652
cytokines, 146
etanercept, 691, 1897
fibroblasts, 1680
fibromyalgia, 146
FK506, 2193
GTP cyclohydrolase, 652
IgG receptors, 648
immune complexes, 648
infertility, 1897
interleukin, 146
interleukin 1 beta, 2193
interleukin 10, 648
interleukin 6, 2193
lenercept, 680
nitric oxide, 652
polymorphism, 1406
randomized controlled trials, 680
rheumatoid arthritis, 648, 680, 691, 1406, 1680, 2193
skin, 146
synovial membrane, 1680
tumor necrosis factor receptors, 1680

U

Ultrasonography
Achilles tendon, 774
aged, 1881 (ab)
anserine, 352
arthritis, 774
arthroscopy, 2170
bone density, 179, 1881 (ab)
bursitis, 352
calcaneus, 179
cellulitis, 417
chronic disease, 179
diabetes mellitus, 352
diagnosis, 908, 966, 2177
Doppler, 2170
gout, 417
ischemia, 1344
juvenile rheumatoid arthritis, 179
knee, 908, 966
magnetic resonance imaging, 774
memory disorders, 1881 (ab)
musculoskeletal system, 1191
osteoporosis, 179
pediatric rheumatic diseases, 179
polyarteritis nodosa, 1344
rheumatoid arthritis, 908, 966, 1191
rheumatoid nodule, 1191
synovitis, 2170
temporal arteritis, 2177
tendinitis, 352
Ultraviolet rays
autoimmune diseases, 276
glutathione transferase, 276
metabolism, 276
systemic lupus erythematosus, 276
United Kingdom
arthritis, S67–36
Bone and Joint Decade Conference, S67–36
disability, S67–36
jurisprudence, S67–36
United States of America
Arthritis Foundation, S67–32
Bone and Joint Decade Conference, S67–32
Preventive medicine, S67–32
Upper extremity
musculoskeletal system, 7, 139
neck, 1124
pain, 7, 139, 1124
psychology, 7
sick role, 7, 139
Uric acid
beer, 1036
exercise, 1036
gout, 849
gouty arthritis, 1036
hypouricemia, 849
parenteral nutrition, 849
Urine
biological markers, 1561
cartilage erosion, 1561
experimental arthritis, 1561
matrix metalloproteinases, 1561
Urological manifestations
disorders of excessive somnolence, 2406
muscarinic receptors, 2406
Sjögren's syndrome, 2406

V

Validation studies
fibromyalgia, 1054
France, 1054
outcome and process assessment, 1054
pain, 1054
quality of life, 1054
questionnaires, 1054
Valpromide
iatrogenic diseases, 208
lupus-like syndrome, 208
systemic lupus erythematosus, 208
vasculitis, 208
Vascular endothelial growth factor
angiogenesis, 1529
capillaries, 1529

giant cell arteritis, 2160
ischemia, 2160
polymorphism, 2160
scleroderma, 1529
systemic sclerosis, 1529
Vasculitis
antineutrophil cytoplasmic antibodies, 1534
azithromycin, 2292
biliary liver cirrhosis, 2710
central nervous system, 2059
child, 1875 (ab)
diagnosis, 1621
disease susceptibility, 1534
etanercept, 2287
genetics, 1534
glomerulonephritis, 2710
HLA, 1534
iatrogenic diseases, 208
infliximab, 2287
juvenile dermatomyositis, 2059
laparotomy, 1621
leukemia, 846
lupus-like syndrome, 208
polyarteritis nodosa, 2165
purpura, 1621
recurrence, 80
remission induction, 80
rheumatoid arthritis, 2287
systemic lupus erythematosus, 208
temporal arteritis, 846, 2165
treatment, 80
valpromide, 208
Wegener's granulomatosis, 80, 2165
Vertical disease transmission
ankylosing spondylitis, 2054
disease susceptibility, 2054
inflammatory bowel disease, 2054
Vietnam
Community Oriented Program for Control of Rheumatic Diseases, 2252
rheumatic diseases, 2252
Vimentin
autoantibodies, 1884 (ab)
rheumatoid arthritis, 1884 (ab)
Vision screening
antimalarials, 1756
drug toxicity, 1756
ophthalmologic monitoring, 1756
systemic lupus erythematosus, 1756
Vitamin C
diet, 747
disease activity, 747
fats, 747
systemic lupus erythematosus, 747
Vitamin D
bisphosphonates, 132
calcium, 1, 132
corticosteroids, 1
cost-benefit analysis, 1, 132
glucocorticoids, 1, 132
osteoporosis, 132
Von Willebrand factor
endothelium, 1963
systemic lupus erythematosus, 1963

W

Weather
rheumatoid arthritis, 2728
Wegener's granulomatosis
antineutrophil cytoplasmic antibodies, 618, 2064, 2420
chemokine receptors, 1541
chemokines, 1541
Churg-Strauss syndrome, 618
corticosteroids, 622, 1017
Crohn's disease, 305
diagnosis, 2070
family, 618
genetic predisposition to disease, 305
glottis, 1017
HLA, 618
Kaposi's sarcoma, 622
meningitis, 2070
mutation, 305
polyarteritis nodosa, 2165
polymorphism, 1541
proteinases, 2064
recurrence, 80
remission induction, 80
respiratory system, 2420
rheumatoid arthritis, 2064
rheumatoid factor, 2064
stenosis, 1017
temporal arteritis, 2165
treatment, 80, 1017
vasculitis, 80, 2165
Weightings
Rasch analysis, 292
SLICC/ACR Damage Index, 292
systemic lupus erythematosus, 292
Whiplash injuries
Canada, 1882 (ab)
Lithuania, 1882 (ab)
motor vehicles, 1882 (ab)
Whipple's disease
arthritis, 1347
bacterial infections, 1347
central nervous system, 1347
orchitis, 1347
WOMAC index
hip, 2452
knee, 2452
osteoarthritis, 2452
outcome and process assessment, 2452
patient satisfaction, 2452
Women
aged, 2689
cost of illness, 1886 (ab)
disability, 1880 (ab), 2689
exercise, 2039
fibromyalgia, 1880 (ab), 1886 (ab)
lower extremity, 2689
osteoarthritis, 2039
pain, 2689
quality of life, 2689
tai chi, 2039
World Health Organization
Bone and Joint Decade Conference, S67–6
health policy, S67–6
musculoskeletal system, S67–6
Wrist
pain, 2718
rheumatoid arthritis, 2718

X

Xerophthalmia
androgens, 2413
estrogens, 2413
Sjögren's syndrome, 2413
Xerostomia
dysgeusia, 1841
fibromyalgia, 1841
glossodynia, 1841
lacrimal flow, 206
Sjögren's syndrome, 206
temporomandibular joint, 1841

Y

YKL-40
inflammation, 2147
interleukin 2, 2147
joints, 2147
systemic sclerosis, 2147
Yohimbe
CREST syndrome, 2503
impotence, 2503
Raynaud's phenomenon, 2503
sildenafil, 2503